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The association between major depressive disorder (MDD) and various physical 
diseases is well recognized. However, previous studies have mainly focused on 
depression in physically ill individuals. My thesis aims to investigate the reverse 
direction, i.e. the occurrence of physical diseases including obesity in individuals 
with MDD. First, I found evidence for higher prevalence rates for eight out of the 16 
common physical diseases studied here in depressed people compared to controls 
with no history of MDD. Affected and unaffected siblings of the depressed subjects 
showed a similar pattern. The diseases that were significantly more common in 
depressed subjects were hypertension, hypercholesterolemia, myocardial infarction, 
asthma, allergic rhinitis/ hay fever, gastric ulcer, osteoarthritis and thyroid disease. In 
addition, factor and correlational analyses showed that groups of physical diseases 
tended to cluster together in families where one or more individuals suffered from 
depression. The most striking of these was a ‘metabolic syndrome’ cluster, which 
was associated with high body mass index (BMI). Second, I explored personality 
factors as possible mediators of the link between MDD and physical diseases. 
Neuroticism, as measured by the Eysenck Personality Questionnaire, was associated 
with an increased number of self-reported physical diseases in individuals with MDD. 
Among individual diseases, only asthma had a modest but significant association 
with MDD. However, we did not find a familial correlation between neuroticism and 
asthma, suggesting that the phenotypic association between neuroticism and asthma 
is unlikely to have a genetic component. Third, a new statistical tool was used to 
estimate the proportion of phenotypic variance of complex diseases/ traits that can be 
explained by common tag single nucleotide polymorphisms (SNPs), termed “SNP 
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heritability”. Analysis indicated that a substantial proportion of phenotype variance 
of both BMI and MDD was explained by common genetic variants. There was also 
suggestive evidence for a substantial genetic correlation between BMI and MDD, 
although the estimates had large standard errors. This imprecision almost certainly 
reflects the fact that, although the samples used here were large, even greater sample 
sizes are required for analyses of SNP heritability. Fourth, I used 32 SNPs identified 
from a published meta-analysis of genome-wide association studies (GWAS) on 
BMI to construct both weighted and un-weighted genetic risk scores (GRS) for BMI. 
Perhaps surprisingly, only 1.27% of the variance of BMI score was explained by the 
GRSs derived from these SNPs. Subsequent analyses showed that neither GRS alone, 
nor GRS combined with ‘traditional’ risk factors, can provide, in our present state of 
knowledge, a useful tool to discriminate the presence or absence of obesity in 
depressed people. Fifth, Mendelian randomization (MR) was used to attempt to 
disentangle the causal relationship between increased BMI and MDD. Although 
conventional regression analysis suggested a strong association between increased 
BMI and MDD, MR analysis failed to support the hypothesis that increased BMI is a 
causal factor in the development of MDD. Finally, I further explored the association 
between MDD and physical diseases by reviewing published genome wide 
association study (GWAS) data on MDD to examine whether identified risk loci for 
MDD overlapped with loci implicated in physical diseases. I then analysed our own 
GWAS data on depression to examine the presence of case/control differences at loci 
where there had been physical disease ‘hits’ in published studies. Analyses indicated 
that the SNP rs1342326, near the IL33 gene, which was genome-wide significant in a 
GWAS on asthma, was over-represented in individuals with MDD. However, MR 
analysis did not support a causal relationship between suffering from asthma and 
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having MDD. These results could suggest a single point of genetic overlap between 
asthma and MDD that might contribute to the observed phenotypic overlap between 
the two disorders, and highlight the need for further studies in larger samples.  
In summary, the analyses presented in this thesis show that the relationship between 
MDD and physical diseases/ obesity is complicated, but suggests that genetic factors 
play a role in the overlap between depression and BMI and, by implication, diseases 
associated with high BMI. Only one non-BMI associated disease, asthma, has an 
identifiable polymorphism that is also associated with depression and withstands 
correction for multiple testing. Further larger scale studies searching for disease 
associated variants are vital in order to understand the pathogenesis of the co-
occurrence between MDD and physical diseases/ obesity. These will include 
genome-wide and, eventually, deep sequencing studies of very large cohorts such as 







I am extremely grateful to my supervisors Professor Peter McGuffin, Dr Gerome 
Breen and Dr Oliver Davis for their expert guidance, encouragement and continued 
support during my PhD study. Without their support and patience, I do not think I 
could have completed my PhD study. I would like to thank Kaohsiung Chang Gung 
Memorial Hospital, Taiwan for providing me financial support to study in London. I 
also want to express my appreciation to all the members of the Depression 
Consortium Team at the Institute of Psychiatry, especially Professor Cathryn Lewis 
for her support and help. 
 
 In addition, I would like to thank my friends, Dr Margarita Rivera, Dr Sarah-Cohen 
Woods, Ms Celeste Cheung and Ms Elizabeth O’Nions for their support and 
friendship. It is really a wonderful experience to work with these excellent people at 
SGDP. Finally, I will say thanks to my wife who gave up her professional job in 
Taiwan and who, with our children, accompanied me to London to support me to 
fulfil my dream. Of course, I would like to give a big hug to my two lovely daughters 
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Before commencing my PhD, the phenotype and genotype data had already been 
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Chapter One  
Introduction 
 
1.1 The definition of major depressive disorder 
 
Major depressive disorder (MDD) is a serious public health problem and causes a 
huge burden on societies worldwide. The current diagnosis of major depressive 
disorder relies purely on clinical features, listed as the operational criteria in the 
Diagnostic and Statistical Manual of Mental Disorder (DSM-IV) (American 
Psychiatric Association, 2000), and the descriptive and operational criteria of the 
International Classification of Diseases, Tenth Revision (ICD-10) (Brämer, 1988). 
At present, no reliable laboratory tests for MDD are available. The diagnosis of 
major depressive disorder requires several symptoms (Table 1-1) persisting for at 
least a two-week period. Although the current diagnostic criteria show good 
reliability for diagnosis (evident in high inter-rater agreement), major depressive 
disorder may not be a single disease, but rather a heterogeneous disorder with 
somewhat different clinical manifestations, disease course, and treatment 





Table 1.1 DSM-IV-TR Criteria for Major Depressive Episode  
 
Major depressive episode criterion: 
A. At least five of the following symptoms have been present during the same 2-week 
period and represent a change from previous functioning: at least one of the 
symptoms is either 1) depressed mood or 2) loss of interest or pleasure. 
1. Depressed mood most of the day, nearly every day, as indicated either by 
subjective report (e.g., feels sad and empty) or observation made by others 
(e.g., appears tearful) 
2. Markedly diminished interest or pleasure in all, or almost all, activities most 
of the day, nearly every day (as indicated either by subjective account or 
observation made by others) 
3. Significant weight loss when not dieting or weight gain (e.g., change of 
more than 5% of body weight in a month), or decrease or increase in 
appetite nearly every day 
4. Insomnia or hypersomnia nearly every day 
5. Psychomotor agitation or retardation nearly every day (observable by others, 
no merely subjectively feelings of restlessness or being slowed down) 
6. Fatigue or loss of energy nearly every day  
7. Feelings of worthlessness or inappropriate guilty (which may be delusional) 
nearly every day (not merely self-reproach or guilt about being sick) 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every 
day (either by subjective account or as observed by others) 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal 
ideation without a specific plan, or a suicide attempt or specific plan for 
committing suicide 
B. The symptoms do not meet criteria for a mixed episode. 
C. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning. 
D. The symptoms are not due to the direct physiological effects of a substance (e.g. a 
drug of abuse, a medication) or a general medical condition (e.g. hypothyroidism). 
E. The symptoms are not better accounted for by bereavement, i.e., after the loss of a 
loved one, the symptoms persist for longer than 2 months or are characterized by 
marked functional impairment, morbid preoccupation with worthlessness, suicidal 





1.2 Heterogeneity of major depressive disorder 
 
Although the DSM includes variations on the theme of major depression such as 
melancholia and depression with a seasonal pattern (‘seasonal affective 
disorder’), DSM IV, and its recent successor DSM 5 essentially take a ‘lumper’ 
approach, considering depression to be a single entity. A highly influential 
advocate of ‘lumping’ was the Maudsley Hospital’s Aubrey Lewis (cited in 
Kendell, 1977) who proposed that differences between presentations of 
depression are a matter of degree, rather than of kind. In other words, depression 
is one ‘thing’, with quantitative differences in severity, rather than qualitative 
differences in symptoms or aetiology. However the idea that depression is not 
one disorder but several, perhaps many different conditions has subsequently 
been much debated. The clinical observation that depression is very common but 
also very varied in its presentation has led many to be ‘splitters’, believing that 
heterogeneity is inherently likely. As Kendell (1977) has pointed out, the biggest 
flaw in the ‘single entity’ proposition is that depression is often secondary to 
other disorders.  Perhaps the most explicit form of ‘splitting’ based on this 
phenomenon is the classification system proposed by the Washington 
University, St Louis school (reviewed by Guze, 1990) in which there are two 
main categories, primary and secondary depression. Secondary depression is 
considered to be a broad category that includes any depressive syndrome 
following major physical illness, other major psychiatric disorders such as 
schizophrenia, or depression that occurs only during periods of alcohol or other 
substance abuse. Another important and common category of depression that 
might be considered as ‘secondary’ is that following a viral illness such as 
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glandular fever (White et al., 1998). Here, the prominent feature is often fatigue, 
which may become chronic, and a substantial proportion of patients fulfil 
diagnostic criteria for depression.  
Another important historical distinction discussed by Kendell (1975) is that of 
endogenous versus non-endogenous (also called reactive or ‘neurotic’) 
depression. Although still viewed as important by many, the concept of 
endogenous depression was most topical during the 1960s and 70s following the 
work of Roth and the Newcastle group (cited in Kendell 1977) who used a then 
relatively novel statistical method, discriminant function analysis, to 
demonstrate the existence of two major categories based on symptom patterns 
corresponding to endogenous and neurotic/non endogenous depression. Kendell 
himself was subsequently unable to replicate the Newcastle group’s findings, 
failing to find what he called a ‘point of rarity’ between endogenous and non-
endogenous depression. Kendell (1977) thus concluded that endogenous and 
non-endogenous depression are best viewed as opposite ends of a dimension 
rather than being categorically distinct. The concept of endogenous depression 
as a somewhat distinct category never quite disappeared however, and it staged a 
revival in the United States (where it had previously been a less popular concept 
than in the UK or Europe) in the form of ‘melancholic depression’ in the 1980s 
and 90s. The concept of melancholic/endogenous depression was in part 
supported by the discovery that a proportion of depressed patients fail to show 
the normal pattern of suppression of blood cortisol levels after being given 
dexamethasone (Zimmerman et al., 1986). There is a tendency for such patients 
to show prominent biological symptoms such as early waking, diurnal variation 
of mood, appetite loss and diminished libido. Notably, the dexamethasone 
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suppression test (DST) does not appear to be a stable marker, in that in patients 
who have recurrent depression, the test is positive during some episodes of 
depression but not others (Coryell et al., 1990). Kendell’s (1977) classic review 
of what he called ‘contemporary confusion’ in the classification of depression 
was followed up nearly a decade and a half later by Farmer and McGuffin 
(1989) who suggested that the evidence, including an absence of stable trait 
markers, continued to support Kendell’s view that the apparent heterogeneity, at 
least within primary depression, was dimensional rather than categorical. They 
also considered their own work and that of others relating to adversity and 
familiality of patterns of symptomatology. Endogenous and neurotic patterns of 
depression appear not to ‘breed true’ in families, and furthermore the symptom 
pattern of depression following a threatening life event is as likely to be 
endogenous as reactive/neurotic. Farmer and McGuffin (1989) also concluded 
that a distinction between familial and non-familial depression is, as with other 
common diseases, likely to be unhelpful and misleading.  
Recent studies have continued to take a dimensional approach to studying 
heterogeneity in primary depression. One interesting example focused on the 
first waves of the DeCC and DeNT samples (Korszun et al., 2004). The authors 
examined clustering of symptomatology within a sample of depressed subjects 
using exploratory factor analysis, and identified four dimensions that were then 
supported by confirmatory factor analysis on a different subset of subjects. The 
factors consisted of (1) core depression plus psychomotor retardation, (2) 
anxiety, (3) agitation with guilt and suicidality, and (4) appetite 
gain/hypersomnia. Only the last of these did not show a significant correlation in 
sib-pairs, suggesting that manifestation of symptom clusters 1-3 may be under 
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genetic influence. More recently Kendler et al. (2013) applied multivariate 
genetic analysis in a very large twin sample, where the best model fit was 
obtained with three genetic (and four environmental) dimensions, which 
collectively contributed to symptomatology. The genetic dimensions showed 
some similarities to the familial dimensions of Korzsun et al (2004). In a 
different analysis of a subset of the data in the present thesis, the GENDEP 
sample, Uher et al. (2008) used confirmatory factor analysis to test whether 
depression as measured using three different rating scales to quantify severity 
can be described by a single dimension. Uher et al. found that a minimum of 3 
dimensions was needed to fit the data. Interestingly one of these dimensions 
resembled endogenous/ non endogenous depression, with higher score being 
associated with a good response to a tricyclic antidepressant, rather than a 
selective serotonin reuptake inhibitor.  
 
In summary the evidence to date suggests that, although there is clinical 
heterogeneity in symptomatology, course and treatment response in MDD, the 
observed differences are quantitative rather than qualitative. That is, with the 
probable exceptions of primary/secondary and the bipolar / unipolar depression 
distinctions that have withstood the test of time (Farmer and McGuffin 1989), 







Life time prevalence estimates for major depressive disorder depend crucially on 
the precise definition that is applied. In population surveys in the USA, the 
overall lifetime prevalence rates are approximately 12.7% in men and 21.3 % in 
women (Kessler et al., 1993). However incorporating indicators of severity, such 
as hospital treatment, reduces estimates of lifetime prevalence markedly to 
around 4% in men and 8% in women (McGuffin et al., 1996). Whatever the 
definition, females have almost two-fold higher risk of major depressive disorder 
compared to males. The mean age of onset for major depressive disorder is 
approximately 30 years, ranging between the ages of 20 and 50 in most cases 
(Kessler et al., 2005). Individuals with major depressive disorder tend to have a 
higher risk of other psychiatric co-morbidities such as anxiety disorder and 
substance misuse (Belmaker and Agam, 2008).  
 
1.4 Increased mortality in people with major depressive disorder 
 
It is now well established that major psychiatric disorders are associated with 
excess mortality (Laursen et al., 2007) and the causes can be divided into natural 
and unnatural. Unnatural causes of death include suicide, homicide and accident, 
whilst natural causes of death include cardiovascular diseases, malignancy 
neoplasms, endocrine and metabolic diseases, and other common chronic medical 
conditions. Both may contribute to higher mortality rates in depressed individuals. 
Although female patients with MDD have been reported to have a higher relative 
excess of mortality than males (Laursen et al., 2007) this is not supported by 
other studies (e.g., Joukamaa et al., 2001). The risk of excess mortality is higher 
in patients of all ages, with an even higher relative risk of mortality in young- and 
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middle-age patients (Cuijpers and Smit, 2002). Another striking finding is that 
even psychiatric healthy people have excess mortality if their first degree 
relatives have a history of psychiatric admission (Laursen et al., 2007). The 
results highlight the importance of co-morbidity of physical diseases in 
individuals with major depressive disorder and their near kin, which have yet 
been investigated thoroughly. 
 
The excess mortality due to natural causes can be attributed to both genetic and 
environmental factors. For example, depressed people may be more likely to live 
in a sedentary and unhealthy life style, fail to exercise and use tobacco or alcohol 
(Leas and McCabe, 2007). In addition, those with a history of   depression have 
higher rates of overweightness and obesity  than healthy controls, leading to a 
higher risk of various chronic physical diseases (Katon, 2003, Farmer et al., 
2008). The excess of natural deaths in depressed individuals and their psychiatric 
healthy relatives may also be due to genetic factors that contribute to both major 
depressive disorder and physical diseases (or obesity). If there is genetic 
correlation between liability to develop major depression and chronic medical 
diseases or obesity, it might explain why depressed individuals have an excess of 
natural deaths.  
 
1.5 Physical diseases and major depression  
 
Depression has been found to exert adverse effects on outcome of several 
physical illnesses, including cardiovascular diseases (Lichtman et al., 2008), 
cancer (Reich, 2008), and chronic pain related illness (Gatchel et al., 2007). 
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Although a number of studies have examined the prevalence rates of depression 
among people with chronic physical illness, fewer studies have investigated the 
reverse process, i.e. the prevalence rate of physical illness in depressed patients. 
These studies consistently report higher rates of physical illness in depressed 
patients.  
 
One large population cross-sectional study (Ortega et al., 2006) found that 
depression was positively associated with a history of asthma, but not with other 
physical illness. A meta-analysis (Van der Kooy et al., 2007) showed that 
clinically diagnosed major depression exerts a high risk for the development of 
cardiovascular disease, equalling the burden of risk associated with smoking or 
diabetes. Another study (Carroll et al., 2010) suggested that depression was 
significantly associated with an increased risk of hypertension in male Vietnam 
veterans, although the comorbidity of generalized anxiety disorder (GAD) and 
major depression conferred a greater risk. Using the same dataset, Phillips et al., 
(2009) found that both GAD and its comorbidity with major depression predict 
both all-cause and cardiovascular disease mortality. A recent study (Gili et al., 
2011) also compared prevalence of medical conditions in patients with recurrent 
depression and those with first episode depression. Even after controlling for 
possible confounding factors, all physical illnesses except myocardial infraction, 
psoriasis and migraine were significantly more prevalent in patients with 
recurrent depressive episodes compared to those with a single depressive episode. 
 
Longitudinal studies have also addressed the question of whether depression 
predicts physical illness. Two reviews (Rugulies, 2002, Wulsin and Singal, 2003) 
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suggested that the relative risk for the onset of coronary heart disease was 1.64 
for depressed patients compared to non-depressed people over a 10 year follow-
up period. Another study reported that depressed patients had an almost two-
thirds higher incidence of physical illness during a10-year follow-up period, 
compared to non-depressed people (Holahan et al., 2010). This prospective 
association between depression and subsequent physical illness was observed for 
both serious and less serious physical illnesses.  Similar effects of were reported 
in another study (Patten et al., 2008), in which higher rates of several physical 
illnesses, including heart disease, hypertension, asthma, arthritis and migraine 
were reported in depressed patients. 
 
Several lines of evidence suggest that high body mass index (BMI) and obesity 
could mediate the relationship between depression and physical illnesses. 
Recently, secondary analysis of a large case–control sample provided evidence 
suggesting that depression is a risk factor for a broad range of physical illnesses, 
some of which are also related to high BMI (Farmer et al., 2008). The study 
found that depressed patients had significantly higher rates of a total of 14 
physical illness compared to healthy controls. Depressed patients were also more 
likely to be overtly obese than healthy controls (24% v. 10%).  In a regression 
model controlling for age, BMI, and using correction for multiple testing, the 
associations between depression and myocardial infarction or 
hypercholesterolaemia were no longer significant. However, even after these 
adjustments, depressed patients had higher rates of certain illnesses (gastric ulcer, 




Several disease patterns of major depression have been shown to impact the 
association between depression and physical illness, and appear to be related to 
high BMI. One study (Lamers et al., 2010) used latent class analysis to identify 
subgroups of patients with depression using symptoms as well as demographic 
and physical health features. The findings indicated that patients with severe 
atypical features of depression had more somatic symptoms (e.g. more 
‘metabolic syndrome’, reflecting high BMI and high risk for  type II diabetes, 
coronary heart disease and hypertension), compared to those with a more 
moderate severity of illness, or those with a severe melancholic sub-type. This 
finding suggests that metabolic abnormalities play a more prominent role in those 
with a severe atypical depression subtype. Since there is evidence to suggest that 
the relationship between physical and depressive illnesses may, at least in part, be 
related to high BMI/ obesity, the following section will examine the relationship 
between depression and obesity. 
 
1.6 Definition and epidemiology of obesity 
 
Obesity is defined as abnormal or excessive fat accumulation that may impair 
health (World Health Organization, 1997). The body mass index (BMI) is a 
simple measure of body fat based on an individual’s height and weight. It is 
defined as an individual’s weight in kilograms divided by the square of their 
height in meters (kg/m2). Adults with a BMI between 18.5 and 25 are considered 
normal weight and people with a BMI between 25 and 30 are overweight, whilst 
individuals with a BMI equal to 30 or above are obese. Although BMI is an easy 
to use method to determine body fat, it may over- or under-estimate body fat in 
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certain populations, such as athletes (Ode et al., 2007). In addition, it does not 
distinguish whether the body fat comes from intra-abdominal fat or subcutaneous 
fat. 
 
Obesity is a serious public health problem because, as already mentioned, it is an 
important risk factor for various physical conditions such as hypertension, type 2 
diabetes mellitus, hyperlipidemia, and cardiovascular diseases, which are leading 
causes of natural deaths in developed countries (Danaei et al., 2009, Willett et al., 
2013). The prevalence rate of obesity in the UK rose from 6-8% in 1980, to 23-
25% in 2002, with the largest increase in the prevalence of obesity in the younger 
age group (Rennie and Jebb, 2005). A recent study based on the past trend of 
obesity in the UK forecasts a further increase its prevalence rate to 41-48% in 
men, and 35-43% in women, by 2030 (Wang et al., 2011). Obesity is more 
common in individuals with low educational attainment and low socio-economic 
status. 
 
1.7 The relationship between depression and obesity  
 
Although some studies (Farmer et al., 2008, Simon et al., 2006) have suggested 
patients with major depressive disorder are likely to be obese or overweight, 
other studies (Papakostas et al., 2005, Patten et al., 2009) have not found 
evidence for this association.  A recent meta-analysis (Luppino et al., 2010) 
found that major depression had only a modest effect on the risk of obesity 
(OR=1.58). Another study (Blaine, 2008) suggested that depressed patients are 
more likely to become obese at follow-up than non-depressed people, especially 
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in female adolescents. Depression and obesity may share common pathways or 
interact with each other, leading to health complications such as cardiovascular 
diseases and diabetes (Chapman et al., 2005). The following sections will 
examine evidence for whether depression predicts obesity, and obesity predicts 
depression. Factors that may be involved in the relationship between depression 
and obesity, including demographic, psychosocial and physiological factors, are 
then considered.  
 
1.7.1 The effects of depression on obesity  
 
In addition to the cross sectional findings reviewed above, longitudinal 
studies have found evidence to suggest that depressive illness predicts 
subsequent obesity. A diagnosis of major depression (but not depressive 
symptoms alone) in adolescents predicts a greater body mass index (BMI) in 
adult life compared to those who are not depressed (Pine et al., 2001). 
Another study (Hasler et al., 2005) also suggested that depression severity 
showed a dose-response-type relationship with the magnitude of body weight 
variability. This association was independent of antidepressant use, smoking, 
physical activity and demographic variables. A recent meta-analysis (Luppino 
et al., 2010) found that baseline depression (either symptoms or disorder) did 
not predict being overweight, but did increase the risk of obesity over time. 
 
1.7.2 The effects of obesity on depression 
 
In addition to studies showing that depression predicts subsequent obesity, a 
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number of studies suggest that obesity may predict subsequent depression. A 
longitudinal study (Kasen et al., 2008) suggested that young female adults 
with baseline BMI≧30kg/m2 were at a significantly increased risk for 
subsequent major depression and generalized anxiety disorder. A meta-
analysis (Atlantis and Baker, 2008) found that there was a weak level of 
evidence to suggest that obesity increases the odds of future depression. Ma 
and Xiao (2010), however, argued that the association between obesity and 
depression in females is dose-dependent. Several studies (Ma and Xiao, 2010, 
Dong et al., 2004) also suggested that not only obesity but also chronic 
medical conditions, race, marital status, age, income and having fewer years 
of education contribute to depressive symptoms among obese women.  
 
Gender differences may also play a role in moderating the relationship 
between obesity and depression. For example, in one report, obesity in 
females was associated with a 37% increase in major depression, whereas 
obesity in males was associated with a 37% decrease in major depression 
(Carpenter et al., 2000). Another study (Goldney et al., 2009) also reported 
that obese men were less likely to have major depression compared to those 
of normal weight. This may suggest that factors linking obesity and 
depression are gender specific and involve different mechanisms. However, 
another study (Simon et al., 2006) suggested that obesity is associated with an 
increased risk of mood disorders in both genders. Dong et al., (2004) found 
that only extremely obesity (BMI≧40kg/m2) was associated with increased 
risk of depression across both genders. Having examined evidence for the 
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relationship between depression and obesity, factors underpinning this 
association are now considered. 
 
1.8 Psychological and social links between obesity and depression 
 
Socio-demographic and psychosocial factors may  influence the relationship 
between major depressive disorder and obesity. Previous studies (Everson et al., 
2002; Gavin et al., 2010) have suggested that socioeconomic status, education 
and gender may contribute to the co-occurrence of these two disorders. For 
example, female gender and low level of education have been reported to make 
people with higher BMI more vulnerable to becoming depressed (Gavin et al., 
2010), although not all studies have reached the same conclusion (Everson et al., 
2002). Obesity and body image dissatisfaction were associated with depression in 
people with lower levels of education (<16 years) (Gavin et al., 2010). Whilst 
low socioeconomic status has been linked to obesity and depression in some 
studies, one study (Beydoun & Wang, 2010) suggested that socioeconomic status 
was only inversely associated with body mass index in women through lower 
food insecurity and reduced physical activity which account for 79% of 
association between major depression and body mass index. 
 
Several mechanisms, including behavioural, cognitive and psychosocial 
mechanisms, have been proposed to explain the higher risk of depression in obese 
people. Two pathways based on possible moderation of the link between obesity 
and depression have been suggested (Markowitz et al., 2008). First, a “health 
concern” pathway may lead individuals with morbid obesity to experience 
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depression because of functional impairment and poor self-rated health. Obese 
people have more physical disabilities, resulting in impaired physical activity, 
which is associated with the development of depressive symptoms (Ferraro et al., 
2002). Poor self-rated health may affect the development of depression via 
distorted cognitions, in which people who regard themselves as unhealthy also 
have more depressogenic beliefs. Second, an “appearance pathway” may lead 
individuals to become depressed due to body image distortion and dieting. Obese 
individuals are more likely to be discriminated by other people, leading to lower 
self-esteem and increased negative affect (Kessler et al., 1999). Such 
discriminatory experiences may contribute to higher level of depression in obese 
people. In addition, obesity is associated with body image dissatisfaction. Body 
image dissatisfaction is further associated with depression. Several studies have 
shown that body image dissatisfaction mediates the relationship between obesity 
and depression (Friedman et al., 2002; Gavin et al., 2010). Repeated dieting may 
cause individuals to feel like failures because they are unable to successfully shed 
body weight, resulting in depression. 
 
Childhood maltreatment has also been associated with both major depression and 
obesity, and may play a role in some cases. Both childhood sexual and physical 
abuse are associated with both depression and obesity in women during middle 
age, although obesity and depression may be independent outcomes of childhood 
abuse (i.e. reflecting separate pathophysiological pathways) (Rohde et al., 2008). 
Another study suggested that childhood neglect but not corporal punishment or 
psychological aggression is associated with obesity and depression in children 
16 
 
(Whitaker et al., 2007).    
 
1.9 The physiological mechanism linking depression and obesity/ 
physical illness 
 
Depressed patients are more likely than non-depressed people to experience 
chronic stress. A proposed physiological mechanism that could mediate the 
relationship between depression and obesity is via activation of the 
hypothalamic-pituitary-adrenal (HPA) axis (de Bellis et al., 1993). Elevated 
cortisol levels, associated with HPA axis dysfunction, have been found in major 
depressive disorder, especially the melancholic subtype (Gold and Chrousos, 
2002). Elevated cortisol levels are also common in obese people. It has been 
suggested that such elevation is mediated by acute and chronic stress (Seckl and 
Meaney, 2004). Heightened levels of cortisol have shown to contribute to weight 
gain, with a particular impact on increased visceral adiposity (Pasquali et al., 
2002). Numerous studies have demonstrated that visceral fat (intra-abdominal fat) 
is associated with components of ‘metabolic syndrome’ including type 2 diabetes 
mellitus, hypertension and hyperlipidaemia. 
 
An additional physiological link between depression and physical illness is 
inflammation. Production of high levels of pro-inflammatory cytokines such as 
tumour necrosis factor-α (TNF- α), interleukin-1 (IL-1), IL-6 and interferon—γ 
has been linked with both depression (Kenis and Maes, 2002) and obesity (Miller 
et al., 2002). It has also been proposed that cytokine production by systemic 
inflammation acts on the brain to cause depression-like manifestations (Dantzer 
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et al., 2008). For example, a substantial proportion of patients with hepatitis C 
receiving interferon treatment develop depression (Asnis and De La Garza, 2006) 
and major depression is more prevalent in patients with cardiovascular disease, 
which may in turn be related to chronic inflammation (Lichtman et al., 2008). 
Depression has been suggested as a maladaptive version of cytokine induced 
sickness (Dantzer et al., 2008).  
 
High sensitivity C-reactive protein (hsCRP) has been proposed as a biological 
marker for acute and chronic inflammation. People who reported episodes of 
major depression within a year before measurement of CRP had increased plasma 
levels (Surtees et al., 2008). In addition, past-year major depression is a risk 
factor for subsequent ischemic heart disease. However, hsCRP levels did not 
account for the association between depression and heart disease. Another study 
(Kling et al., 2007) further suggested hsCRP and serum amyloid A (SAA) were 
elevated in remitted and un-medicated women with major depression. This 
finding suggests that sustained low grade inflammation persisted even after 
depression remitted, and that it might contribute to development of 
cardiovascular disease in later life. In addition, IL-6, a potent inducer of the 
hepatic acute phase response, might play a role in the development of coronary 
artery disease via metabolic, endothelial and coagulant mechanisms (Yudkin et 
al., 2000). Psychosocial stress can elevate plasma levels of IL-6 (Zhou et al., 
1993), which in turn stimulates the HPA axis, resulting in a tendency towards 
obesity and cardiovascular disease. 
 
Another physiological pathway that may contribute to the relationship between 
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depression and obesity is leptin, a peptide hormone, encoded by the obese (OB) 
gene. Leptin not only acts as an anti-obesity hormone, but can also influence 
emotion control and cognition (Lu, 2007). Epidemiological studies have reported 
high plasma levels of leptin in both depression and obesity, suggesting leptin 
resistance instead of leptin insufficiency in these two conditions (Pasco et al., 
2008, Stunkard et al., 2003). One possibility is that leptin resistance serves as a 
common pathophysiological pathway for the comorbidity of depression and 
obesity. Other possible physiological mechanisms linking depression and 
physical illness/ obesity include increased platelet adhesion (Walsh et al., 2002), 
higher plasma concentration of lipoprotein(a) (Emanuele et al., 2006), and altered 
autonomic function (Yeragani et al., 2002).  
 
Having reviewed evidence for factors at the psychological, behavioural and 
physiological levels that could mediate the relationship between depression and 
obesity/ physical illness, the following section considers the role of genetics in 
the aetiology of depression and obesity, and genetic overlap between depression 
and obesity/ physical illness.  
 
1.10 The genetics of major depressive disorder 
 
Family and twin studies have shown that genetic factors contribute to the 
development of major depressive disorder, with a mean heritability estimate of 
37%, but some with studies estimating heritability in excess of 70% (Sullivan et 
al., 2000). Higher heritability estimates for major depressive disorder are 
associated with ascertainment in clinical settings (McGuffin et al., 1996) or 
19 
 
incorporation of severity indices in the analysis (Kendler et al., 1993). Numerous 
candidate gene studies have been conducted to investigate the association 
between major depression and common genetic polymorphisms. These candidate 
genes have included serotonin related genes (e.g. 5-HTTLPR) and brain derived 
neurotropic factor gene (BDNF). However, the results of these studies have been 
inconsistent (Lasky‐Su et al., 2005, Lohmueller et al., 2003, Levinson, 2006). 
One of possible explanation is the lack of consideration of gene environment 
interaction in these studies. A seminal work by Caspi et al. (2003) has shown that 
the interaction between the short allele of 5HTTLPR and stressful life events 
predicts the development of major depressive disorder. Although one meta-
analysis failed to find evidence to support this relationship (Risch et al., 2009), a 
more recent meta-analysis using a broader range of studies (Karg et al., 2011) 
found strong evidence for a moderating role of 5-HTTLPR genotype on stress 
reactivity. As such, the gene-environment interaction may still play a significant 
role in major depressive disorder (Uher and McGuffin, 2010).  
 
Another genetic approach, genome-wide linkage study (Breen et al., 2011) has 
identified a locus at chromosome 3p25-26 associated with recurrent major 
depressive disorder, which has been replicated by independently (Pergadia et al., 
2011). However, fine mapping of variants identified in association studies  has so 
far not identified a specific gene contributing to major depressive disorder. 
Genome-wide association studies (GWAS) have also provided disappointing 
results. While genome-wide significant variants have been identified in 
individual studies (Lewis et al., 2010, Shyn et al., 2011) these have not replicated 
across studies, and a mega-analysis of GWAS of major depression by the 
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Psychiatric Genome-wide Consortium (PGC) including more than 25, 000 
patients with MDD failed to identify a risk variant reaching genome-wide 
significance (Major Depressive Disorder Working Group of the Psychiatric 
GWAS Consortium, 2012; Wray et al., 2012). This is a surprising result 
considering the twin evidence of moderate to substantial heritability of major 
depressive disorder.  
 
Possible explanations for the negative GWAS findings include the causal variants 
being rare, or not tagged in commercial kits; or there being a very high degree of 
polygenicity, potentially due to common variants of very small effect, which 
require very large sample sizes. Other explanations include over-estimation of 
heritability by the twin method, and imprecise classification of the phenotype.  
 
 It is therefore of interest that a new analysis tool called genome-wide complex 
trait analysis (GCTA) has been developed to estimate the proportion of 
phenotypic variance explained by genome- or chromosome-wide SNPs for 
complex traits (Yang et al., 2011a) without the necessary assumptions of the twin 
study method. A recent study (Lubke et al., 2012) using two methods to estimate 
the SNP-heritability found that 28-32% of phenotypic variance of major 
depression can be explained by common variants, which is consistent with 
previous twin studies. The GCTA approach in depression and body mass will be 
explored later in this thesis. 
 




Personality characteristics, in particular neuroticism, are thought to confer 
vulnerability to depression (e.g. Kendler et al., 1993). Personality 
characteristics have long been considered to have a partly genetic basis 
(Bouchard Jr and Loehlin, 2001). Twin studies suggest that there is 
substantial genetic influence on the ‘big five’ personality dimensions of 
open-mindedness, conscientiousness, extraversion, agreeableness and 
neuroticism (Jang et al., 1996), ranging from  41% and 61%. In addition, 
twin studies have also found that there is a substantial genetic overlap 
between neuroticism and depression, and to a lesser extent, between 
extraversion and depression (Kendler and Myers, 2010, Middeldorp et al., 
2005). Genome-wide linkage analysis (Nash et al., 2004) has indicated two 
suggestive but not genome-wide significant quantitative trait loci (QTL) in 
chromosome 1p and chromosome 6p which may confer risk for neuroticism. 
Genome-wide association studies (Terracciano et al., 2008, Shifman et al., 
2008) also failed to identify any locus reaching genome-wide significance 
for personality traits. The negative results may attributable to underpowered 
studies since it is likely that there are genetic variant of small effect on 
personality characteristics. A meta-analysis of GWAS on personality 
identified several SNPs responsible to various personality traits in discovery 
sample but failed to replicate in independent samples (de Moor et al., 2010). 
One recent study (Vinkhuyzen et al., 2012) using GCTA analysis suggested 
that 6% of the variance in neuroticism and 12% of extraversion can be 
explained by common variants. Compared to twin studies, “SNP heritability” 
provides relatively small estimates of heritability, partly because GCTA 
only takes common variants into account. Another study (Luciano et al., 
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2012) also suggested common genetic effect existed between neuroticism 
and mood disorder.  
 
1.12 The genetics of obesity 
 
Like neuroticism/ depression, obesity is a complex trait, which is influenced 
by both genetic and environmental factors. Family and twin studies have 
estimated the heritability of BMI between 40% and 80% (Stunkard et al., 
1986, Allison et al., 1996), and reported that the heritability tends to 
increase with age (Haworth et al., 2008). Numerous candidate gene studies 
have been conducted to identify the possible genes contributing to obesity. 
Associations have been reported with genes encoding leptin, serotonin 
receptor 2C (HTR2C) and dopamine receptor 2 (DRD2) genes (McCarthy et 
al., 2005, Thomas et al., 2000, Mizuta et al., 2008). However, most of 
candidate gene studies have yielded mixed results, probably due inadequate 
sample size and possibly confounded by population substructure. Genome-
wide association studies have uncovered more risk variants, including the 
fat mass and obesity-associated (FTO) gene, which was robustly associated 
with obesity (Frayling et al., 2007). This finding has been confirmed in 
following GWAS studies (Peng et al., 2011). A large meta-analysis 
including more than two hundred thousand individuals has subsequently 
identified 32 BMI related loci at genome-wide significance (Speliotes et al., 
2010). Although so many risk variants being identified, all of them together 
explain less than 5% of the variance in BMI. The results of GCTA analysis 
(Yang et al., 2011b) suggest that 16% of BMI variance is explained by 
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common genetic variants, suggesting that many of causal variants are just 
‘hiding but not missing’, with larger sample sizes needed to discover them. 
 
1.13 Genetic overlap between depression and obesity/ physical 
illness 
 
As reported above, family and twin studies have shown that genetic factors 
account for a substantial proportion of the variance of both BMI (Maes et al., 
1997) and depression (McGuffin et al., 1996). Although several factors may 
account for the relationship between obesity and depression, it is possible 
that a shared common heritable pathogenesis contributes to both medical 
conditions (McElroy et al., 2004). Comings et al. (1996) first reported that a 
dinucleotide repeat polymorphism, D7S1875 near the human obesity (OB) 
gene may contribute to risk for both depression and obesity. Furthermore, a 
significant association between the BMI and homozygosity for the OB1875 
< 208-bp alleles and/or the presence of the DRD2 Taq A1 allele was found 
across the whole sample, and in women in particular. For women alone 
these two genes accounted for up to 22.8% of the variance of in BMI. In 
addition, several candidate genes have been found to associate with both 
obesity and depression.  For example, a study in mice identified two 
polymorphisms in galanin gene (GAL), rs2513280 and rs2513281 which 
affect expression of GAL in the amygdala, which has been found to 
modulate intake of alcohol and fat, and affect mood, suggesting that 
differential expression of GAL related to common genotypes may confer 
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risk for the development of  obesity, alcoholism and major depression 
(Davidson et al., 2011).  
 
Another study (McCaffery et al., 2009) used a candidate gene approach to 
investigate the variants affecting depressive symptoms in coronary heart disease 
patients. The study suggested that a genetic variant relating to endothelial 
dysfunction predicts depressive symptoms, which might represent a biological 
pathway for depression in heart disease patients. Other potential candidate genes 
with effects on both depression and obesity/ heart disease include 5-HT2A gene 
(Rosmond et al., 2002), the serotonin transporter gene (5HTTLPR) (Nakatani et 
al., 2005, Sookoian et al., 2007) and the D2 dopamine receptor gene (DRD2) 
(Spitz et al., 2000). 
 
Recently, genome-wide association studies have revealed some new loci 
responsible for obesity and heart disease (Thorleifsson et al., 2008, Willer et al., 
2008). Many of these loci are the genes that are highly expressed in the brain, 
particularly in the hypothalamus, which is known to be associated with emotional 
control. One of these identified genes is brain derived neurotropic factor (BDNF) 
gene, which has been widely reported to play a role in depression and its 
treatment (Yulug et al., 2010).   
 
These studies provide preliminary evidence to support the hypothesis that some 
common genes contributing to risk for both depression and obesity/ or 
cardiovascular disease,. Further studies are needed to deliver a systematic search 







Major depressive disorder is associated with obesity, and various physical 
diseases, some of which are obesity related. Both major depressive disorder 
and obesity are prevalent in developed countries and cause a severe disease 
burden. Although there is a strong association between these two traits, the 
nature of the relationship  remains unclear. Several mechanisms (e.g. 
psychological, physiological) have been proposed to explain the association 
of  these two traits. In addition, evidence suggests that there may be 
overlapping mechanisms and aetiology between depression and other 
physical illnesses, such as those related to inflammation (e.g. cardio-
vascular disease, asthma). 
 
More research is needed taking a  genetic approach  to examine whether 
there is shared genetic risk for depression and obesity/ physical illness. This 
PhD project investigates the complex relationship between these traits.  
 
1.15 Research questions 
The principal issues that will be addressed in this thesis are as follows: 
 
1) Are physical diseases more prevalent in siblings as well as those with major 
depressive disorder themselves, and what is the physical disease pattern in 
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depressive families? (Chapter 3) 
 
2) Do personality traits influence the co-morbidity of physical diseases in 
individuals with major depression, and in particular, is there any familial 
correlation between asthma and neuroticism? (Chapter 4) 
 
3) What is the ‘SNP heritability’ of major depression and body mass index, 
estimated from a large case control study, and is there a genetic correlation 
between these two traits arising from common variants? (Chapter 5) 
 
4) To what extent can genetic risk score constructed by SNPs from a large meta-
analysis of GWAS of BMI be used to explain the variation of BMI and the 
prediction of obesity in individuals with major depressive disorder? (Chapter 
6) 
 
5) Can Mendelian randomization analysis using instrumental variables 
disentangle the causal relationship between increased BMI and major 











2. 1 Study population 
 
Throughout this thesis, individuals with major depressive disorder were mainly from 
RADIANT, an umbrella term for three studies comprising the Depression Network 
(DeNT) study, the Depression Case-Control (DeCC) study and the Genome-Based 
Therapeutic Drugs for Depression (GENDEP) study. In addition, data from the 
Munich depression case control study (which had a very similar in design to DeCC) 
were used in some analyses. Each study design and inclusion/ exclusion criteria are 
described as follows and a summary of the design and demographic data for each 
study is shown in Table 2.1. 
 
2.1.1 Depression Network Study (DeNT) 
 
The DeNT study is a multisite sib-pair genetic linkage study designed to identify 
genetic loci linked to and/ or associated with susceptibility to recurrent unipolar 





Subjects over the age of 18 were identified from various sources including 
psychiatric clinics, hospitals, general medical practices and from volunteers who 
responded to advertisements. Full siblings were recruited where two or more had 
experienced at least two episodes of major depression of at least moderate severity, 
separated by at least 2 months of remission. The psychiatric diagnoses were made 
according to the Diagnostic and Statistical Manual 4th edition operational criteria 
(DSM-IV) or International Classification of Diseases 10th edition operational criteria 
(ICD-10) for major depressive disorder. They were excluded if one of the siblings 
fulfilled the criteria of bipolar disorder, schizophrenia, intravenous drug dependence, 
substance induced mood disorders or experienced mood-incongruent psychotic 
features. Affected siblings were questioned about the lifetime occurrence of various 
physical health problems and psychiatric disorders. All subjects were white, of 
European origin, and recruited from eight different sites: Aarhus, Denmark; Bonn, 
Germany; Dublin, Ireland; Laussane, Switzerland; St. Louis, USA and Birmingham, 
Cardiff, and London, UK. Each participant provided written informed consent and 






The psychiatric interviews were carried out by graduate psychologists trained to use 
the Schedules for the Clinical Assessment of Neuropsychiatry (SCAN) (Wing et al., 
1990). Diagnoses using the operational criteria of DSM-IV or ICD-10 were 
generated by a computer-aided interview tool, iShell. The severity and duration of 
depressive symptoms were rated for the worst and second worst episodes. In order to 
assess the severity, subjects were asked to identify within each of these episodes of 
depression a 4-6 week period when they experienced the worst symptoms. All 
interviewers attended a 4-day SCAN training course and regular subsequent 
meetings to ensure good inter-rater reliability (the average kappa was coefficient 
0.77 (range 0.63-0.89)).  
 
Self-reported questionnaires and other information 
 
To assess the presence of medical diseases, all participants were given a short 
structured interview to ask whether they had ever been diagnosed or treated by their 
general practitioner for any of the following 16 physical illness: asthma, diabetes 
mellitus (type1 or type2), epilepsy, gastric ulcer, hypercholesterolemia, hypertension, 
kidney disease, liver disease, myocardial infarction, osteoarthritis, osteoporosis, 
rheumatoid arthritis, allergic rhinitis or hay fever, stroke or thyroid diseases. The 
selection of physical illness was based on a list of the most common non-
communicable, non-malignant diseases in developed countries (Beaglehole and Yach, 
2003). Self-reported diagnoses collected in this way have previously been shown to 
have good agreement with clinical records (Farmer et al., 2008). All participants 
completed the Eysenck Personality Questionnaires to assess the personality traits of 
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extraversion, neuroticism, and psychoticism. Body mass index (BMI) was calculated 
using self-reported height and weight. BMI was defined as weight in kilograms 
divided by height in meters squared (kg/m2).  
 
2.1.2 Depression Case control study (DeCC) 
 
The DeCC study is a UK based multi-centre case control study designed to identify 
genetic variants associated with recurrent major depressive disorder. 
 
Subjects 
Individuals with recurrent major depressive disorder were recruited from three 
clinical UK sites, namely London, Cardiff and Birmingham using the similar 
methods as the DeNT study to identify the participants from psychiatric clinics, 
hospitals, general medical practices and from volunteers responding to media 
advertisements. Individuals were recruited if they were over age of 18 and had 
experienced two or more major depressive episodes separated by at least 2 months of 
remission as defined by DSM-IV or ICD-10. The exclusion criteria were the same as 
for the DeNT study. The psychiatric diagnoses of participants were made by graduate 
psychologists trained in using SCAN interview, again, as in the DeNT study.  
 





GENDEP is a multi-centre partially randomized pharmacogenetic study aiming to 




Individuals with major depressive disorder were recruited from eight European 
countries, Belgium, Croatia, Denmark, Germany, Italy, Poland, Slovenia and the UK, 
via clinical referrals, or in response to advertisements. Participants were included if 
they had experienced at least one major depressive episode of at least moderate 
severity, according to the operational criteria of DSM-IV or ICD-10. The exclusion 
criteria were: a first-degree relative with bipolar disorder or schizophrenia, a history 
of manic or hypomanic episode, mood-incongruent psychotic symptoms, substance 
misuse, organic affective disorder, current treatment with an antipsychotic or a mood 
stabilizing medication, pregnancy or lactation. Individuals were also excluded if they 
had medical contra-indications or adverse reactions to both study medications, 
namely escitalopram and nortryptiline.  Trained psychologists or psychiatrists 
conducted the clinical interviews using the SCAN interview. In addition to clinical 
diagnoses, age, sex, self-reported BMI, and measured BMI, which was highly 
correlated with self-reported BMI, were collected. 
 




Munich depression Case Control study was conducted using the same study design 




Individuals with recurrent major depressive disorder were recruited at the Max-
Planck Institute of Psychiatry in Munich, Germany. Some participants were also 
recruited from two satellite recruiting hospitals in the Munich area. Experienced 
research assistants made research diagnoses for psychiatric disorders using the 
SCAN. Individuals were recruited if they fulfilled the operational criteria for 
recurrent major depressive disorder of moderate or severe intensity according to 
DSM-IV or ICD-10. Individuals were excluded if they received the diagnosis of 
schizophrenia, schizoaffective disorder, bipolar I disorder or any other Axis I 
diagnosis, except anxiety disorders. Individuals were also  excluded if they had 
experienced mood incongruent psychotic symptoms, a lifetime history of intravenous 
substance misuse or substance dependence, or depression secondary to medical 
illnesses or substance/ medication use. 
 
Controls were randomly recruited from a Munich-based community survey. They 
were screened for the presence of depression or anxiety disorders using the 
Composite International Diagnostic Screener. Individuals who had no depression or 




The following variables were used in our analyses: age, sex, self-reported BMI and 
clinical diagnoses. 
 
2.1.5 PsyCoLaus Study 
 
A total of 2,993 participants (1,296 cases and 1,697 controls) were recruited from a 
psychiatric portion (PsyCoLaus) of a community survey (CoLaus) carried out in 
Lausanne, Switzerland. A DSM-IV diagnosis of major depressive disorder (MDD) 
was ascertained using the Diagnostic Interview for Genetics Studies (DIGS) 
(Nurnberger et al., 1994). Individuals were included as control subjects if they had 
never fulfilled criteria for MDD. The PsyCoLaus study has been described in more 
detail elsewhere (Preisig et al., 2009).  In brief, the PsyCoLaus study included a 
semi-structured diagnostic interview and numerous self-rated instruments that 
evaluated personality traits, attitudes, functioning and sleep patterns. Weight and 
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Variables used in analyses 
 
  
  Age         
  Sex         
  BMI         
  Genotype         
  Physical   
diseases  X X X X X X X 
  EPQ  X X X X X X X 
 
DENT: Depression network study;  DeCC: Depression Case control study 
GENDEP: The Genome-Based Therapeutic Drugs for Depression study 
GSK-Munich: GSK Munich depression case control study 
BMI: body mass index; EPQ: Eysenck Personality Questionnaire 
SCAN: Schedules for Clinical Assessment in Neuropsychiatry 
PHS: Past History Schedule; CIDS: Composite International Diagnostic Screener 
DIGS: diagnostic interview for genetic studies; MDE: Major depressive episode  
35 
 
2.2 Genotyping and Quality control  
 
All the participants were genotyped using the Illumina HumanHap610-Quad 
BeadChips (Illuminia, Inc., San Diego, CA, USA) produced by the Centre National 
de Genotypage (CNG), Evry, France. All barcoded DNA samples were processed 
under full Laboratory Information Management System (LIMS) controls, which 
ensured stringent quality control. 
 
Individuals were excluded if their >1% of their genotype data was missing, if there 
was conflicting information regarding genotypic sex assignment and phenotypic 
data, if they appeared to be related (up to second degree) to other participants, or if 
they were of non-European ancestry. SNPs with minor allele frequency <1% or 
showing departure from Hardy-Weinberg equilibrium (p<1*10-5) were excluded from 
the analyses. Principal component analysis was carried out using EIGENSTRAT 
after quality control processes were applied. 
 
2.3 Statistical analyses  
 
Analyses conducted for each chapter are outlined below.  
 
Chapter 3 Prevalence and family aggregation of physical diseases  
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in families with recurrent depression 
  
The analyses for Chapter three used data from the DENT study only. The lifetime 
prevalence of each medical diseases was compared between cases and controls using 
mixed-effect logistic regression, controlling for family membership (that is, 
controlling for the clustered nature of the case data for subjects from the DeNT 
dataset). Since obesity has been shown to contribute to several medical diseases, we 
grouped the participants into three categories according to BMI: normal (BMI under 
25 kg/m2), overweight (BMI between 25 kg/m2 and 30kg/m2) and obese (BMI 
30kg/m2 or over). The BMI categories together with age and sex were also entered 
into our logistic regression as co-factors. Tetrachoric correlations were used to 
calculate within-family intra-trait correlation and within-individual cross-trait 
correlation. Principal components analysis was used to examine the extent to which 
the 16 disorders tended to co-occur. Principal components analysis with oblique 
rotation revealed the presence of six components with eigenvalues exceeding 1. All 
analyses were carried out using STATA, version 12. Statistical significance was 
defined as p<0.05 and Bonferroni correction was applied. Bonferroni correction 
should be considered as a conservative method for correcting multiple testing and 
may incur several problems such as (1) irrelevant null hypothesis, (2) inference 
defies common sense and (3) increase in type II error (Perneger, 1998). The 
interpretation should be cautious as it may represent a flout measure of the strength 




Chapter 4 Neuroticism is associated with asthma and total number 
of physical disease but no familial correlation exists between 
neuroticism and asthma 
 
Analyses for Chapter four used data from the DeNT study. The analyses tested 
whether there were any differences in personality trait scores between the siblings of 
individuals with recurrent depression and healthy control subjects. Regression 
analyses were conducted with the following predictor variables: neuroticism, 
psychoticism, extraversion, age, gender, body mass index and depression status. For 
simplicity in the analysis, I treated each physical disease (event) as independent 
although in practice, as I have shown in chapter 3 some physical diseases tend to 
cluster together. The following outcome variables related to the presence of physical 
illnesses were used: (1) total number of physical illnesses (poisson regression); (2) 
any physical illness (logistic regression); (3) a specific physical illness (logistic 
regression). The cluster command was used to group the data by family to take into 
account the non-independence of the DeNT sibling pairs. All analyses were carried 
out using STATA, version 12. Statistical significance was defined as p<0.05, and 
Bonferroni correction was applied. .  
 
For those diseases that remained associated with personality traits after taking into 
account possible confounding variables, analyses were conducted to investigate 
whether these diseases and personality traits shared familial affects. This was based 
on sib-pair modelling derived from the twin modelling approach implemented in the 
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package Mx (Neale et al., 2006). Typically, twin modelling compares the similarity 
of monozygotic and dizygotic twins to estimate additive genetic effects (A), shared 
environmental effects (C) and specific environmental effects (E) (also often referred 
to as residual effects, since non-shared environment and measurement error are 
indistinguishable). Familial modelling is a more restricted form of modelling using 
sib-pair data to estimate the familial influence (F), which combines A and C. It is 
impossible to calculate the influence of A and C separately, because sib-pair data are 
like dizygotic twin data, where siblings reared together share on average 50% of their 
alleles, but 100% of their shared environmental factors. The Cholesky decomposition 
can describe the extent to which traits share common ‘F’ influence. As the method 
requires ordinal data for the analysis, 95% confidence intervals cannot be estimated. 
The statistical significance was determined by dropping each parameter in turn, and 
comparing the chi-square of the reduced model to that of the full model, with degrees 
of freedom calculated as the difference in the number of parameters between the full 
and reduced models and taking an alpha level of p<0.05 . As noted, the analyses 
were conducted using structural equation modeling in Mx (Neale et al., 2006). To 
account the selected nature of the subjects, the selection variable (disease status) was 
included in all models, with prevalence and familiality parameters fixed (Wood et al., 
2011). Since the Mx program cannot include both dichotomous and continuous data 
in the same analysis, the age- and sex-regressed residuals of neuroticism score was 
ordinalised into five equal-sized categories. Ordinal data analysis was used to reflect 
the underlying normal distribution of traits, with one or more thresholds per liability 




Chapter 5 Estimation of the genetic correlation between major 
depressive disorder and body mass index using common genetic 
variants 
 
Analyses for Chapter five used data from the RADIANT study and GSK-Munich 
study. Genomewide complex trait analysis (GCTA) (Yang et al., 2011) was used to 
estimate the genetic relationship matrix (GRM) between individuals, and assess 
pairwise genomic similarity. Individuals whose relationship to another subject in the 
dataset was greater than 2.5% (equal to a fourth cousin) were removed to avoid the 
possible phenotypic similarity between close relatives being due to non-genetic (i.e. 
shared environmental) effects. The GRM was fitted in a mixed linear model to 
estimate the proportion of phenotypic variance for BMI and MDD explained by all 
the autosomal SNPs. For the univariate analysis used to examine which SNPs 
contribute to variance on BMI or MDD, the variance of a trait or disorder was 
partitioned into the additive genetic effects of all measured SNPs, and a residual 
component using a residual maximum likelihood estimation method. For bivariate 
analysis used to examine which SNPs contribute to variance on both BMI and MDD, 
the genetic covariance and genetic correlation between the two traits or diseases was 
estimated, to measure genome-wide pleiotropy (Lee et al., 2012a). Five principal 
components were used to control for population stratification, and age and sex were 
included as covariates. The test statistic for the bivariate analysis was obtained by 
dividing the square of the estimated genetic correlation coefficient by its sampling 
variance. The p-value was calculated assuming that the test statistic was distributed 
as a chi-square, with 1 degree of freedom. 
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 Chapter 6 A genetic risk score combining 32 SNPs is associated with 
body mass index and improves obesity prediction in people with 
major depressive disorder 
 
Analyses for Chapter six used data from the RADIANT study, GSK-Munich study 
and PsyCoLaus study.  
 
Selection of SNPs 
SNP ‘risk’ alleles associated with increased BMI identified in previous studies were 
used to construct a 32-SNP additive genetic risk score (GRS) using the approach 
reported by Speliotes et al. (2010) and Belsky et al. (2012). Of the 32 GRS SNPs, 14 
were extracted from GWAS data after applying the quality control measures 
described above, and another 13 were extracted using proxy SNPs. In addition, 5 
SNPs, namely rs11847697, rs11083779, rs11165643, rs7640855, rs1475219 were 
imputed from 1000 Genomes data. The quality of imputation for these SNPs was 
checked, and was >.8 for all . The call rate for the SNPs was > 96%, with the 
exception of rs1475219, for which it was approximately 91%. The detailed 
information for the 32 SNPs was shown in Table 6.1. 
 




To evaluate the cumulative effects of these 32 SNPs on BMI, an additive model was 
used to construct both un-weighted and weighted genetic risk scores. The un-
weighted GRS (uGRS) was calculated by summation of the number of risk alleles 
across the 32 variants (Table 2.2). The weighted GRS (wGRS) was calculated by 
multiplying the number of risk alleles at each locus (0, 1, 2) by the corresponding 
effect sizes, in kg/m2 per allele, as reported by Speliotes et al. (2010), and then 
summing the products. In order to reduce bias, only the participants without any 




Table 2.2. Single Nucleotide Polymorphisms Included in the Genetic Risk Score in 
RADIANT study 











1 NEGR1 rs2568958 A/G A 62.5% 0.13 99.95% 
TNNI3K rs1514175 A/G A 42.3% 0.07 99.86% 
PTBP2 rs11165643 C/T T 58.8% 0.06 99.07% 
SEC16B rs10913469 C/T C 19.2% 0.22 100% 
2 TMEM18 rs2867125 C/T C 82.9% 0.31 99.98% 
ADCY3,RBJ rs10182181 A/G G 46.9% 0.14 99.40% 
FANCL rs759250 A/G A 28.4% 0.1 100% 
LRP1B rs6714473 C/T T 9.7% 0.09 99.85% 
3 CADM2 rs7640855 A/G A 19.0% 0.1 96.83% 
ETV5 rs7647305 C/T C 79.0% 0.14 99.93% 
4 GNPDA2 rs12641981 C/T T 44.1% 0.18 100% 
SLC39A8 rs13107325 C/T T 7.5% 0.19 99.91% 
5 FLJ35779 rs253414 C/T T 66.4% 0.1 99.93% 
ZNF608 rs6864049 A/G A 47.2% 0.07 100% 
6 TFAP2B rs987237 A/G A 18.2% 0.13 100% 
NUDT3 rs206936 A/G G 18.0% 0.06 95.99% 
9 LRRN6C rs2183825 C/T C 32.9% 0.11 99.98% 
11 STK33, 
RPL27A rs10840065 A/G A 51.6% 0.06 100% 
BDNF rs6265 C/T C 79.8% 0.19 100% 
MTCH2 rs10838738 A/G G 34.5% 0.06 100% 
12 BCDIN3, 
FAIM2 rs7138803 A/G A 37.5% 0.12 100% 
13 MTIF3 rs1475219 C/T C 20.4% 0.09 90.61% 
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14 PRKD1 rs11847697 C/T T 3.6% 0.17 96.87% 
NRXN3 rs10146997 A/G G 21.9% 0.13 100% 
15 MAP2K5 rs2241423 A/G G 77.2% 0.13 99.96% 
16 GPRC5B rs12446632 A/G G 86.1% 0.17 99.93% 
SH2B1 rs4788102 A/G A 39.0% 0.15 100% 
FTO rs3751812 G/T T 41.0% 0.39 100% 
18 MC4R rs921971 C/T C 26.6% 0.23 99.98% 
19 KCTD15 rs29941 A/G G 68.3% 0.06 100% 
ZC3H4, 
TMEM160 rs2303108 C/T C 71.4% 0.09 100% 
QPCTL rs11083779 C/T T 95.8% 0.15 98.28% 
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Regression and ROC models 
A linear regression model was calculated to predict BMI. Predictor variables 
included the ‘known’ risk factors for depression (as found in Chapter 3) and 
‘traditional’ risk factors (age, sex and principal components of ancestry), as well as 
the GRS. Since the BMI data did not follow a normal distribution, natural log-
transformed BMI was used for the analyses. Logistic regression, adjusted by age, sex, 
depression status and ancestry, was used to predict the probability of obesity with 
each model. Receiver-operating characteristic (ROC) curve analysis was conducted 
to calculate the area under the curve (AUC), to evaluate how well the model could 
discriminate between obesity and non-obesity.  First, the difference between AUCs 
for models incorporating traditional risk factors (age, sex and ancestry) with and 
without GRS was compared. Subsequently, models comprising wGRS only, and 
models incorporating other risk factors (e.g. age, sex) were compared. To control for 
the possible presence of population stratification, all analyses were adjusted for the 
first five principal components of ancestry, which were calculated with EIGENSOFT 
(Price et al., 2006). All data were analysed using STATA version 12.1 (STATA Corp, 
Texas). Two-tailed values of p<0.05 were considered significant. 
 
Chapter 7  Relationship between obesity and the risk of clinically 
significant depression: Mendelian randomisation study 
 




Construction of the weighted GRS (wGRS) 
 
Risk alleles were defined as alleles associated with an increased risk of BMI. As 
described above, an additive genetic risk score (GRS) was derived from the 32 SNPs 
reported by Speliotes et al., (2010) including rs3751812 of FTO gene. As in Chapter 
6, we have shown GRS explained a modest but significant proportion of BMI. In 
order to reduce the bias caused by missing data, only the participants without any 
missing data were included in our MR analysis while using weighted genetic risk 




Prior to the analysis using the GRS, the observed increase in risk of major depression 
per 1kg/m2 change in BMI was assessed using probit regression, after controlling for 
age, sex and principal components of ancestry. The association between (1) FTO 
genotype and BMI, and (2) wGRS and BMI was analyzed using linear regression, 
with the covariates mentioned above. The predictor variable, FTO genotype, was 
modelled in an additive model (i.e. 0, 1, 2 copies of risk alleles). F statistics derived 
from the first-stage regression were used to evaluate the predictive strength of the 
variables (FTO genotype and wGRS), with values greater than 10 indicating a strong 
instrument suitable for instrumental-variables regression. We then performed an 
instrumental-variables regression analysis using the ivprobit command in STATA, to 
examine whether FTO genotype or wGRS was associated with major depression 
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through their associations with BMI. To correct for the possible presence of 
population stratification, all analyses were adjusted for the first five principal 
components of ancestry which were calculated with EIGENSOFT (Price et al., 2006). 
All the analyses were conducted using STATA version 12.1 (StataCorp., College 
Station, TX). 
 
Chapter 8 Further exploration of the associations between physical 
diseases and major depression 
 
Chapter 8 examined whether individual polymorphisms associated with physical 
diseases are overrepresented in our sample of depressed individuals. A GRS for 
asthma was then calculated, based on findings from Chapter 3 suggesting that asthma 
was more prevalent and showed familial aggregation with MDD. Finally, an analysis 
using Mendelian Randomization (MR) was conducted, given that the analysis of 
GWAS data suggested that the phenotypic overlap of asthma and MDD may have a 
molecular genetic underpinning. The motivation for the MR analysis is that the 
interpretation of an association between a modifiable risk factor and a disease found 
in traditional epidemiological studies is potentially limited by confounding factors, 
resulting in lack of ability to make causal inference about the association between a 
risk factor and a disease.  The principle of MR analysis (Smith and Ebrahim, 2003) is 
to use genetic variants contributing to the levels of a possible risk factor for a disease 
to examine the causal effect between levels of that risk factor (as reflected in number 
of risk alleles) and disease risk (Sheehan et al., 2008).  The random assortment of 
genetic variants from parents to offspring at meiosis provides a relatively robust 
47 
 
method for assessing the causal nature of environmental risk factors, because the 
assortment of risk alleles is independent of confounding factors.  
 
Method 1 
First, all Genome-wide association studies (GWAS) on body mass index (BMI), 
obesity, asthma, allergic rhinitis, hypertension and myocardial infarction were 
searched using publications in National Human Genome Research Institute 
(http://www.genome.gov/gwastudies/). Hypercholesterolemia was not included in the 
search, because the published GWAS on cholesterol are separated into studies on 
HDL(High Density Lipoprotein)-cholesterol and LDL (Low Density Lipoprotein)-
cholesterol as a continuous variable, and not, as in our data, the disease status of 
hypercholesterolemia (present/absent). Second, all SNPs with p values > 5 x 10-8 in 
the initial GWAS reports were dropped, because we wanted to include genetic 
variants that are reliably associated with physical illnesses only.  Third, reports on 
independent samples were examined to see whether hits reported in published studies 
were replicated. If associations were not replicated, the Medline database was 
searched to find whether the same hits had been reported in any other papers. Fourth, 
candidate SNPs founds in GWAS studies were examined in GWAS data sets from 
Psychiatric Genetic Consortium (PGC)- Major depressive disorder (MDD) 
(http://www.broadinstitute.org/mpg/ricopili/) to see whether these genetic 
polymorphisms were over-represented in patients with MDD. The aim of the 
Psychiatric Genomics Consortium (PGC) is to conduct meta- and mega-analyses of 
genome-wide genomic data for various psychiatric disorders by uniting the 
investigators around the world. The PGC was established in early 2007 and now 
includes more than 800 investigators from 38 countries. Currently over 900,000 
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individuals were recruited for analyses. Initially, the PGC focused on five major 
psychiatric disorders, namely autism, attention-deficit hyperactivity disorder, 
schizophrenia, bipolar disorder and major depressive disorder and now other 
important psychiatric diseases were included as well.  
 
When a candidate SNP was not present on a particular genotyping array used in 
depression studies, proxy SNPs in linkage disequilibrium (LD) with that candidate 
SNP were identified using SNP annotation and proxy search, with the r2 threshold set 
at 0.8 (http://www.broadinstitute.org/mpg/snap/). Fifth, all of the remaining SNPs in 
the same region were compared with each other to identify those that were in linkage 
disequilibrium, and two SNPs with LD > 0.5 were considered as the same hit. 
Finally, correction for multiple testing using the Bonferroni method was applied. The 




   
Find candidate SNPs reported in 
GWAS on certain diseases and 
 
Retain those SNPs with p<5*10-8 
Check p value of candidate SNPs in  
PGC-MDD GWAS data set 
Compare retained SNPs in the 
same region and leave only one 
   
Exclude SNPs if they are not 
replicated in other independent 
 
Use proxy SNPs (r2>0.8) if candidate 
SNPs are not present in MDD data set 




After identifying rs1342326, which is reliably associated with asthma, and was 
significantly over-represented in MDD based on data from the Psychiatric Genetic 
Consortium (PGC)- Major depressive disorder (MDD) 
(http://www.broadinstitute.org/mpg/ricopili/), a Mendelian randomisation analysis 
was conducted using our RADIANT sample to see whether we could confirm this 
association. The details of participants and phenotype information in RADIANT are 
described in Table 8.2. Again, two instrumental variables (IVs) were used for the 
Mendelian randomisation analysis. The first IV was rs1342326, identified in the 
analysis described in Method 1. The second IV was a GRS for asthma, which was 
constructed as follows. First, published GWAS studies on asthma conducted before 
October, 2012 were searched. Seventeen SNPs, including rs1342326, were found to 
fulfil our requirements. Of the 17 SNPs, 12 SNPs were extracted from GWAS data 
after applying stringent quality control measures. The other four SNPs were 
extracted using proxy SNPs. One SNP, rs4129267, was not available in our GWAS 
data, and proxy SNPs could not be identified. As such, this allele was excluded. 
Subsequently, another four SNPs (rs9807989, rs2381416, rs11078927 and 
rs4794820) were excluded due to high linkage disequilibrium with other identified 
SNPs (r2 value between 0.58 and 0.91). The call rates for all of these twelve SNPs 
was > 99% (Table 7.1). An additive model was applied to construct a weighted GRS 
using the 12 SNPs. The weighted GRS (wGRS) was calculated by multiplying the 
number of risk alleles at each locus (0, 1, 2) with the corresponding effect size as 
reported in each GWAS study, and then summing the products. Only participants 
without any missing data were included in the GRS analysis.   
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Logistic regression was then used to investigate the relationship between asthma and 
MDD after controlling age, sex and principal components of ancestry. The 
association between rs1342326 genotype/ wGRS and asthma was then analysed 
using logistic regression, with inclusion of the covariates mentioned above. The 
predictor variable rs1342326 genotype was modelled with an additive model (i.e. 0, 
1, 2 copies of risk alleles). As in Chapter 7,  F statistics from the first-stage 
regression were used to evaluate the strength of the instrumental variable, with 
values > 10 indicating a strong instrument suitable for instrumental-variables 
regression. An instrumental-variables regression analysis was then performed using 
the ivprobit command in STATA to examine whether rs1342326 genotype or the 
wGRS was associated with major depression through their association with asthma. 
To correct for the possible presence of population stratification, all analyses were 
adjusted for the first five principal components of ancestry which were calculated 
with EIGENSOFT (Price et al., 2006). All the analyses were conducted using 





 Chapter Three 
 
Prevalence and family aggregation of physical diseases  




As described in Chapter 1, there is accumulating evidence that certain common 
physical diseases are associated with major depression, but the causal underpinnings 
of such associations remain unclear. This chapter describes a study that aimed to 
replicate previous work at the MRC SGDP Centre comparing the prevalence of 
physical diseases in depressed patients and psychiatrically healthy controls. A further 
study investigating familial aggregation of physical diseases and their inter-
correlation in 721 families with recurrent depression is also described.  
 
After controlling for age, gender, body mass index (BMI), family membership, and 
having applied correction for multiple comparisons, the following disorders were 
significantly more frequent in depressed patients:  hypertension, 
hypercholesterolemia, myocardial infarction, asthma, allergic rhinitis/ hay fever, 
gastric ulcer, osteoarthritis and thyroid disease.  Hypertension, hypercholesterolemia, 
asthma, osteoarthritis and gastric ulcer appeared to cluster in families in depressed 
patients. Principal components analysis of the 16 diseases conducted identified six 
groups of disorders, with the most significant component relating to a ‘metabolic 
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syndrome’ group, consisting of type 2 diabetes, hypertension, hypercholesterolemia 
and myocardial infarction. These findings confirmed that patients with recurrent 
depression have substantially increased rates of several common physical diseases, 
and suggest that familial aggregation of such diseases is significant. Common 
physiological pathways linking depression and physical diseases (e.g. via 
hypothalamus-pituitary axis dysfunction and/or inflammatory processes) might 






Major depression is a serious public health problem in its own right, but there is also 
emerging evidence of its co-occurrence with various chronic medical disorders 
(Farmer et al., 2008). According to World Health Organization’s report (WHO, 
2008), unipolar depressive disorder will become the top leading cause of burden of 
disease in 2030, followed by ischemic heart disease. The disability-adjusted life 
years (DALYs) is a measure of overall disease burden, expressed as the number of 
year lost because of illness, disability or premature death, and unipolar depression 
comprises 10% of total DALYs in high-income countries. Comorbidity of major 
depression and chronic medical disorders significantly influence the life quality and 
impact the DALYs even more.  
 
Chapter 1 presented evidence suggesting that there is a substantial co-occurrence 
between MDD and various chronic medical disorders (Farmer et al., 2008), and that 
the relationship between major depression and chronic medical disorders is likely to 
be bi-directional. On one hand, major depression can influence the occurrence or 
progression of medical disorders via biological mechanisms such as increased 
inflammation and autonomic dysfunction (Dantzer et al., 2008, Koschke et al., 
2009).In addition, major depression is associated with various risk factors related to 
chronic medical disorders, including cigarette smoking, alcohol misuse, sedentary 
life style, poor adherence to treatment and obesity (Hämäläinen et al., 2001). On the 
other hand, poor physical health is likely to increases the risk of onset or persistence 




Chapter 1 also highlighted the high rates of co-morbidity between certain physical 
diseases and depression (Gatchel et al., 2007, Lichtman et al., 2008). For example, 
up to one third of people developed major or minor depression following acute 
myocardial infarction (MI) during one-year follow-up (Strik et al., 2004) and patients 
with moderate to severe post-MI depression have a higher risk of five-year mortality 
(Lespérance et al., 2002). In particular, previous work from our group has shown 
higher rates of common physical diseases and obesity in patients with recurrent 
depression compared to healthy controls (Farmer et al., 2008). Not only case-control 
studies but also population-based studies showed people with major depression have 
a higher rate of various medical diseases (Wu et al., 2012, Chien et al., 2013). 
Elsewhere, it has been shown that depressed patients have a higher likelihood of 
experiencing physical illness during a follow-up period compared to community 
controls (Holahan et al., 2010) and that depressed patients with comorbid physical 
illness tend to have an increased health care cost (Creed et al., 2002), a poorer quality 
of life (Small et al., 1996), poor medical compliance (DiMatteo et al., 2000) and 
increased all-cause mortality (Axon et al., 2010).  
 
Previous studies have shown that many common diseases are familial, for example 
being more prevalent in siblings of individuals with those diseases than in the general 
population. It seems likely that the same pattern should be seen in families of patients 
with depression. That is, if causal pathways implicated in depression and physical 
illness are shared, co-existent physical diseases should also be seen more commonly 
in siblings of depressed patients.  Such a finding would have implications for both 




 Principal component analysis (PCA) is a variable reduction technique used to reduce 
the number of highly correlated observed variables to a smaller number of principal 
components, which account for a certain proportion of the variance of the observed 
variables. Evidence has shown that a number of physical diseases are correlated with 
each other, suggesting that they may have similar mechanisms of pathogenesis. PCA 
has the advantage of being able to detect latent disease structure, allowing us to 
detect possible common underlying pathways for certain clusters of medical diseases.  
 
Here, we aimed to replicate previous findings from the DeCC study (Farmer et al., 
2008) of increased rates of physical diseases in patients with recurrent major 
depression, and to explore the phenomenon further by assessing familiality in 
depressed siblings. We also examined the extent to which groups of physical 
disorders clustered together across a sample of depressed individuals. The decision 
was taken not to include migraine in these analyses because the co-occurrence of 
migraine and depression within the DeCC and DeNt samples has been extensively 
explored in another PhD thesis, and in publications arising from it (e.g. Samaan et al., 




The cases of recurrent depression used in this study were from the Depression 
Network (DeNT) Study. The details of the sampling, clinical assessments, measures 






A total of 1670 participants with recurrent depression and 85 unaffected siblings 
were recruited from 721 families. Their medical history interview data was compared 
with that from 803 healthy controls. Seventy-four per cent of the case group were 
women, compared with 55 % of the control group (x2=87.26, d.f.=1, p<0.001). The 
mean age at interview of the case group was higher than control group (47.78 
(S.D.=9.19) vs 45.01 (S.D.=12.00), t=6.344, d.f..=2009.85, p<0.001). The median 
age across all subjects was 46. Twenty four per cent of the case group was obese, 
compared with 10% of the control group (x2=68.52, d.f.=1, p<0.001), and 48% of 
cases and 58% of controls were within the normal weight range.    
 
Lifetime prevalence rates of common medical diseases stratified by group are shown 
in Table 3.1. Nine out of 16 diseases were more common in depressed patients 
compared to healthy controls, after controlling for family membership. The medical 
diseases with the highest prevalence rates in the case and control groups were asthma, 
hypertension and hypercholesterolemia. Differences in disease prevalence between 
cases and controls were assessed using mixed-effect logistic regression, with the 
explanatory variables being depression status (case or control), BMI, gender, age and 
family membership. The Bonferroni method was used to correct for multiple 
comparisons, resulting in a  critical p value of 0.003125 (0.05/16). The pattern of 
higher prevalence rates of various physical diseases was observed not only in 
depressed probands, but also in their unaffected siblings for five diseases. Table 3.2 
shows that eight diseases remained significantly more common in depressed patients 
after adjusting for BMI, gender, age and family membership: namely asthma, gastric 
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ulcer, hypercholesterolemia, hypertension, myocardial infarction, osteoarthritis, 
rhinitis/hay fever and thyroid disease (odds ratios ranged between 2.37 and 5.81). 
Asthma (33.3% vs. 15.8%) and thyroid diseases (10.3% vs. 2.8%) were more 
prevalent in female depressed patients than male depressed patients, whereas 
hypercholesterolemia was more common in males than females (17.9% vs. 11.0%). 
We did not find an interaction effect between sex and depression for any physical 
diseases with the exception of asthma (prevalence: 6.9% in male controls, 12.5% in 
female controls, 15.8% in male patients and 33.3% in female patients, p<0.01).  
 
Although some physical diseases are more prevalent with increasing age, our results 
are unlikely to have being influenced by an unequal proportion of older (>55 years) 
participants among the depressed sample compared to the healthy controls (21.7% v. 
24.5%. x2=2.41, p=0.12). Apart from a higher rate of asthma in the UK sites (34.8% 
v. 23.3%, p<0.001), the prevalence rate for each medical disease was not 
significantly different between UK and non-UK sites. Although the prevalence rates 
of various physical diseases in unaffected siblings was similar to that in depressed 
probands, only hypercholesterolemia was significantly more prevalent in unaffected 
siblings than in healthy controls after adjusting for the effects of age, gender, BMI 
and family membership, and using Bonferroni correction (Table 3.2). 
 
Table 3.3 shows familial intra-trait correlation in sibling pairs affected by depression. 
The findings suggest that hypertension, hypercholesterolemia, asthma, osteoarthritis 
and gastric ulcer are familial in depressed patients. Table 3.4 shows the results of 
principal component analysis used to examine the inter-relationship of the 16 
diseases among the depressed patients. Six components were extracted, taking a cut-
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off eigenvalue of 1.0 or more. The six components explained a total of 47.7% of the 
variance, with component1 contributing 12.9%, the remaining five components 
contributing 6.3% to 7.6%. Although component 5 appeared to only tap variance 
relating to one variable, type I diabetes mellitus, this could be attributed to the fact 
that (1) underlying components were inferred from the correlation among all 
variables and each factor is estimated as the weighted sum of each variables; and (2) 
type I diabetes usually develops in childhood, and therefore may be more weakly 
related to other common medical diseases with an onset in mid-adulthood. 
Substantial correlations between sibling pairs for components1, 2 and 4 were 




Table 3.1 Lifetime prevalence rates of self-reported medical diseases 
Medical Disorder 
Life time prevalence (%) DC vs. controls 
OR (95% CI) 
P 
US vs. controls 







N 1670 85 803   
Asthma 28.7 14.3 9.3 3.89(3.01~5.03) 1.61 (0.85~3.05) 
    <0.001* 0.145 
Diabetes type 1 0.7 0 1.1 0.61(0.27~1.40) 
0.25 
--- 




Epilepsy 2.1 0 0.4 6.12(1.88~19.95) 
0.003* 
--- 




















































Stroke 1.5 0 0.5 3.23(1.11~9.39) 
0.03 
--- 





* Statistically significant after Bonferroni correction for multiple testing i.e. the 
adjusted critical alpha level was taken as p=0.003125  
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Table 3.2 Logistic regression adjusted or non-adjusted for age, gender, body mass 
index and family membership 
Medical diseases 
Cases v. Controls 
OR(95% CI)  
p 





 unadjusted adjusted  Unadjusted adjusted 












































































  0.24 

























* statistically significant after Bonferroni correction for multiple testing i.e. the 
adjusted critical alpha level was taken as p=0.003125  
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Table 3.3 Familial Intra-trait correlation of physical diseases 
Physical diseases Tetrachoric rho (SE) P 
Hypercholesterolemia 0.34 (0.08) <0.0001* 
Hypertension 0.35 (0.07) <0.0001* 
Myocardial Infarction 0.32 (0.14) 0.03 
Asthma 0.23 (0.06) 0.0004* 
Hay fever 0.21 (0.09) 0.015 
Diabetes Type1 -1.0 1.00 
Diabetes Type2 0.36 (0.18) 0.06 
Epilepsy 0.31 (0.23) 0.19 
Gastric Ulcer 0.33 (0.10) 0.002* 
Kidney Disease 0.18 (0.22) 0.34 
Liver Disease -1.0 1.0 
Osteoarthritis 0.40 (0.08) <0.0001* 
Osteoporosis 0.52 (0.15) 0.0036 
Rheumatoid Arthritis 0.10 (0.21) 0.47 
Stroke 0.38 (0.23) 0.14 
Thyroid Disease 0.25 (0.10) 0.015 
* statistically significant after Bonferroni correction for multiple testing i.e. the 








Item component1 component2 component3 component4 component5 component6 
Diabetes mellitus type2 0.57 -0.16 -0.03 -0.10 -0.06 -0.02 
Myocardial infarction 0.59 0.18 0.02 -0.21 0.01 0.08 
Hypercholesterolemia 0.63 0.16 -0.14 0.04 -0.10 -0.05 
Hypertension 0.66 -0.17 0.08 0.14 0.08 -0.01 
Osteoporosis -0.04 0.76 -0.04 -0.08 -0.13 0.16 
Thyroid disease 0.17 0.43 -0.23 0.03 0.21 -0.03 
Gastric ulcer -0.07 0.51 0.40 -0.02 -0.01 -0.06 
Kidney disease 0.04 0.01 0.50 -0.03 0.32 0.26 
Liver disease -0.06 -0.03 0.73 0.06 0.10 0.03 
Rheumatoid disease 0.16 0.02 0.46 -0.17 -0.34 -0.37 
Allergic rhinitis -0.03 -0.08 -0.02 0.87 -0.11 -0.09 
Asthma -0.01 0.14 0.14 0.37 -0.47 0.13 
Osteoarthritis 0.18 0.30 0.07 0.39 0.22 -0.13 
Diabetes Mellitus type 1 -0.01 -0.05 0.16 -0.08 0.73 -0.10 
Stroke 0.29 -0.12 0.07 0.11 -0.08 0.48 
Epilepsy -0.05 0.17 0.02 -0.16 -0.10 0.76 
       
Eigenvalue 2.07 1.21 1.18 1.11 1.05 1.01 



















3.4.1 Increased prevalence of physical diseases in depressed 
probands and siblings 
 
Nine physical diseases were more common in patients with recurrent major 
depression than in psychiatrically healthy controls after controlling for family 
membership and adjusting for multiple testing. After further controlling for BMI, age 
and gender, eight physical diseases including asthma, gastric ulcer, 
hypercholesterolemia, hypertension, myocardial infarction, osteoarthritis, allergic 
rhinitis/hay fever and thyroid disease remained significantly more frequent in 
depressed patients. Similar prevalence rates of physical diseases were found in un-
affected siblings of depressed patients, but only hypercholesterolemia showed a 
significant unaffected sibling/control group difference after multiple testing 
correction, which may be due to the small sample size in un-affected siblings. The 
overall pattern of results suggests a familial predisposition to physical diseases that is 
partially independent of a familial predisposition to depression. In our study, one 
quarter of depressed patients were obese, compared to only 10% of psychiatric 
healthy people, and obesity remain significantly associated with all of these eight 
diseases, except for gastric ulcer, in our models.  
 
Our results largely support those reported by Farmer et al. (2008): asthma, gastric 
ulcer, hypertension, osteoarthritis, rhinitis/ hay fever and thyroid disease were found 
to be more frequent in patients with recurrent depression. We additionally found that 
two other conditions, namely hypercholesterolemia and myocardial infarction,were 
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also more common in cases. Notably, the two studies applied the same methods to 
assess psychiatric disorders and medical diseases. The only difference between the 
studies was the sample characteristics and source; the present study recruited sibling 
pairs with recurrent depression from the UK, Europe and the United States, whereas 
Farmer’s study recruited unrelated patients with recurrent depression from the UK. 
Although in our study the prevalence rate of hypercholesterolemia (14.3% vs. 10.5%) 
and myocardial infarction (4.3% vs. 3.8%) seemed slightly higher in non-UK sites 
than in UK sites, this difference did not reach statistical significance after correction 
for multiple testing. All of the cases in the present study had recurrent depression, 
which is in keeping with recent findings (Gili et al., 2011) that medical conditions 
were more prevalent in patients with recurrent depression compared to those with a 
first episode.  
 
3.4.2 Major depression and obesity 
 
Our finding of an excess of obesity in depressed individuals is in keeping with some 
previous studies (Farmer et al., 2008, Simon et al., 2006), but not all (Papakostas et 
al., 2005, Patten et al., 2009).  A recent meta-analysis (Luppino et al., 2010) found 
that depression had only a modest effect on the risk of obesity (OR=1.58). although 
some of included studies were community-based, in which the severity of depression 
was likely milder. Another study (Blaine, 2008) suggested that depressed patients are 
more likely to become obese at follow-up than non-depressed people, especially 
female adolescents. Long term use of antidepressant medication has an established 
association with weight gain, although the effect of individual antidepressants may 
vary (Serretti and Mandelli, 2010). Our cases had all experienced recurrent major 
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depressive episodes, and the majority have had multiple exposures to antidepressants, 
which may have contributed to the observed higher rates of obesity in our cases. A 
recent study in which the samples overlapped both with those of Farmer et al. (2008) 
and the recent study (Rivera et al., 2012) found that the association between the fat 
mass and obesity associated (FTO) gene and BMI was amplified in depressed 
patients compared to healthy controls, suggesting a first molecular-level clue as to 
why depressed patients may have an increased liability towards being overweight 
and developing diseases associated with being overweight. 
 
3.4.3 Major depression and medical diseases 
 
Many of the associations that we have found between common medical diseases and 
depression have been previously noted. Asthma has long been suggested to be 
associated with ‘psychosomatic’ factors, and the prevalence rate of depression in 
patients with asthma is higher than the general population (Afari et al., 2001). 
Corticosteroid use in patients with asthma could induce or exacerbate depression 
(Patten, 2000) and conversely, low mood may cause airway instability and asthma 
exacerbation (Ritz et al., 2001). Allergic diseases such as rhinitis/ hay fever have also 
been reported to be associated with major depressive episodes (Hurwitz and 
Morgenstern, 1999). A twin analysis suggested that 64% of the association between 
allergic diseases and depressive symptoms was due to shared familial vulnerability, 
mainly additive genetic factors (Wamboldt et al., 2000). Major depressive disorder, 
along with other mood or anxiety disorders, has been associated with peptic ulcer 
disease in a community sample (Goodwin et al., 2009). Hypertension is more prevalent 
in depressed patients (Adamis and Ball, 2000) and depression may be a risk factor for 
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the development of hypertension (Jonas et al., 1997). Iit has been postulated that the 
common underling pathophysiology between hypertension and depression is related to 
increased sympathetic nervous system tone (Lambert et al., 2010).  Osteoarthritis has 
also previously been linked to depression (Kim et al., 2011), and the intensity of 
perceived pain in patients with osteoarthritis is a predictor for depression (Hawker et 
al., 2011). Hypothyroidism has long been associated with depression (Teixeira et al., 
2006), and high levels of thyroid stimulating hormone (TSH) have also been found to 
increase risk  (Guimarães et al., 2009). Hypercholesterolemia has been linked with 
depression in the elderly (Tyrovolas et al., 2009) and the pathophysiology of mood 
disorder may relate to alternation of lipid profiles associated with high cholesterol 
(Papakostas et al., 2004). Depression has been shown to be associated with myocardial 
infarction, and to increase future risk (Yary et al., 2010). The findings of the present 
study build on previous reports, representing a systematic enquiry across a range of 
physical illnesses, and allowing us to examine possible familial aggregation of physical 
diseases in depressed siblings.  
 
3.4.4 Familial aggregation and physical diseases 
 
Our study of sibling pairs shed light on the familial risk of physical diseases 
comorbid with MDD. For example, we found a moderate correlation within sibling 
pairs for hypercholesterolemia, hypertension, gastric ulcer, osteoarthritis and asthma 
using tetrachoric correlation analysis, which is a technique to estimate the correlation 
between two theoretical normally distributed continuous latent variables underlying 
two dichotomous variables. Higher concordance rate of these diseases within pairs 
implies these diseases are familial in sibling pairs affected by depression. However, 
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we were unable to examine whether the familiality of medical diseases was greater 
among depressed siblings compared to depressed patients and their unaffected 
siblings because of the small sample size of unaffected siblings.  
 
The pattern of correlations between diseases reported here was in line with previous 
evidence. As might be expected, hypertension, hypercholesterolemia and myocardial 
infarction correlated with each other within individuals. A twin study (Scherrer et al., 
2003) reported that there was a significant genetic correlation among depressive 
symptoms, heart disease and hypertension, which may explain this overlap, and our 
finding of increased prevalence of these diseases in depressed patients. A correlation 
within individuals was also found for allergic rhinitis and asthma. Allergic rhinitis 
often precedes the onset of asthma, and the association between asthma and rhinitis/ 
hay fever is also likely to share a common immunopathological process (Braido et al., 
2011). Other recent studies have also reported a high comorbidity between asthma 
and hay fever, with a phenotypic correlation between 0.58 and 0.65 (Fagnani et al., 
2008, Willemsen et al., 2008).  One previous study (Wamboldt et al., 2000) indicated 
that additive genetic factors account for a significant proportion of the covariance 
between atopy (the propensity to suffer from allergies) and depressive symptoms. In 
addition, allergic respiratory disease has been shown to be a risk factor for 
hypertension (Aung et al., 2010), and patients with asthma were 1.3 times more 
likely to have hypertension than patients without asthma (Dogra et al., 2007). 
Previous studies have shown that osteoarthritis is associated with several diseases 
such as gastric ulcer, hypercholesterolemia, hypertension and osteoporosis. Although 
we do not have accurate records of medication use in our cases, patients with 
osteoarthritis are likely take more non-steroid anti-inflammatory drugs (NSAID), 
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which may subsequently contribute to gastric ulcer (Geis et al., 1991). Chronic pain 
is a core symptom of osteoarthritis. Patients with chronic pain tend to report more 
physical conditions and most of self-reported chronic physical conditions are 
significantly associated with chronic pain (Dominick et al., 2012). This might 
explain why osteoarthritis showed associations with a number of other medical 
diseases.  
 
Most complex diseases are thought to involve both genetic and environmental factors. 
For example, lipid profile abnormalities are as a risk factor for cardiovascular disease, 
and the level of total cholesterol aggregates within families (de Miranda Chagas et al., 
2011). It has been shown that heritable factors account for more than 50% of the 
population variation for serum total cholesterol (Fuentes et al., 2000b). Blood 
pressure is an important factor for various cardiovascular diseases, and also 
aggregates within families (Fuentes et al., 2000a); with the genetic contribution to 
blood pressure estimated at between 30% and 60% across ethnicities (Kupper et al., 
2005, Snieder et al., 2003). Estimates of the heritability of osteoarthritis range from 
39% to 60%, depending on the location and definition of osteoarthritis (symptomatic 
or radiographic findings). It is unclear whether the variation in estimates of 
heritability could be attributed to effects on different joints, or is due to a 
heterogeneous phenotype definition (Riyazi et al., 2005). Asthma and hay fever have 
been linked to elevated levels of serum Immunoglobin E (IgE), and the prevalence 
rate of asthma has increased in recent years (Thomsen et al., 2011). Familial 
aggregation of asthma has been widely reported, and estimates of heritability range 
from 60% - 91%, depending on the definition of asthma (Thomsen et al., 2011, 
Willemsen et al., 2008). Furthermore, the genetic correlation between asthma and 
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hay fever has been estimated to be 0.58, and the phenotypic correlation between the 
two diseases appears to be entirely genetically mediated (Fagnani et al., 2008). 
 
3.4.5 Potential mechanism linking depression and medical diseases 
 
As noted in Chapter 1, there are various physiological mechanisms that could 
mediate the relationship between physical illnesses and depression. One possible 
overlapping mechanism is hypothalamus-pituitary-adrenal (HPA) axis dysfunction, 
with elevated cortisol levels reported in both depressed and obese people. 
Heightened levels of cortisol have shown to contribute to weight gain, with a 
particular impact on increased visceral adiposity (Pasquali et al., 2002). The results 
of the present study, which are in line with previous reports of increased obesity and 
cardiovascular diseases in depressed patients vs. controls motivate further studies 
investigating whether HPA axis dysfunction, potentially related to chronic stress, 
could mediate this relationship.  
 
Another potential mechanism for the relationship is chronic low-grade inflammation. 
Physical illnesses and depression are both related to raised levels of inflammatory 
mediators. As discussed in Chapter 1, pro-inflammatory cytokines such as tumor 
necrosis factor-α (TNF- α), interleukin-1 (IL-1), IL-6 and interferon—γ have been 
reported to be elevated in depression (Kenis and Maes, 2002). In addition, elevated 
levels are reported in gastric ulcer (Sugimoto et al., 2010), asthma (Woodruff et al., 
2009), and rhinitis and osteoarthritis (Valdes and Spector, 2010). An additional 
inflammatory marker, high sensitivity C-reactive protein (hsCRP) has also been 
linked to depression (Kling et al., 2007), and past-year major depression is a risk 
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factor for subsequent ischemic heart disease (Surtees et al., 2008). The present report 
of increased rates of physical diseases related to inflammatory processes in depressed 
patients motivates further studies examining whether inflammation could mediate 




Some limitations of our study should be taken into account when interpreting the 
results. First, history of medical diseases and BMI was collected via self-report, 
rather than from a review of medical case records. However, in our previous study 
(Farmer et al., 2008), 93% of self-reported physical illnesses were confirmed by 
patients’ General Practioners (GPs), and the agreement for reporting on each disease 
between GPs and self-report ranged from 0.65 to 0.91 (kappa co-efficient), 
suggesting substantial to very good agreement.  
 
A second limitation is that this study used a cross-sectional study design. Such a 
design can only show the association between depression and physical illness, and 
cannot determine the temporal relationship. Third, patients with recurrent depression 
who retrospectively report their physical illnesses may be biased by their present 
mood state, although depressive symptoms measured using the Beck Depression 
Inventory only accounted for 1.5% of the variance in the number of physical 
illnesses in a previous study (Farmer et al., 2008). Fourth, depressed people may be 
more likely to be referred or investigated for physical illness compared to non-
depressed people (Berkson, 1946). Fifth, familial aggregation of physical illness does 
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not necessarily reflect co-segregation with depression, since we did not have enough 
non-affected family members in the sample to investigate this.  
 
A further limitation was that our study sample consisted of siblings. This meant that 
it was not possible to differentiate genetic factors from shared environmental factors 
– we were only able to estimate the ‘familiality’ of the disorders. Until recently, 
differentiation of genetic and shared environmental factors could only be achieved 
using twin studies, but a recent method called genome wide complex trait analysis 
(Yang et al., 2011) provides a method of partitioning these two sources of variance 
using genome wide genetic marker data.  
 
Despite these limitations, our study provides compelling evidence that certain 
physical diseases and traits including obesity are more prevalent in depressed 
patients. Familial aggregation of physical diseases, and cross-trait correlations further 
suggest the importance of comorbid physical diseases in depressed patients. These 
findings suggest that clinicians should be alert to the presence physical diseases in 
depressed patients. Future studies should focus on finding the common pathways 






Neuroticism is associated with asthma and total number of 
physical disease but no familial correlation exists between 




In Chapter 3, evidence showing that major depressive disorder (MDD) is associated 
with various physical diseases was presented. Previous studies have suggested that 
there is an association between MDD and certain personality traits, especially 
neuroticism, so it is possible that the association between MDD and physical diseases 
could also be related to personality traits that render individuals susceptible to the 
effects of stress. After controlling for age, sex, body mass index (BMI) and 
depression status, neuroticism was positively associated with the total number of 
physical diseases, although the effect was small. A similar pattern was found for the 
presence of any physical disease. Of the specific diseases investigated, only asthma 
was modestly but significantly associated with neuroticism, after correcting for 
multiple testing. Since both asthma and neuroticism were correlated in siblings 
suggesting familiality, the familial correlation between neuroticism and asthma was 
then examined. However, the bivariate modelling results did not find evidence for a 
significant familial correlation between the phenotypes. As such, it is therefore 
unlikely that neuroticism plays an important role in the association between MDD 
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and physical diseases. Even in the case of asthma where a modest phenotypic 
correlation was observed, there was no evidence to suggest that common genetic 






In the previous chapter, evidence showing that several common physical diseases 
were significantly more common in patients with recurrent depression than in 
controls was presented. In addition, there was evidence for familiality of physical 
diseases in depressed patients: siblings who were both affected with depression 
tended to be concordant for coexistent physical diseases. There was also an increased 
rate of physical disorders among unaffected siblings compared with controls, 
although only hypercholesterolemia showed a significant unaffected sibling/control 
group difference after multiple testing correction, potentially due to the small sample 
size. In this chapter,  I explore whether personality traits play a role in the 
comorbidity between recurrent depression and physical disorders, first by examining 
whether personality factors, as measured by the Eysenck Personality Questionnaire 
(EPQ) (Eysenck and Eysenck, 1975) are associated with physical disorders, and 
second by examining whether any personality traits phenotypically associated with a 
physical disorder show evidence of familial overlap with the physical disorder, using 
structural equation modelling  on sib-pair data. 
 
The hypothesis that personality might be involved in the relationship between 
physical diseases in depression is evidenced by previous studies that have shown a 
relationship between depression and personality traits, both in terms of susceptibility 
to depression (Farmer et al., 2002) and its prognosis (Ranjith et al., 2005). In addition, 
studies have shown that certain personality traits and disorders are associated with 
various somatic complaints or physical diseases. In particular, personality disorders, 
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which represent the extremes of various personality traits, might be expected to 
predict physical complaints, fatigue and pain (Powers and Oltmanns, 2012). In a 
recent study, borderline personality disorder was associated with an increased risk of 
numerous physical diseases such as cardiovascular disease and arthritis (El-
Gabalawy et al., 2010). In addition, individuals with symptoms of personality 
disorder were reportedly more likely to develop coronary artery disease (Pietrzak et 
al., 2007). There is also evidence to suggest that people with extreme scores on 
certain personality traits have more somatic complaints or physical diseases. For 
example, studies have shown that a high levels of neuroticism are associated with the 
total number of somatic symptoms (Costa and McCrae, 1985, Charles et al., 2008). 
Neuroticism has been reported to be significantly more strongly related to 
psychosomatic symptoms than to infectious/ allergic symptoms (Rosmalen et al., 
2007). Neuroticism has also been reported to be associated with ulcer, asthma and 
heart disease (Friedman and Booth-Kewley, 1987).  
 
Studies have consistently reported a strong association between major depression and 
neuroticism, although there is evidence that neuroticism as a trait is partly 
confounded with depressive states (Farmer et al 2002). However, the question of 
whether the association between depression and physical diseases (Farmer et al., 
2008) is mediated by neuroticism warrants investigation, and could have implications 
for understanding the relationship between the two.  
Although most studies focus on neuroticism, other personality traits have also been 
reported to be associated with physical diseases. For example, conscientiousness is 
associated with significantly reduced likelihood of numerous physical diseases 
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(Goodwin and Friedman, 2006). Extraversion has been reported to relate to positive 
health outcomes for both current and retrospective symptoms (Williams et al., 2004). 
A recent study (Klabbers et al., 2013) suggested that a comprehensive psychosocial 
profile including psychological attributes, psychological functioning and coping style 
could predict health risk more accurately than traditional single personality traits; and 
an adverse psychosocial profile could also indicate increased risk of mortality and 
poorer self-rated health. 
 
In summary, in this chapter will first examine the relationship between personality 
traits and the number of reported physical diseases/ the presence of any physical 
disease. Phenotypic associations will then be investigated using bivariate modeling to 
explore whether there is familial overlap between specific physical diseases or 
physical diseases generally and personality traits.  
 
4.2 Methods 
The analytic methods used in this study are described in detail in Chapter 2. The 
study sample was identical to that in chapter 3.  
For simplicity in the analysis, each physical disease (event) was treated as 
independent although in practice, the findings in Chapter 3 indicate that some 





Descriptive statistics indicated that traits of neuroticism and psychoticism were 
significantly higher in depressed people than healthy controls (mean (SD), 
neuroticism: 15.45 (5.06) v 5.26 (3.30), P<0.001; psychoticism: 3.81 (2.22) v 2.92 
(1.79), P<0.001). In contrast, extraversion was significantly higher in healthy 
controls than depressed subjects (10.13 (5.16) v 14.78 (4.68), P<0.001) (see Table 
4.1). The mean of the total number of physical diseases was 0.90, and the variance 
1.52 across the whole sample. Neuroticism was significantly positively associated 
with the number of physical diseases (Coef.=0.04, SE=0.005, P<0.001), whilst 
extraversion (Coef.=-0.02, SE=0.005, P=0.001) and psychoticism (Coef.=-0.03, 
SE=0.01, P=0.02) were negatively associated with the number of physical diseases 
reported on. The effect sizes of these associations were small, and only neuroticism 
was still associated with the number of physical diseases after taking into account 
depressive status, sex, age and body mass index (BMI) (Coef.=0.02, SE=0.007, 
P=0.004). The results were similar when the dependent variable was changed to the 
presence of any physical disease. Only neuroticism was associated with the presence 
of any physical disease after controlling the confounding factors (as above) and 
adjusting for multiple testing (Coef.=0.05, SE=0.01, P=0.001).  
Given that neuroticism was associated with the presence of any physical disease, we 
then examined whether specific physical diseases were associated with neuroticism. 
Among 16 common physical diseases, only asthma (Coef.=0.07, SE=0.02, P<0.001) 
was associated with neuroticism after controlling for confounding factors and 




Table 4.1 Personality traits difference between individuals with MDD and healthy controls 
 
 Total Cases  Controls p-
value 







Median 12.00 16.00 5.00  







median 12.00 10.00 15.00  














Table 4-2 Mixed-effect logistic regression controlling for age, gender, body mass index, 
extraversion, psychoticism and depression status 
 Coef. (95% CI) SE P 
Asthma 0.07 (0.04~0.10) 0.02 <0.001* 
Type 1 Diabetes  -0.06 (-0.18~0.07) 0.06 0.37 
Type 2 Diabetes 0.05 (-0.06~0.15) 0.05 0.41 
Epilepsy -0.02 (-0.12~0.07) 0.05 0.65 
Gastric Ulcer 0.09 (0.03~0.15) 0.03 0.004 
Hypercholesterolemia -0.02 (-0.07~0.03) 0.02 0.39 
Hypertension 0.01 (-0.03~0.05) 0.02 0.67 
Kidney Disease 0.01 (-0.07~0.09) 0.04 0.71 
Liver Disease 0.03 (-0.05~0.12) 0.04 0.43 
Myocardial Infarction 0.04 (-0.02~0.11) 0.04 0.43 
Osteoarthritis 0.07 (0.02~0.13) 0.03 0.01 
Osteoporosis 0.01 (-0.08~0.10) 0.05 0.79 
Rheumatoid Arthritis 0.00 (-0.07~0.07) 0.04 0.98 
Allergic Rhinitis 0.02 (-0.02~0.06) 0.02 0.33 
Stroke 0.04 (-0.08~0.15) 0.06 0.53 




Although the size of the association between asthma and neuroticism was small, data 
from sib-pairs both affected by depression was used to investigate whether there was 
a familial correlation between asthma and neuroticism (Figure 4.1). The model 
described in Wood, Rijsdijk et al. (2011) was used, with fixed parameters for the 
selection trait (i.e. disease status). The threshold for asthma status was fixed to a z-
value of 1.64 to give a population prevalence of 10% (Brogger et al., 2003). 
Additional parameters were fixed to the expected population estimates based on 
previous reports, with the familiality of asthma fixed at 60% (Thomsen et al., 2010). 
After removing the parameter for the correlation between asthma and neuroticism, 
the reduced model was not inferior in terms of model fit to the full model (difference 
chi-squared=1.48, difference d.f.=1, P=0.22), suggesting that there is no familial 




 Fig 4-1 Parameters F_n, F_a, E_n, E_a are estimates from the Cholesky model, partitioning 
the variance of the overlap between neuroticism and asthma into familial and non-shared 






These results indicate that neuroticism is associated with the reported number of 
physical diseases, as well as with the presence of any physical diseases in the study 
sample. Several previous studies have reported similar results, indicating that 
neuroticism is associated with total number of physical symptoms or physical 
diseases after controlling comorbid psychiatric disorders (Neeleman et al., 2004, 
Goodwin and Friedman, 2006, Williams et al., 2004, Johnson, 2003, Rosmalen et al., 
2007). As noted in the introduction, one study argued that neuroticism was more 
associated with psychosomatic symptoms than with infectious/ allergic symptoms 
(Rosmalen et al., 2007), and a second suggested that neuroticism is only related to 
‘tension’ type diseases such as hypertension, migraine or neck pain (Johnson, 2003).  
However other studies have suggested that neuroticism has more general effects, and 
is related to poorer health behaviour self-efficacy, especially in the presence of low 
extraversion (Williams et al., 2004). This pattern is in contrast with 
conscientiousness, which was reported to be associated with lower rates of physical 
diseases (Goodwin and Friedman, 2006).  
 
Several mechanisms might explain the association between neuroticism and 
increased physical illnesses. First, neurotic people are more likely to over-report their 
physical problems, or be more sensitive to or anxious about their bodily sensations 
and visit their doctors more frequently. Therefore, more physical diseases may have 
been diagnosed by their doctors. The absence of a link between neuroticism and 
premature natural mortality supports the possibility of over-reporting of physical 
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illnesses as an explanation for the association we have found (Neeleman et al., 1998). 
However, other studies have argued that neurotic people seek medical help during 
early stages of physical diseases and take interventions earlier, resulting in a lower 
mortality rate (e.g. O'Carroll et al., 2001).  
 
Second, the association between neuroticism and physical conditions could be a 
reverse causal relationship, i.e. people with more physical conditions tend to be more 
neurotic as a result. For example, Neeleman et al.( 2004) reported that neuroticism 
was associated not only with current somatic morbidity, but also with future 
morbidity during a follow-up period. On the other hand, somatic morbidity was also 
associated with increased neuroticism during follow-up.  
 
An alternative explanation for the link between neuroticism and physical conditions 
is via psycho-physiological pathways. Previous studies have shown that certain 
specific personality traits are associated with increased levels of interleukin-6 (IL-6) 
and C-reactive protein (CRP) in clinically depressed individuals, and in the general 
population (Coccaro, 2006, Marsland et al., 2008). A recent study (Armon et al., 
2013) found further evidence for positive associations between neuroticism and 
extraversion and two inflammatory markers at baseline and when measuring change 
over time across a four year follow-up period. Although the associations were 
significantly positive, only a small proportion of variance (approximately 2%) of 
these two inflammatory markers was explained by the personality traits. Turiano et al. 
(2013) reported a significant interaction effect between neuroticism and 
conscientiousness on IL-6 level, suggesting that people with both high neuroticism 
and high conscientiousness had lower IL-6 plasma levels (indicative of reduced 
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inflammation) compared to people with all other configurations of neuroticism and 
conscientiousness. However, this study did not investigate the relationship between 
neuroticism and specific physical diseases. 
 
In general, our findings are in keeping with previous studies reporting a positive 
relationship between neuroticism and self-reports of illnesses. However, the effect 
was weak overall, as reflected in the small correlation coefficients. In the analysis of 
single diseases, only asthma was still significantly associated with neuroticism after 
controlling for potential confounding factors (Coef.=0.07, SE=0.02, P<0.001). This 
finding is in keeping with previous studies suggesting a link between asthma and 
various stress and psychological factors. A large scale community study (Huovinen 
et al., 2001) suggested that asthma prevalence was associated with high levels of 
neuroticism. A further study reported that high neuroticism predisposed to develop 
asthma (Loerbroks et al., 2009). Another study (Wainwright et al., 2007) suggested 
various psychological factors, such as current mood disorder, adverse childhood 
circumstances, stressful life events and poor social support were associated with 
asthma hospital admission.  
 
In our preliminary analysis, asthma was the only disease that was still related to 
neuroticism after controlling for potential confounding factors. We then examined 
the familial relationship between asthma and neuroticism, and found no significant 
correlation between asthma and neuroticism within our sample of depressed siblings. 
As such, this analysis did not support a common familial aetiology hypothesis for the 
co-occurrence of asthma and neuroticism. To the best of our knowledge, no previous 
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studies have investigated the genetic or familial correlation between neuroticism and 
asthma. One potential criticism of the approach I have taken is that sometimes fitting 
a Cholesky is invalid when it does not produce fit statistics that are distributed as a 
X2 or if the distribution of the fit statistic is X2, then the degrees of freedom are not 
always the difference between the number of parameters in the general model less 
the number of parameters in a constrained model (Carey, 2005). Using either general 
model or constrained model does not change the statistical significance. However, 
the familial relationship between neuroticism and other physical conditions included 
in the present study has been explored in previous research. One study (Charles et al., 
2008) used co-twin control analysis, and reported that genetic influences mediate the 
association between neuroticism and four of the thirteen physical conditions included 
in the present study. The results showed that familial influence explained the 
association between neuroticism and following diseases: joint pain, tension headache, 
migraine and coronary heart disease. Notably, asthma was not included in that 
analysis. Another recent twin study (Vassend et al., 2012) examined the heritability 
and genetic correlation between neuroticism and somatic complaints. The heritability 
of neuroticism was 46%, and of somatic complaints was approximately 45%. Nearly 
60% of the phenotype correlation between neuroticism and somatic complaints could 
be attributed to common genetic factors. A key difference between their study and 
ours was the methods used to assess physical health. Whereas Vassend et al., (2012) 
used subjective reports of somatic symptoms, the present study used self-report of 
clinician diagnosed asthma.  
 
Several limitations of this study should be taken into account when interpreting these 
results. First, physical diseases were measured using self-report of what the subjects 
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had been told by their doctors, rather than objective clinical diagnoses obtained from 
medical records. This raises concerns about possible recall bias or over-reporting. 
However, a previous sub-group analysis of one of the studies contained in this study 
(DeCC) demonstrated that self-reported physical diseases are reliable in relation to 
GP records (Farmer et al., 2008). A second limitation of the study was the fact that it 
was a cross-sectional in design. As such, temporal analysis could not be used to 
explore whether level of neuroticism predicts change in asthma symptoms over time. 
A third limitation is that, although a sibling design is able to examine shared familial 
effects, it cannot separate genetic from shared environmental effects. A fourth 
limitation is that confidence intervals could not be computed using the Mx package, 
because the data were ordinalised. Fifth and finally, the analysis was restricted to sib-
pairs where both were affected by recurrent depression. As such, this sample was 
likely selected from the high end of the distribution of neuroticism, and restricted 
variance may have attenuated the effect sizes of the associations between personality 
traits and physical diseases.  
 
In summary, these findings suggest that neuroticism was associated with both the 
total number of physical diseases, and the presence of any physical diseases, after 
controlling for potential confounding factors. When the relationship between 
neuroticism and individual common chronic physical diseases was investigated, only 
asthma was significantly associated with neuroticism after correction for multiple 
testing. No familial correlation among sib-pairs was observed between neuroticism 
and asthma. However, this issue may warrant further investigation in family or twin 
data that are more representative of the population as a whole with respect of the 





Estimation of the genetic correlation between major 
depressive disorder and body mass index using common 




As described in Chapter 1, both obesity and major depressive disorder (MDD) are 
prevalent in developed countries and cause a huge disease burden. Previous studies, 
including Chapter 3 of this thesis, have reported an association between obesity and 
MDD, but it is unclear whether common genetic factors are responsible for the 
overlap between these two disorders. A recently developed method was used to 
estimate the proportion of variance in disease liability explained by common single 
nucleotide polymorphisms (SNPs), and the genetic correlation between obesity and 
MDD in 3872 unrelated individuals from the RADIANT study, plus an additional 
1645 individuals from the Munich depression study. Findings indicate that the 
percentage of the overall variance accounted for by common SNPs is 15% for BMI, 
and 32% for MDD. Our results support evidence suggesting that both BMI and MDD 
are heritable, with a significant proportion of phenotypic variance explained by the 
additive genetic effects of common SNPs. Furthermore, this is the first study to 
suggest that there is a significant large, but as yet imprecise, genetic correlation 





The prevalence of obesity has been reported to be approximately 30% in developed 
countries (Flegal et al., 2010) while the life time prevalence rate of major depressive 
disorder (MDD) may be as high as 15% to 20% (Blazer and Kessler, 1994). Both 
obesity and MDD are associated with various chronic medical diseases and have 
major impacts on public health (Sturm, 2002, Katon, 2003). As discussed in Chapter 
1, there have now been several studies indicating a strong association between MDD 
and obesity (Luppino et al., 2010, Farmer et al., 2008, Rivera et al., 2011). However, 
the reasons as to why they should cluster together remain unclear.  
 
5.1.1 Potential underling mechanisms contributing to obesity and 
MDD 
 
Chapter 1 addressed a range of possible factors that could explain the association, 
including psychological factors such as lack of confidence and stigma, especially in 
obese women (Puhl and Brownell, 2003), sedentary life style, overeating and chronic 
antidepressant use (Cassidy et al., 2004). Chapter 1 also considered that both 
depression and obesity could be influenced by a common underling 
pathophysiological mechanisms such as low grade inflammation and hypothalamic-
pituitary-adrenal axis dysfunction (Dantzer et al., 2008), and that both obesity and 
MDD may share some genetic variance (Afari et al., 2010). 
Previous work has proposed a moderator-mediator framework has also been 
proposed to explain the relationship between obesity and depression (Faith et al., 
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2002). Potential moderators included socio-demographic factors, predisposing 
genotypes and binge eating disorder, while negative verbal commentary, eating and 
physical activities were suggested to be potential mediating factors. 
 
5.1.2 Twin studies suggested high heritability in obesity and MDD 
but genome-wide association studies have limited findings 
 
As noted in Chapter 1, family and twin studies have indicated that both BMI and 
MDD have a substantial heritable component (> .4), with variation related to whether 
participants were recruited from community or clinical settings (Sullivan et al., 2000, 
McGuffin et al., 1996). Given importance of genetic factors in contributing to 
population variance on both traits, the issue of whether common genetic factors may 
contribute to the clustering of MDD and obesity warrants investigation.  
 
Despite the evidence for a substantial heritable component for both BMI and MDD, 
the results of genome-wide association studies (GWAS) have been somewhat 
disappointing. As discussed in Chapter 1, GWAS have identified at least 32 common 
variants contributing to BMI, but together they only account for less than 2% of 
variance (Speliotes et al., 2010). Furthermore, no single nucleotide polymorphism 
(SNP) passing genome-wide significance threshold in MDD GWAS has yet been 
replicated in an independent sample (Wray et al., 2010). These findings have raised 
concerns about ‘missing heritability’ (Manolio et al., 2009), that is the gap between 
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the estimates of heritability from twin studies and the total variance actually 
explained by SNP associations.  
 
5.1.3 Genome-wide complex trait analysis provides different method 
to investigate “SNP heritability” 
 
The heritability estimates derived from twin methods rely on several major 
assumptions such as equal environment assumption (Hettema et al., 1995), which 
might not be sound. Recently, an alternative method has been developed to estimate 
the heritability of non-Mendelian traits, called genome-wide complex trait analysis 
(GCTA) (Yang et al., 2011a). GCTA correlates genomic similarity across hundreds 
of thousands SNPs derived from GWAS data with phenotypic similarity pair by pair 
across large samples of unrelated individuals.  GCTA decomposes the phenotypic 
variance into additive genetic (“SNP heritability“) and non-genetic components of 
variance, and has been successfully applied to various traits such as height, weight, 
and a variety of psychiatric and medical diseases (Yang et al., 2011a, Lee et al., 2011, 
Yang et al., 2011b, Lee et al., 2012b). The genetic influence on a trait or disease 
estimated by GCTA is usually smaller than the heritability found in twin studies. One 
reason for this is that GCTA only includes common variants tagged by GWAS which 
are in imperfect linkage disequilibrium with causal SNPs. Recently, the GCTA 
method has been extended to perform bivariate analysis of two quantitative traits in 
general populations, or two qualitative traits in case-control studies. by decomposing 
the phenotypic covariance between traits into components of covariance (Lee et al., 
2012a). In addition, GCTA can run bivariate analysis using both binary/ continuous 
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traits, or a binary trait and a continuous trait. In this study, we used GCTA to 
investigate the phenotypic variance of BMI and MDD explained by genetic variants 
captured by GWAS data, and the genetic correlation between BMI and MDD related 
to these variants. 
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5.2 Results  
 
 
After quality control procedures, the sample consisted of 3872 individuals, including 
2865 cases and 1007 controls from the RADIANT studies. These data were used to 
estimate the genetic relationship matrix using autosomal SNPs that also passed 
stringent quality control procedures. The reliability of self-reported height and 
weight measurements were checked against measured height and weight in the 
GENDEP dataset, where both types of measure were available. The correlation for 
measured versus self-reported height was 0.95 (P<0.0001) and for measured versus 
self-reported weight 0.97 (P<0.0001). The correlation for BMI-based measured data 
versus self-report was 0.95 (P<0.0001).  
 
Analyses were initially performed on the RADIANT sample (N=3872). The 
proportion of phenotypic variance in BMI and MDD related to the additive effects of 
common SNPs was estimated at approximately 0.17 (S.E.=0.12, P=0.10) and 0.36 
(S.E.=0.12, P=0.001), respectively. The residual variance for BMI was 22.04 
(S.E.=3.48), and for MDD, 0.09 (S.E.=0.02). The residual covariance between BMI 
and MDD was -0.09 (S.E.=0.18). The estimated genetic correlation between BMI 
and MDD was 0.61 (SE=0.26, P=0.02). To obtain greater power, an additional 1645 
individuals (N=793 cases, N=852 controls) genotyped with the same commercial 
chip were added to the sample. The results of analysis on the combined sample 
suggested that common SNPs explained 0.15 (SE=0.09, P=0.04) of variance in BMI 
and 0.33 (SE=0.08, P=5*10-6) of variance in MDD. However, the estimated genetic 
correlation between BMI and MDD was no longer significantly different from zero 






Results conducted incorporating both the RADIANT and Munich-GSK data indicate 
that the “SNP heritability”, or proportion of variance explained by additive genetic 
effects, was 0.15 for BMI and 0.33 for MDD. As expected, the genetic variance 
explained by common variants estimated using GCTA was lower than the heritability 
estimated from twin studies. The reasons are probably two-fold. First, GCTA only 
estimates the effect of common variants, rather than all genetic variants including 
rare alleles that might contribute to variation. Second, there is incomplete linkage 
disequilibrium between casual variants and genotyped variants, meaning that the 
effect will be exaggerated if un-genotyped real causal variants have a lower allele 
frequency than the tagged SNPs in commercial arrays (Yang et al., 2010). That said, 
our results confirm that both BMI and MDD are heritable, and further suggest that a 
significant proportion of phenotypic variance can be explained by the additive 
genetic effects of common SNPs. In addition, our findings are largely in line with 
previous univariate studies, which have suggested that the “SNP heritability” of BMI 
is 17% (Yang et al., 2011b) and 32% for MDD (Lubke et al., 2012). Although 
GWAS have identified dozens of genetic risk alleles for BMI, the cumulative effects 
of these variants only explain a tiny proportion of the phenotypic variants. In MDD, 
no genome-wide significant SNPs have replicated. Our results suggest that the 
‘missing heritabilities’ of BMI and MDD are not so much missing as hiding. Further 
variants exerting very small effects could be identified by increasing the sample size 
in GWAS studies to obtain enough power.  The different magnitudes in the 
proportions of additive genetic variance captured by common variants between BMI 
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(18%~33%) and MDD (44%~83%) could suggest that the allelic architecture of 
these two complex traits differs. 
 
When calculating the genetic correlation between a continuous trait and a binary 
trait, GCTA analysis treats both traits as though they are continuous. This does not 
influence the estimate of the genetic correlation, as this estimate is not affected by 
scale or ascertainment (Lee et al., 2012a). However, GCTA will not treat the binary 
trait as a disease, and therefore the estimate of the variance explained for the disease 
trait is not adjusted for scale and ascertainment (i.e., it is not on the scale of liability). 
Therefore, the results for the disease trait might be slightly different from those on 
using a univariate analysis on that trait or a bivariate analysis with a continuous trait.  
 
The GCTA genetic correlation between BMI and MDD was 0.61 in the RADIANT 
sample, and 0.40 in the combined sample, with the 95% confidence interval for the 
latter estimate overlapping with zero, meaning that it was not significant using 
conventional criteria. As such, conclusions should be drawn with caution. The 
discrepancy between these two estimates and the large standard errors suggest that 
bivariate GCTA analysis almost certainly needs even larger sample sizes to arrive at 
definitive estimates. Although the phenotypic variance explained by genetic factors 
estimated using GCTA is usually smaller than that reported in twin studies, the 
genetic correlation between BMI and MDD should be independent of the estimate of 
heritability, and therefore unbiased. This is because the ratio between genetic 
variance and genetic covariance are assumed to be biased to the same extent in both 
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traits, so they offset each other. In addition, the genetic correlation between two traits 
can be high even when the heritability of both individual traits is low.  
 
Family and twin studies have previously suggested a significant genetic correlation 
between BMI and depression, but the findings have been somewhat inconsistent. A 
recent large family-based study (Choy et al., 2009) in a genetically isolated 
community attempted to disentangle the contribution of shared environment factors 
and genetic factors to the correlation between depressive symptoms and body 
composition (including BMI, lean mass index, fat mass index and waist-hip ratio). 
Although there was a significant phenotypic correlation between depressive 
symptoms and body composition, there was no evidence to support the contribution 
of shared genetic factors to the co-occurrence between depressive symptoms and 
body composition. A twin study in males (McCaffery et al., 2003) reported an 
association between obesity-related metabolic syndrome and depressive symptoms, 
but this appeared to be attributable to common environmental factors rather than to 
shared genetic factors. In contrast, twin study in females (Afari et al., 2010) 
suggested that 12% of the genetic component of depression was shared between 
depression and obesity. Our results suggest that an even larger genetic correlation 
could exist, but a much larger sample is needed to increase the reliability of the 
estimate. 
 
One advantage of our study is the robustness of MDD diagnoses. In all previous 
studies examining a possible genetic relationship with obesity, depression was 
assessed using self-reported scales of symptoms, or self-report of doctor-diagnosis of 
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depression. For our subjects, the diagnosis was based on face-to-face semi-structured 
interview, and at least moderate severity was required for inclusion. This is likely to 
be of relevance, since there is evidence that the phenotypic association between 
obesity and depressive disorder is stronger than that between obesity and depressive 
symptoms (Luppino et al., 2010). This may explain a stronger genetic correlation 





One potential limitation of this study is that the calculation of BMI was based on 
self-reported weight and height. However, for a substantial subset of subjects (N = 
811), we were able to compare self-reported weight and height with measured weight 
and height, and we found that the correlations were very high. This suggests that 
using a self-report of BMI does not introduce much error, and contradicts the claim 
(Gorber et al., 2007) that people systematically under-report their BMI.  An 
additional potential problem is that this analysis combined studies where the subjects 
were collected from multiple sites. Although they were all of white European origin, 
there is still a risk of introducing population genetic substructure, as well as adding 
country specific environmental variation (non-genetic risk factors). Both effects 
could bias the estimate of heritability. To mitigate this problem, principle 
components derived to estimate population substructure were included as fixed 
effects, although this approach cannot be regarded as foolproof (Browning and 
Browning, 2011). A final limitation is that, although RADIANT is one of the largest 
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samples on which both information on clinical depression and BMI is available, and 
although we expanded the dataset by adding in the Munich sample, we are still faced 
with an imprecise estimate of the true size of the genetic correlation between BMI 







The present study indicated that fairly substantial proportion of the variance of BMI 
and MDD can be explained by common SNPs tagged by commercial arrays, 
although estimates are lower than the heritability suggested by twin studies. It is also 
the first to demonstrate using GCTA that there may be a genetic correlation between 
BMI and MDD. However, the results at this stage are only suggestive, and further 







A genetic risk score combining 32 SNPs is associated with 
body mass index and improves obesity prediction in people 
with major depressive disorder 
(This chapter forms the basis of a paper of the same title by Hung CF et al; that has 
now been published in BMC Medicine 13:86, 2015) 
 
Abstract 
Obesity is strongly associated with major depressive disorder (MDD) and various 
medical diseases. As described previously, genome-wide association studies (GWAS) 
have identified multiple risk loci robustly associated with body mass index (BMI). In 
this study, we aimed to investigate whether a genetic risk score (GRS) combining 
multiple BMI risk loci might have utility in the prediction of obesity in patients with 
MDD. Linear and logistic regression models were conducted to predict BMI and 
obesity, respectively, in three independent large case-control studies of major 
depression (RADIANT, GSK-Munich, PsyCoLaus). The analyses were first 
performed in the whole sample and then separately in depressed cases and controls. 
An unweighted GRS was calculated by summation of the number of risk alleles. A 
weighted GRS was calculated as the sum of risk alleles at each locus multiplied by 
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their effect sizes. Receiver operating characteristic (ROC) analysis was used to 
compare the discriminatory ability of predictors of obesity. 
 
In the discovery phase, a total of 2,521 participants (1,895 depressed patients and 
626 controls) were included from the RADIANT study. Both unweighted and 
weighted GRS were highly associated with BMI (p<0.001) but explained only a 
modest amount of variance. Adding ‘traditional’ risk factors to GRS improved the 
predictive ability significantly, with the area under the curve (AUC) in the ROC 
analysis increasing from 0.58 to 0.66 (CI 0.62-0.68, x2=27.68, p<0.0001). Although 
there was no formal evidence of interaction between depression status and GRS, 
there was further improvement in AUC in the ROC analysis when depression status 
was added to the model (AUC=0.71, CI 0.68-0.73, x2=28.64, p<0.0001). We further 
found that the GRS accounted for more variance of BMI in depressed patients than in 
healthy controls, and discriminated obesity better in patients than in controls. We 
later replicated these analyses in two independent samples (GSK-Munich and 
PsyCoLaus) and found similar results.  
As such, the GRS proved to be a highly significant predictor of obesity in people 
with MDD, but accounted for only modest amount of variance. Nevertheless, as 
more risk loci are identified, combining a GRS approach with information on non-
genetic risk factors could become a useful strategy for identifying MDD patients at 







As noted in earlier chapters, obesity is already a serious public health problem, and 
obesity rates continue to rise (Wang et al., 2011). Previous studies, including Chapter 
3, indicate that people with major depressive disorder (MDD) are more likely to be 
overweight or obese compared to psychiatrically healthy controls (Farmer et al., 
2008). In addition, Chapter 3 reported that depressed people have a higher risk for 
various medical diseases, many of which are obesity-related. Given the high 
prevalence rate of both obesity and MDD, understanding the nature of their 
relationship is a pressing clinical problem. 
 
Previous chapters have discussed the possibility that physiological or psychological 
mechanisms, possibly mediated by common genetic and environmental factors, 
might contribute to the overlap between obesity and MDD. In Chapter 5, genome-
wide complex trait analysis (GCTA) was used to demonstrate that the phenotypic 
variance of both BMI and MDD is modulated by genes tagged by SNPs. 
Interestingly, the role of such common variants appeared more pronounced for 
depression than BMI. Furthermore, examination of the genetic correlation between 
MDD and BMI suggested a substantial overlap, although the estimate had a large 
standard error using bivariate GCTA as currently implemented.  
 
In this chapter I will describe how we further aimed to investigate whether a genetic 
risk score (GRS), constructed using the risk variants identified in published genome-
wide association studies (GWAS) on BMI, can be used to predict obesity and to 
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explain the variance of BMI. The advance of genome-wide association studies 
(GWAS) has successfully identified multiple polymorphisms associated with the risk 
of obesity and higher BMI (Thorleifsson et al., 2008, Willer et al., 2008, Speliotes et 
al., 2010). Among them, the fat mass and obesity associated (FTO) gene has been 
consistently and reliably replicated in different studies. Our team has found that 
several polymorphisms in the FTO gene, the locus conferring the highest genetic risk 
contribution to obesity, are associated with increased BMI in people with MDD. A 
disease history of depression further moderates the effect of FTO on BMI (Rivera et 
al., 2012). However, each risk variant only confers a modest effect on the risk, 
resulting in a limited ability for obesity prediction by applying single variants. It has 
been suggested that combining multiple loci into a genetic risk score (GRS) might 
improve prediction of obesity.  
 
To date, several studies have examined the joint genetic effect of different numbers 
of identified risk variants to discriminate obesity in general population (Sandholt et 
al., 2010, Peterson et al., 2011, Li et al., 2010). However, to the best of our 
knowledge, at present no study has the GRS-based prediction of obesity in people 
with MDD. In this study, we aimed to investigate whether a GRS incorporating a 
number of well-defined common single nucleotide polymorphisms (SNPs) might 










After excluding people with any missing genotype data, a total of 2,521 participants 
(2,086 non-obese people and 435 obese people) were included in the analysis from 
the RADIANT study. There were no differences in sex, age and depression status 
between included and excluded members of the sample (all p>0.05). The mean 
age±s.d. of participants was 43.9±12.8 (non-obese people 43.2±13.1, obese people 
47.3±10.7, t=-6.08, p<0.0001). In total, 67.7% of the sample were female (72.9% of 
the obese sample, and 66.6% of the non-obese sample, x2=6.50, p=0.011). Analyses 
indicated that obese people were more likely to be depressed (90.3% vs 72.0%, 
x2=64.87, p<0.001). 
 
As described in Chapter 2, the weighted and unweighted GRS for BMI was 
calculated from the 32 SNPs identified by Speliotes et al., (2010). The frequencies of 
uGRS and wGRS were approximately normally distributed (Figure 6.1). The mean 
uGRS (i.e. the total number of risk alleles of 32 SNPs), was 29.5±3.5 in obese people 
and 28.6±3.5 in non-obese people (t=-4.47, p<0.0001). The mean wGRS was also 
slightly higher in obese people compared to non-obese people (4.14±0.50 vs 




Principal component analysis was used to control for population stratification. The 
top five principal component scores were used to discriminate subpopulations of 
white Europeans. Principal component 1 (PC1, distinguishing southeastern European 
ancestry from northwestern European ancestry) and principal component 2 (PC2, 
distinguishing eastern European from western European ancestry) were significantly 
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Linear regression analyses with BMI as the outcome variable 
 
A base linear regression model including age, sex, depression status, ancestry and the 
interaction between ancestry and age accounted for 8.29% of the variance in log-
transformed BMI. After adding the weighted GRS to the base model, there was an 
improvement in fit, and an additional 1.27% of phenotypic variance in BMI was 
explained, bringing the total to 9.56% (Table 6.1). Using either weighted or 
unweighted GRS made little difference to the proportion of variance in BMI 
explained (9.56% vs 9.58%). No interactions between traditional covariates or 
between GRS and traditional covariates were found (data not shown). Although the 
interaction between depression and GRS on BMI did not meet the conventional 5% 
level of significance (ß=0.27, s.e.=0.02, p=0.078), stratifying the sample by 
depression status with GRS incorporated in the model explained an extra 1.63% of 
the variance in BMI in depressed patients, but only an extra 0.34% of the variance in 
BMI in healthy controls.
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Table 6.1.  Linear regression models with BMI as the outcome variable 
 
Study/sample Model F Adj. R2 Additional variance 





    
Total 
 
Model 1: adjusted by age, sex and 
depression     
 










Depressed cases Model 1: adjusted by age and sex    
 








Controls Model 1: adjusted by age and sex  
 












    
Total Model 1: adjusted by age, sex and 
depression     
 










Depressed cases Model 1: adjusted by age and sex 
 








Controls Model 1: adjusted by age and sex   
 












    
Total Model 1: adjusted by age, sex and 
depression     
 










Depressed cases Model 1: adjusted by age and sex  
 








Controls Model 1: adjusted by age and sex  
 











Prediction of obesity 
Logistic regression models were used to examine the relationship between GRS and 
obesity, in addition to age, sex, ancestry and depression status. The discriminative 
power of the regression model was measured by calculating the AUC. The AUC was 
significantly higher in the model combining all non-genetic risk factors (age, sex, 
ancestry and depression status) and genetic factors compared to the model only 
applying non-genetic risk factors (AUC increased from 0.69 to 0.71, x2=9.83, 
p=0.0017). We further investigated whether GRS alone is able to discriminate 
obesity or not across depressed individuals. When only the genetic risk score and 
ancestry was included in the base regression model, the AUC was only 0.58 (95% CI 
0.55-0.61). However, the AUC increased to 0.65 (95% CI 0.62-0.68) after adding 
traditional risk factors such as age and sex (x2=21.46, p<0.0001). The AUC further 
increased to 0.71 (95% CI 0.68-0.73) when depression status was also incorporated 
into the model (x2=32.33, p<0.0001) (Figure 6.2). Again, incorporating the 
unweighted GRS produced similar results to the wGRS (AUC increased from 0.58 to 
0.65 to 0.70). 
 
Similar to the analysis conducted to predict BMI, we stratified the sample based on 
depression status, and found that in depressed patients, the AUC increased from 0.58 
(95% CI 0.55-0.61) to 0.61(95% CI 0.58-0.64) (x2=5.65, p=0.0175); whilst in healthy 
controls it remained at 0.67 (95% CI 0.60-0.73) (x2=0.00, p=0.98). No interaction 
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Figure 6.2 Receiver operating characteristics curves for models predicting obesity. 
The AUC for full model combining depression status, age, sex and GRS is significantly greater 
than AUC for the model combining age, sex and GRS, which in turn is significantly greater than 
AUC for the base model with only GRS. 
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A total of 1,679 participants from the GSK-Munich study (244 obese people and 
1,435 non-obese people) were included in this study. The mean age ±s.d was 51.49 
±13.50 (53.29 ± 11.51 for obese people and 51.19 ± 13.80 for non-obese people, 
p=0.01). There were no gender differences between obese and non-obese people 
(64.75% obese people were female and 67.24% non-obese people were female, 
p=0.44). Obese people were more likely to be depressed (64.75% v. 46.27%, 
p<0.001).  
 
Linear regression analyses with BMI as the outcome variable: data from the 
GSK-Munich study 
 
The replication phase repeated analyses conducted during the discovery phase in two 
independent samples. First, analyses were conducted in the GSK-Munich study. 
Linear regression models predicting BMI suggested that the wGRS accounted for 
0.63% of the variance in log-transformed BMI. When the sample was stratified by 
depression status, the wGRS was found to explain an extra 1.32% of phenotypic 
variance of BMI in depressed patients, but only accounted for 0.23% of variance in 
healthy controls (Table 6.1). No significant interaction was found between 
depression and GRS on the prediction of BMI (ß=0.25, s.e.=0.01, p=0.18). 
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 Prediction of obesity: data from the GSK-Munich study 
 
Logistic regression models were used to examine the relationship between GRS and 
obesity in addition to age, sex, ancestry and depression status. The AUC was 
approximately 0.59 (95% CI 0.55-0.63) when only wGRS and ancestry were 
included in the base regression model. The AUC increased to 0.64 (95% CI 0.60-
0.68) when traditional risk factors such as age and sex were added to the model 
(x2=8.21, p=0.004). The AUC further increased to 0.69 (95% CI 0.66-0.73) when 
depression status was also incorporated into the model (x2=10.67, p=0.001). 
Analyses on the sample stratified by depression status showed that using the wGRS 
to discriminate obese from non-obese individuals significantly increased the 
accuracy of prediction in depressed patients (AUC increased from 0.53 (95% CI 
0.48-0.58) to 0.58 (95% CI 0.53-0.63), x2=4.19, p=0.041), but not in healthy controls 
(AUC remained at 0.66 (95% CI 0.60-0.72), x2=0.34, p=0.56). No significant 
interaction was found between depression and GRS on the prediction of obesity 





2,993 subjects (409 obese people and 2,584 non-obese people) were included in 
PsyCoLaus study. The mean age ±s.d is 50.19 ± 8.84 (52.94 ± 8.80 for obese people 
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and 49.76 ± 8.77 for non-obese people, p<0.0001). There were no gender differences 
between obese and non-obese people (49.87% obese people are female and 53.44% 
non-obese people are female, p=0.18). Obese people and non-obese people have 
equal depression rate (40.83% v. 43.69%, P=0.28).  
 
Linear regression analyses with BMI as the outcome variable: PsyCoLaus study 
 
The second part of the replication study repeated the analysis on data from the 
PsyCoLaus study. Linear regression analysis to predict BMI suggested that the 
wGRS accounted for 0.90% of the variance in log-transformed BMI in this sample. 
When the sample was stratified by depression status, the wGRS explained extra 
1.09% of phenotypic variance of BMI in depressed patients, but only accounted for 
0.77% of variance of BMI in healthy controls (Table 6.1). No significant interaction 
was found between depression and GRS on BMI (ß=0.09, s.e.=0.01, p=0.52). 
 
Prediction of obesity: PsyCoLaus study 
Logistic regression models were again used to examine the relationship between 
GRS and obesity, in addition to age, sex, ancestry and depression status. The AUC 
was approximately 0.56 (95% CI 0.53-0.58) when only GRS and ancestry were 
included in the base regression model. The AUC increased to 0.62 (95% CI 0.59-
0.65) when traditional risk factors such as age and sex (x2=14.61, p=0.0001) were 
added. The AUC remained at 0.62 (95% CI 0.59-0.65) when depression status was 
also incorporated into the above model (x2=0.11, p=0.74). Analyses on the sample 
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stratified by depression status demonstrated that using wGRS to discriminate obese 
from non-obese individuals was not statistically significant in either depressed 
patients (AUC increased from 0.61 (95%CI 0.56-0.66) to 0.63 (95%CI 0.58-0.67), 
x2=3.66, p=0.0558) or in healthy controls (AUC increased from 0.61 (95%CI 0.57-
0.65) to 0.62 (95%CI 0.59-0.66), x2=2.66, p=0.1). No significant interaction was 




In this study, we developed both weighted and unweighted GRS based on 32 well 
established risk loci for BMI from a recent meta-analysis of GWAS (Speliotes et al., 
2010). We aimed to investigate whether the GRS derived from these loci are 
associated with BMI and predict obesity in depressed patients and controls.  
 
6.3.1 Prediction of BMI 
Both uGRS and wGRS were associated with BMI (p<0.0001) and accounted for 
1.27%, 0.63% and 0.90% of the phenotypic variance of BMI in the RADIANT, GSK 
Munich and PsyCoLaus studies, respectively. The amount of variance in BMI 
explained by the GRS was very similar across studies. For each unit increase in 
uGRS, which is equal to one additional risk allele, BMI increased by approximately 
0.175 kg/m2. Our overall result was thus in keeping with previous findings (Speliotes 
et al., 2010), which used the same method to construct a GRS for BMI, but which did 
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not address the relationship between BMI and depression, or the predictive utility of 
the GRS in depressed individuals specifically.  
Our results suggest that the GRS explained more of the phenotypic variance in BMI 
in depressed patients compared to healthy controls, analyses of the interaction 
between depression status and GRS were suggestive in the discovery sample 
(RADIANT), but not significant in the replication samples (GSK Munich and 
PsyCoLaus). This could reflect the fact that significant interactions are often difficult 
to detect when the outcome variable has been log transformed. Interestingly the 
case/control difference in the effect of GRS was more prominent when depression 
was diagnosed in clinical settings (the RADIANT and GSK Munich studies) than in 
a community sample (PsyCoLaus study). 
 
6.3.2 Prediction of obesity 
We further explored the utility of a GRS approach in the prediction of obesity using a 
ROC analysis to compare the discriminatory ability of different predictors. 
Conventionally, it is accepted that the AUC in a ROC analysis should be >0.8 to be 
of clinical value for screening. In our discovery phase, the AUC for our predictive 
models fell short of this threshold, but combining genetic factors and non-genetic 
factors proved better than using GRS alone in the prediction of obesity (with the 
AUC increasing from 0.69 to 0.71). In our replication phase, findings were similar, 
except that depression had a small and non-significant association with obesity in the 
PsyCoLaus study. This could reflect the fact that PsyCoLaus was a community based 
study with less severe cases of MDD than the clinically ascertained RADIANT and 
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Munich GSK samples. Our results suggest that GRS might improve obesity 
prediction more in depressed patients compared to controls.  
 
In other respects, our results were similar to those of other studies that used only 
genome wide significant genetic variants to construct a GRS (Sandholt et al., 2010), 
in finding that the optimum AUC was obtained by combining GRS and non-genetic 
risk factors. A significant novel feature of the present study was that combining these 
factors with depression status further improved the prediction of obesity. This is in 
keeping with the reported association between obesity and MDD in both general 
population or clinical settings (Farmer et al., 2008, Zhao et al., 2009, Luppino et al., 
2010). In addition, the fact that GRS has a larger predictive utility on BMI and 
obesity in depressed patients, especially clinically severe depression suggests that 
genetic effects on the association between obesity and clinically significant 
depression may be more important at the more severe end of the distribution. 
 
6.3.3 Limitations 
Several limitations of the present study should be mentioned. First, we only selected 
the risk loci that reached genome-wide levels of significance (Speliotes et al., 2010) 
to construct the GRS. It is highly probable that there are additional, as yet un-
identified loci that will emerge when even larger sample sizes are include in GWAS. 
Incorporating these variants into a GRS may well improve predictive utility.  Second, 
since the common variants identified in GWAS explain only a small proportion of 
the variation in BMI (Chapter 6 identified the SNP heritability at 15%), future 
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studies should include rare variants with larger effects and copy number variants to 
construct the GRS. In addition, gene-gene interactions and gene environment 
interactions should be taken into account to maximise the predictive utility of the 
GRS. For example, our group (Rivera et al., 2012) has found that depression status 
moderates the effect of FTO gene on BMI, although we did not find evidence of 
interaction between depression and GRS in current study. Third, the 32 BMI loci we 
used to construct the GRS were identified in GWAS of individuals of white 
European origin. The allele frequencies and their effect sizes may be different in 
populations of non-Europeans, and our results may not be generalize to other 
ethnicities. Furthermore, our study is a cross sectional study, and cannot therefore 
take into account BMI fluctuations across the life span. A further minor limitation is 
that PsyCoLaus is a subset of the CoLaus study, which was one of the 46 studies 
from which the BMI associated risk variants was derived (Speliotes et al., 2010), and 
therefore cannot on its own provide an independent estimation of the risk score effect. 
 
6.3.4 Conclusions 
In summary, we found that either a weighted GRS or an unweighted GRS based on 
32 well established risk loci for BMI on the basis of a meta-analysis were 
significantly associated with BMI in our samples. The GRS on its own explained 
only a small fraction of the variance in BMI, although including non-genetic risk 
factors together with GRS and depression status in predictive models came close to 
reaching the conventional threshold for clinical utility used in ROC analysis, and 
improved the prediction of obesity compared to GRS alone.  
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Our results suggest that the GRS might predict obesity prediction better in depressed 
patients than in healthy controls. This has potential clinical implications, as well as 
implications for future research directions in exploring the links between depression 
and obesity–associated disorders. While it is likely that future genome wide studies 
with very large samples will detect other than common variants, it seems probable 
that a combination of genetic and non-genetic information will still be needed to 







Relationship between obesity and the risk of clinically 
significant depression: Mendelian randomisation study. 
 
(This chapter forms the basis of a paper of the same title by Hung CF et al; that has 
now been published in British Journal of Psychiatry, 205(1) 24-28, 2014) 
 
Abstract 
As noted in previous chapters, obesity is associated with depression, and it has been 
suggested that higher body mass index (BMI) might increase the risk of depression 
and other common mental disorders. However, the causal relationship between BMI 
and depression remains unclear. Chapter 7 describes a study using Mendelian 
Randomisation, a form of instrumental variable analysis, to investigate whether 
higher BMI increases the risk of major depression. Two instrumental variable 
analyses were conducted to test this causal relationship in the RADIANT sample, a 
large case-control study of major depression. A single nucleotide polymorphism 
(SNP) in FTO, and a genetic risk score (GRS) based on 32 SNPs with well-
established associations with BMI were used in the analysis. 
Linear regression analysis, as expected, showed that individuals carrying more risk 
alleles of FTO, or with higher score of GRS had a higher BMI. Probit regression 
suggested that higher BMI was associated with an increased risk of major depression. 
However, our two instrumental variable analyses did not support a causal 
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relationship between higher BMI and major depression (FTO genotype: coefficient –
0.03, 95% CI –0.18 to 0.13, P = 0.73; GRS: coefficient –0.02, 95% CI –0.11 to 
0.07, P = 0.62). The positive associations between higher BMI and major depression 
evidenced in probit regression analyses might be explained by reverse causality 





As discussed in Chapter 1, the reasons for the well-established phenotypic 
association between obesity and depression are unclear. Evidence presented in 
Chapter 5 demonstrated that both major depressive disorder (MDD) and body mass 
index (BMI) have a heritable component related to common SNPs (“SNP-
heritability”). The results of Chapter 5 also suggested that there is a probable genetic 
correlation between MDD and BMI. However, cross-sectional studies cannot rule out 
the possibility that there might also be a causal relationship between obesity and 
depression. Most previous studies have only examined the relationship between 
obesity and depressive symptoms, rather than depressive disorder per se. Although 
depressive symptoms could be predictors of subsequent depressive disorder, it is 
preferable to examine the relationship between obesity and clinically significant 
major depression assessed by a standardized interview. Longitudinal studies provide 
some pointers towards disentangling the direction of the association between the 
phenotypes. A recent systematic review and meta-analysis of such studies (Luppino 
et al., 2010) showed that obesity at the baseline increased the risk of onset of 
depression in the follow-up period (OR=1.55). Further, the analysis found that the 
association was even stronger for depressive disorder than for depressive symptoms. 
However, there were limitations. First, only 25% of studies included in the meta-
analysis were rated as sufficiently high quality by the authors to warrant inclusion. 
Second, only two studies assessed a clinical diagnosis of major depression, rather 




Amongst longitudinal studies, one report (Anderson et al., 2007) found that obese 
adolescent girls (but not boys) were more the likely to develop major depression 
twenty years later. Another study (Roberts et al., 2003) recruited people in late 
adulthood (mean age=63), and found that obesity increased the risk of onset of 
depression. However, since vascular factors plays a role in late-onset depression 
(Hickie et al., 2001), and given that obesity increases the risk of cardiovascular 
disease, the increased incidence of late-onset depression may be confounded by this 
shared physiological mechanism. The association between obesity and major 
depression might also be confounded by other unmeasured factors such as diet or 
exercise (Beydoun and Wang, 2010).  
 
As described in Chapter 5, Mendelian randomization (MR) analysis has been 
suggested as a means to clarify causal inference in observational studies (Sheehan et 
al., 2008). To date, three studies have taken this approach to examine the BMI-
depression association (Jokela et al., 2012, Kivimaki et al., 2011, Lawlor et al., 2011). 
The underlying idea is that genetic variants that are reliably associated with BMI or 
obesity can be used as instrumental variables (IVs) to investigate the causal effect of 
obesity on major depression. Recently, the advance of genome-wide association 
studies (GWAS) has provide the opportunity to examine the relationship between 
obesity and major depression, as numerous loci have been identified as risk genetic 
variants for BMI or obesity (Speliotes et al., 2010). Among them, the fat mass and 
obesity-associated (FTO) gene has been repeatedly and consistently associated with 
BMI. However, FTO genotype alone is not ideal for MR analysis because it only 
explains a very limited amount of variance in BMI. Compared to a single genetic 
variant, a composite genetic risk score based on multiple associated loci should be a 
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better instrument to examine the relationship between polygenic traits such as obesity 
and major depression, and should provide increased statistical power (Palmer et al., 
2012). As discussed in Chapter 6, a weighted genetic risk score (wGRS) constructed 
from 32 single-nucleotide polymorphisms (SNPs), weighted by their effect size 
explained a modest but significant proportion of BMI, and inclusion of the GRS in 
the predictive model improved the prediction of obesity, particularly in depressed 
patients.  
 
This study aimed to take an MR approach to investigate whether higher BMI 
increases the risk of major depression, and selecting two IVs, namely FTO genotype 
and wGRS. 
 
7.2 Results  
 
A total of 3,222 participants from the RADIANT study with complete BMI, age, sex 
and GWAS data were included in the analysis. Individuals with major depression 
were predominantly female, older, and had a higher BMI compared to healthy 
controls, but there was no difference in FTO genotype and wGRS between depressed 
patients and healthy controls (see Table 7.1). The distribution of BMI was slightly 
positively skewed, so BMI was natural log-transformed for further analyses. The call 
rate of FTO genotype (rs3751812) was 100%. The wGRS was obtained from 2521 
participants (78.2%) with complete data for the 32 SNP genotypes. There were no 
differences in demographic characteristics between people with and without 
complete genotype data (all P>0.05). Neither FTO genotype nor wGRS were 
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associated with sex (FTO:x2=0.17, p=0.72; wGRS: t=-0.93, p=0.35) or age (FTO: 
F=0.49, p=0.61; wGRS: cor=-.002, p=0.94). 
 
Both FTO genotype and wGRS were significantly associated with log-transformed 
BMI after adjusting age, sex, depression status and principal components of ancestry 
(B=0.048, P=0.011 for one risk allele in FTO genotype; B=0.062, P =0.001 for two 
risk alleles in FTO genotype; and B=0.114, P<0.001 for wGRS). This suggests that 
both FTO genotype and wGRS were valid indicators of risk of high BMI. A formal 
test for evidence against weak instruments as mentioned in the statistical analysis 
section (Chapter 2) confirmed these findings (F value for FTO genotype was 11.32, 
and for wGRS 33.26 in a model predicting BMI).  
 
Results of the probit regression analysis indicated that BMI was associated with 
major depression (coefficient=0.05, 95% CI =0.04, 0.06, P<0.001). FTO genotype 
and wGRS were not directly associated with the relative risk of major depression 
when adjusting for covariates (1 risk allele of FTO genotype: coefficient=-0.06, CI=-
0.17, 0.05, P =0.31; 2 risk allele of FTO genotype: coefficient=-0.01, CI=-0.15, 0.14, 
P =0.93; wGRS: coefficient=-0.03, CI=-0.14, 0.07, P =0.54). When using FTO 
genotype or wGRS was used as an instrumental variable for BMI, the change in BMI 
was not able to predict the risk of MDD (FTO genotype: coefficient=-0.03, 95%, CI 












P value (X2 or t) 
Female 69.79 % 61.11% X2=20.58, P<0.001 
Age 45.2 (12.2) 39.9 (13.7) t=-10.37, P<0.0001 
BMI 26.4 (5.5) 24.30 (4.5) t=-9.75, P<0.001 
FTO genotype    
  GG 834 (34.3%) 260 (32.8%) X2=1.29, P =0.53 
  GT 1177 (48.4%) 402 (50.8%) 
  TT 419 (17.2%) 130 (16.4%) 




Table 7.2 Comparison of conventional linear and instrumental-variables regression 




coefficients (95% CI) for major depression 




    












Although a positive association between obesity and major depression was found in 
our conventional probit regression, our independent variable analysis did not support 
the hypothesis that obesity increases the risk of a clinical diagnosis of major 
depression, using either FTO genotype or wGRS as the instrumental variable. Our 
results are not in line with the findings from other MR studies, which have suggested 
that obesity does have a causal influence on mental health problems. For example, 
the longitudinal Whitehall study (Kivimaki et al., 2011) suggested that long-term 
obesity is a risk factor for common mental disorder (CMD) in men. Although the 
Whitehall study met most of the requirements for MR analysis (Glymour et al., 2012), 
some important assumptions were made. First, the association between the 
instrumental variable, FTO genotype, and obesity was significant only in males but 
not females, in contrast to evidence from GWAS of FTO genotype, which have 
indicated associations with BMI in both genders (Speliotes et al., 2010). Second, the 
independent variable used in the Whitehall study might be invalid under the 
assumption that net unmeasured confounding is positive (Glymour et al., 2012). 
Third, the study did not assess CMD directly, but instead used a self-report general 
health questionnaire (GHQ) (Goldberg, 1972), which is a screening tool for 
depression and anxiety with relatively low specificity.  
 
Another longitudinal cohort study (Jokela et al., 2012) reported that high BMI 
increased symptoms of depression using a genetic risk score similar to the one we 
used (31 SNPs). However, the association between their IV and smoking violated the 
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exclusion restriction assumption, as smoking might be a confounding factor between 
BMI and depression because there is a bidirectional relationship between smoking 
and depression (Chaiton et al., 2009). In addition, depression symptoms were 
assessed by a modified version of Beck’s Depression Inventory (BDI) (Beck et al., 
1996), which is essentially an instrument for measuring symptom severity rather than 
for assigning a diagnosis. Both MR studies found that higher BMI (obesity) 
increased the risk of depressive symptoms in the follow-up period. In contrast, one 
cross-sectional study (Lawlor et al., 2011) found that higher BMI was positively 
associated with psychological distress using conventional multivariable analysis, but 
the result was reversed while using independent variable analysis. The authors 
suggested that greater adiposity exerts protective effects against psychological 
distress via biological mechanisms, whilst the effects of stigmatization for being 
overweight and low self-esteem might increase the risk of psychological distress. 
The study was also limited in its assessment of psychological distress, which was 
measured using only four closed-ended questions, which have at best a modest 
relationship with the clinical diagnosis of major depressive disorder defined by 
DSM- IV (American Psychiatric Association, 2000). Our study differs from previous 
MR studies that mainly examined depressive symptoms or psychological distress. 
Instead we focused on clinically significant depression, showing that increased BMI 
cannot be considered as causal factor in the development of major depressive 
disorder severe enough to warrant treatment, and associated with a definite 
functional impairment. 
 
To the best of our knowledge, our study did not violate the assumptions of an MR 
study (Glymour et al., 2012). First, the two independent variables used in our study, 
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FTO genotype and wGRS, were reliably associated with BMI and obesity, 
suggesting the first assumption outlined by Glymour et al., (2012) is met. Second, we 
did not find an association between our independent variables (genotype) and age, 
sex and various obesity-related physical diseases such as diabetes, hypertension and 
myocardial infarction, which are known to associate with major depression, 
suggesting that any association between FTO and MDD is related to obesity or high 
BMI. Third, for the known exposure status (i.e. BMI or obesity) and known 
confounders, the independent variables are independent of the outcome (major 
depression). However, until the underlying mechanisms linking FTO genotype (or 
GRS) and major depression are comprehensively understood, it is impossible to 
exclude the possibility that the second and third assumptions of MR analysis were 
violated.  
 
Our probit regression analysis showed higher BMI was associated with major 
depressive disorder but no association was found in the independent variable analysis, 
suggesting either reverse causality, or the existence of important unmeasured 
confounders not entered into our conventional regression analysis. Unfortunately, no 
replicated genome-wide significant SNPs have so far been identified in GWAS of 
major depression (Wray et al., 2012), preventing us from carrying out an MR 
analysis to explore the  reverse direction of causation, where depressive disorder 
leads to obesity. The severity of major depression in our study was at least moderate, 
so most participants had at some point taken antidepressant or other psychotropic 
agents. A recent meta-analysis (Serretti and Mandelli, 2010) suggested that some 
antidepressants might cause weight change during long term treatment. In addition to 
antidepressant induced weight change, diet and sedentary lifestyle in depressed 
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people might cause them to be more likely to become obese. We did not measure all 
the possible confounding factors such as smoking, alcohol consumption or 
socioeconomic status, which might also influence the association between higher 
BMI and major depression. Another possible explanation for our negative result is 
the psychological impact of obesity on the development of major depressive disorder. 
In Western society, obese people are more likely to be stigmatized and develop low 
self-esteem, resulting in the onset of depression (Puhl and Heuer, 2010). If this were 
the case, the association between obesity and MDD might be hypothesized to be 
stronger in females compared to males, and in the younger population compared to 
the elderly, who may be more susceptible to social stigma. However, our study did 
not support this explanation. 
 
Several limitations of the present study should be considered. First, only prospective 
cohort studies can provide evidence regarding clear temporal relationships between 
risk exposures and outcomes, whereas our study was cross-sectional. Since genetic 
factors could influence the phenotype of BMI differently across the life-span, the 
choice of a relevant period of exposure may be important. However, since BMI is 
moderately correlated between adolescence and adulthood (Srinivasan et al., 1996, 
Guo et al., 2000), BMI measured at interview might be suitable as a proxy for BMI 
before onset of depression. This method has been applied in other Mendelian 
randomization studies (Lawlor et al., 2011, Mumby et al., 2011). Second, our results 
only pertain to the relationship between obesity and the risk of clinical depression of 
at least moderate severity. Therefore, we cannot rule out the possibility that obesity 
has a causal role in mild depression or subclinical depressive disorder. Third, our 
study was entirely based on white Europeans, so our results might not generalize to 
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other ethnicities. Fourth is the issue of power. Unfortunately, no formal methods 
currently exist that satisfactorily address the estimation of required sample size in 
MR studies (Pierce et al., 2011). However, the current sample is of a comparable or 
larger size than previous MR studies that have suggested a causal relationship 
between high BMI and depression (Kivimaki et al., 2011).  Finally, a caveat pointed 
out by Palmer et al. (2011) is that independent variable estimators rely on the 
assumption of “no effect modification”, rather than the assumption of “no defiers”. 
However, both assumptions are impossible to test from observable data, suggesting 
that they are problematic to evaluate in practice. 
 
7.4 Conclusion 
Although our conventional multivariate regression analysis found that increased BMI 
was strongly associated with major depression, our genetic independent variable 
analysis did not support the hypothesis that increased BMI raises the risk of onset of 
major depression, using either FTO genotype or wGRS for high BMI as the 
independent variable. As described above, Mendelian randomisation studies depend 
on several assumptions, which are not possible to completely verify. Although our 
study had several limitations, the evidence presented suggests that being overweight 







Further exploration of the associations between physical 




Throughout this thesis, evidence for the association between MDD and various 
physical illnesses has been presented. This chapter takes the same approach to that 
used in Chapter 5 which focused on BMI and MDD to examine a) whether genetic 
risk loci associated with physical diseases in published studies are over-represented 
in depressed patients, and b) whether Mendelian randomisation analysis using risk 
loci as instrumental variables suggests that physical illnesses cause depression, 
taking asthma as an example disorder (since the results of Chapter 2 suggested that 
the phenotypic overlap between asthma and depression may have a molecular genetic 
underpinning). The results indicate that the SNP rs1342326, which is near the IL-33 
gene, and is reportedly significantly and consistently associated with asthma in 
GWAS, is over represented in patients with MDD. However, the Mendelian 
randomisation analysis using two independent variables, namely rs1342326 and a 
weighted genetic risk score (wGRS) for asthma, did not support a direction of 
causality from asthma to depression. Therefore, the results suggest that there is a 
small but significant genetic overlap between the liabilities to depression and to 
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asthma, which may contribute to the excess of asthma in depressed subjects 






As discussed in Chapter 1, recent studies (Farmer et al., 2008) including my own 
(Chapter 3) have shown that MDD and physical diseases are frequently co-morbid. 
Prevalence rates of major depressive disorder are significantly higher in people with 
a chronic medical condition than those without (Fiest et al., 2011). As described in 
Chapter 1, previous work from our group (Farmer et al., 2008) found the highest 
three most prevalent physical diseases in people with recurrent depression are 
asthma, hypertension, and hypercholesterolemia, after controlling for age, sex and 
body mass index (BMI). Analyses presented in Chapter 3 demonstrated that, 
controlling for the same variables, hypertension, hypercholesterolemia and 
myocardial infarction were also over represented in depressed people, as were 
asthma and allergic rhinitis. The nature and directionality of the relationship between 
these physical diseases and MDD, and whether the specific attributes of the diseases 
contribute to the causation of MDD, remains unclear. 
 
As noted previously, GWAS have been designed to detect the common genetic 
variants that are associated with complex traits or diseases (Hirschhorn and Daly, 
2005), and although thousands of risk loci have been identified, the number of loci 
identified per complex trait varies greatly (Visscher et al., 2012), with no replicated 
genome-wide hits yet identified for MDD (Major Depressive Disorder Working 
Group of the Psychiatric GWAS Consortium, 2012). The reasons for these negative 




One consequence of the absence of genome wide significant ‘hits’ for depression is 
that, at present, it is not possible to explore whether depression has a molecular 
genetic overlap with disease X simply by examining whether depression and disease 
X have genome wide significant risk loci in common. There are, however, strategies 
that can exploit genome wide data on depression to examine the molecular genetic 
overlap with other diseases that do not require the stringent significance levels 
employed in a genome wide search.  
 
The first is simply to take polymorphisms that have been robustly associated with 
each of the diseases showing a phenotypic overlap with depression and test them for 
depression case/control differences. Such an analysis requires correction for a much 
smaller number of comparisons, and is therefore much more powerful than analyses 
requiring genome-wide levels of correction. The second and slightly more complex 
approach is to construct a genetic risk score (GRS) for each disease associated with 
depression, using the method described in Chapter 5, and see whether that GRS 
shows any association with depression. A third approach, which gives some purchase 
on the direction of causation, is to use individual disease associated loci and/or a 
GRS in an instrumental variable in a Mendelian randomisation analysis. This method 
was used to examine the causal link between high BMI/obesity and depression in 
Chapter 6. A fourth approach is to use a bivariate genome wide complex trait 
analysis (GCTA), to explore the genetic correlation between depression and “Disease 
X”, the method used to explore the relationship between BMI and depression in 
Chapter 4. A fifth approach would be to use polygenic score analysis and test 
whether a score derived from a GWAS of “disease X” predicts depression.  
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Unfortunately, the fourth and fifth approaches mentioned here require access to 
genome wide data on “disease X”, which we have not been able to obtain for any of 
the diseases shown to be phenotypically associated with depression in Chapter 3. We 
therefore have to rely on published data on risk alleles associated with these 
disorders, and use the second and third approaches described above to investigate the 
relationship and direction of causality. 
 
In Chapter 3, eight diseases are associated with MDD were identified, namely 
asthma, allergic rhinitis, hypertension, hyperlipidemia, myocardial infarction, gastric 
ulcer, osteoarthritis and thyroid disease. As described below (Methods section), only 
asthma was suitable for further analysis in our dataset. Although gastric ulcer was 
among the first disease to be associated with genetic polymorphisms (Edwards, 
1965), no GWAS on gastric ulcer have been conducted. In addition, data from the 
RADIANT study used in these analyses did not separate hypercholesterolemia into 
HDL-cholesterol or LDL-cholesterol, and did not separate thyroid disease into hyper- 
or hypothyroidism, which prevents us from constructing a GRS for further 
investigation of these conditions. There are only a few GWAS identifying risk SNPs 
reaching genome-wide significance for allergic rhinitis (Ramasamy et al., 2011), 
hypertension (Ehret et al., 2011, Padmanabhan et al., 2010, Levy et al., 2009), 
osteoarthritis (Zeggini et al., 2012, Betancourt et al., 2012) and myocardial infarction 
(Aoki et al., 2010, Helgadottir et al., 2007). Therefore, of the diseases 
overrepresented in depressed cases, asthma was the only candidate disease suitable 




The aim of this study was to examine whether individual polymorphisms associated 
with physical diseases are overrepresented in our sample of depressed individuals. A 
GRS for asthma was then calculated. Finally, an analysis using Mendelian 
Randomization (MR) was conducted, given that the analysis of GWAS data 
suggested that the phenotypic overlap of asthma and MDD may have a molecular 
genetic underpinning. 
 
8.2 Results  
A total of 22 studies including 2 studies on myocardial infarction (Aoki et al., 2010, 
Helgadottir et al., 2007), 3 studies on hypertension (Ehret et al., 2011, Padmanabhan 
et al., 2010, Levy et al., 2009), 5 studies on asthma (Heath and Madden, 2012, Wan 
et al., 2012, Ferreira et al., 2011, Moffatt et al., 2010, Ober and Nicolae, 2011), 1 
study on allergic rhinitis (Ramasamy et al., 2011), 4 studies on obesity (Bradfield et 
al., 2012, Jiao et al., 2011, Wang et al., 2011, Meyre et al., 2009) and 7 studies on 
BMI (Frayling et al., 2007, Loos et al., 2008, Willer et al., 2008, Thorleifsson et al., 
2008, Speliotes et al., 2010, Wen et al., 2012, Yang et al., 2012) were included in our 
analysis. All these studies fulfilled the requirement of having at least one hit reaching 
genome-wide significance for a physical illness. One hundred and seven hits were 
found in these studies, and seven hits (rs7775228, rs2155219 and rs17513503 on 
allergic rhinitis; rs6545814, rs9356744, rs261967 and rs1297579 on BMI) that were 
not replicated in the same or in other independent studies were excluded. After 
excluding the SNPs in LD with each other (r2>0.5), 60 SNPs survived. When the 
prevalence of SNPs in cases and controls with MDD was examined, one hit 
(rs1342326 located at 9p24.1, intergenic region between RANBP6 and IL-33 gene) 
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reached the threshold for statistical significance (p< 8.3*10-4) after correction for 
multiple testing (see Table 8.1).  
 
To test whether asthma per se might be a risk factor for MDD, formal MR analysis 
was conducted using our RADIANT data. A total of 2692 participants (1887 cases 
and 805 controls) were included in the analysis. The depressed patients were older 
than healthy controls (mean age (SD): 46.1(12.2) v. 39.9(13.7), t=11.61, P<0.0001) 
and there were more females among cases (72.28% v. 61.37%, x2=31.45, P<0.001). 
However, no difference in rs1342326 genotype and wGRS was observed between 
cases and controls (Table 8.2).The frequency of wGRS was approximately normally 
distributed (Figure 8.1).  
 
The relationship between asthma and wGRS/ rs1342326 genotype was examined 
using logistic regression controlling for age, sex, ancestry and depression status. 
Both wGRS and rs1342326 genotype increases the risk of asthma (wGRS: odds 
ratio=1.10 (95% CI=1.05-1.15, z=4.41, P<0.001; rs1342326: odds ratio=1.31 (95% 
CI=1.05-1.64), z=2.37, P=0.018). Logistic regression indicated that asthma is 
associated with MDD (odds ratio=1.79 (95% CI=1.35-2.37), z=4.06, P<0.001). 
However, we found that both rs1342326 genotype and wGRS are weak instrumental 
variables (IVs) (F value for rs1342326= 8.82 and F value for wGRS=6.64). Using 
these two IVs for asthma, it appears that the presence of asthma cannot predict the 
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 Table 8.2 Demographic Characteristics of Participants 
 




P value (X2 or t) 
Female 72.28 % 61.37% X2=31.45, P<0.001 
Age 46.1 (12.2) 39.9 (13.7) t=-11.61, P<0.0001 
Asthma 19.28% 11.43% X2=24.79, P<0.001 
rs1342326 genotype    
  CC 51 (2.7%) 20 (2.5%) X2=0.998, P =0.61 
  CA 505 (26.8%) 202 (25.1%) 
  AA 1330 (70.5%) 583 (72.4%) 






















Table 8.3 Comparison of Conventional logistic and Instrumental-Variables Regression 
Models (with rs13422326 Genotype and wGRS as Instrument) examining the association 
between asthma and Major Depression 
 
Odds ratio/ Coefficient(95% CI) for major depression 




     
Asthma 1.79 (1.35, 2.37) 
P<0.001 
 0.87(-1.43, 3.18) 
P =0.36  
0.49 (-2.30, 3.29) 
P =0.73 
 
The F value for rs1342326 was 8.82, and the F value for wGRS was  6.64. As such, both 







This study, which used published GWAS data on physical illnesses and MDD, as 
well as data from our own group, attempted to clarify their relationship between 
physical illnesses and MDD at the molecular level. Only asthma had a risk 
polymorphism that was also associated with depression after correcting for multiple 
testing. The asthma risk variant which had a statistically significant difference 
between MDD cases and controls was rs1342326, which is located between the 
RANBP6 and IL-33 genes. The C allele of the rs1342326 polymorphism is associated 
with an increased risk of asthma, and was also over-represented in patients with 
MDD. Because the transmission of genetic variants is randomly distributed during 
the period of gamete formation, the association between rs1342326 and MDD should 
be largely independent of confounding factors. As such, analysis used these asthma-
risk genotypes to examine whether asthma might be a risk factor for developing 
major depression. However, this Mendelian Randomisation analysis conducted in our 
RADIANT data failed to provide evidence that asthma raises the risk of MDD. The 
results therefore suggest that the asthma associated allele of rs1342326 is a probable 
risk factor for depression, but that asthma itself is not a risk factor for depression. 
That said, both rs1342326 and wGRS are weak instrumental variables, which may 
have resulted in a bias in the two-stage least square estimator, even though the 
analysis was conducted in a large sample (Staiger and Stock, 1994).  
 
Both asthma and MDD are two of the most common chronic medical conditions in 
the world. The lifetime prevalence rate of MDD has been estimated as approximately 
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16% in US (Kessler Rc and et al., 2003) whereas the current prevalence rate of 
asthma is approximately 8% and increased steadily in US (Akinbami et al., 2011). 
Studies have shown that individuals with asthma suffer more from depressive 
symptoms or MDD in either clinical settings or general population (Nejtek et al., 
2001, Goodwin et al., 2004, Ng et al., 2007). Other studies (Farmer et al., 2008, 
Loerbroks et al., 2012), including my own (Chapter 2) indicate that depressed 
patients are also more likely to have asthma. Although there is solid evidence 
suggesting that asthma is associated with MDD, the causal relationship between 
these two diseases remains unclear.  To clarify the causal relationship between 
asthma and MDD, it would be useful to investigate their temporal relationship. Since 
MDD often develops in adulthood, less than a quarter of patients who have co-
morbid asthma and MDD develop MDD prior to asthma onset (Solis et al., 2006). 
One of possible explanation of the generally later onset of MDD than asthma is that 
having asthma is itself a risk factor for MDD. Unfortunately, the majority of the 
previous association studies examining the relationship between these two diseases 
are cross-sectional, and cannot provide enough information to detangle the causal 
relationship.  Recently, a longitudinal study using a UK research database to follow 
up more than ten thousand people for ten years found that the incidence of 
depression at baseline in people with asthma was 22.4/1,000 person years, compared 
with 13.8/1,000 person years in people without asthma (Walters et al., 2011). This 
study provides further evidence that asthma might be a risk factor for depression 
from the epidemiological viewpoint.  
 
Nevertheless, the underlying mechanisms driving the association between asthma 
and depression remain unclear. Several candidate pathways have been suggested 
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comprising both genetic factors and environmental factors affecting autonomic 
nervous system and/or immune system dysregulation (Van Lieshout et al., 2009). A 
twin study estimated that 64% of the association between atopy and depression was 
due to shared familial vulnerability, consisting mainly of additive genetic factors 
(Wamboldt et al., 2000).  The asthma associated marker we identified that was 
associated with depression is close to the gene encoding interleukin-33 (IL-33), a 
novel member of IL-1 cytokine family (Liew et al., 2010). IL-33 can be both a 
secreted cytokine and a nuclear binding factor, although its precise function as a 
nuclear factor remains unclear.  It is expressed in various human cells, but its 
function is thought to vary across different tissues. IL-33 signals via a heterodimer 
receptor complex consisting of ST2 and IL-1R accessory protein. Higher 
concentrations of IL-33 protein have been found in patients with chronic asthma, and 
animal studies has shown that IL-33 exacerbate experimental asthma in mice (Louten 
et al., 2011). A recent GWAS study (Moffatt et al., 2010) has also reported an 
association between IL-33 and asthma.  
 
Notably, IL-33 and its receptor ST-2 are also widely expressed in human adipose 
tissue. The IL-33/ST-2 pathway plays a critical role in glucose homeostasis and 
protects against adipose tissue inflammation and atherosclerosis (Miller et al., 2008). 
IL-33 and ST-2 are also expressed in various tissues within the central nervous 
system, and IL-33 may have a pathogenic role in inflammatory diseases of the CNS. 
A polymorphism of IL-33 is also associated with an increased risk of Alzheimer’s 
disease (Morimoto et al., 2011). In addition, IL-33 can induce inflammatory pain in 
peripheral nervous system.  
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 Although no previous reports have investigated the relationship between IL-33 and 
major depression, another IL-1 family member, IL-1B has been reported to be a 
major regulator of the central inflammatory cascade. IL-1B can regulate several 
genes expressed in the brain, including CRH receptor 1 (CRHR1) gene, which has 
been associated with treatment response to antidepressants (Licinio et al., 2004). 
Depending the type of tissue, IL-33 can either initiate or maintain the inflammatory 
process, or resolve the inflammatory state. 
 
Although an association between inflammation and depression or depression-like 
symptoms has been established, the exact biological mechanisms remain unknown. 
Inflammation appears to account for a small proportion of the variance in depression 
in patients with physical diseases, rather than being a major factor in the majority of 
cases (Dantzer et al., 2008). Mechanisms that have been suggested to explain 
inflammation-related depression, irrespective of whether overt physical disease is 
also present, include induction of extra hypothalamic corticotrophin, development of 
glucocorticoid resistance, activation of the kyrurenine pathway and increased 
expression of the serotonin transporter (Miller, 2009). Among these, activation of the 
kynurenine (KYN) pathway is perhaps the most plausible mechanism. The 
kynurenine pathway is a major route of tryptophan catabolism, and the two main 
oxygenases responsible for degradation of tryptophan are tryptophan dioxygenase 
(TDO) and indoleamine 2,3-dioxygenase (IDO). IDO is the rate-limiting enzyme of 
kyrurenine pathway in all extrahepatic tissues. In the brain, microglial cells can 
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express IDO by the stimulation of interferon-gamma (Kwidzinskiand Bechmann, 
2007) and tumor necrosis factor (TNF-α).  
 
KYN may also have a role in depression in patients with cancer (Stone and Perkins, 
1981) and in other disorders where there is peripheral inflammation. Some evidence 
for this hypothesis comes from studies of interferon-gamma induced depression in 
patients with hepatitis C. Depression induced by interferon-gamma has been found to 
be correlate with peripheral tryptophan metabolites and KYN metabolites in plasma 
and in cerebrospinal fluid (Raison et al., 2010). 
 
Before concluding, several limitations of this study need to be considered. First, 
suitable single genetic variants to use as instrumental variables for Mendelian 
randomization studies are not easy to find. The effect size of these genetic variants 
tends to be extremely small, and may not be detectable despite large sample sizes. In 
addition, major depression is a probably a heterogeneous disease. Although we have 
shown that physical diseases are associated with major depression, we have not 
determined whether this applies to certain types of major depression. Furthermore, 
our results suggesting that asthma is a risk factor for depression does not exclude the 
possibility of a reverse causal relationship, or a shared physiological pathway. Third, 
the formal test of Mendelian randomisation analysis using two IVs for asthma did not 
support a direction of cause effect from asthma to depression. Therefore, the results 
only suggest that there is a small but significant genetic overlap between the 
liabilities to depression and to asthma that may contribute to the excess of asthma in 




Discussion and Conclusions 
 
The overall aim of my PhD study was to investigate the relationship between major 
depressive disorder (MDD) and a range of common physical diseases, plus obesity. 
Although both MDD and common physical diseases cause significant amount of 
disease burden, it is only comparatively recently that studies have begun to place 
much emphasis on their co-morbidity. In addition to investigating the prevalence 
rates and familial aggregation of physical diseases in depressed people, this thesis 
aimed to disentangle the relationship between MDD and physical diseases using 
various genetic approaches. Below, I will briefly consider my main research 
questions and principal findings. 
 
9.1 Review of Research Questions  
 
Question 1: Are physical diseases more prevalent in patients with major 
depressive disorder and their siblings and what is the pattern of physical disease 
resemblance for physical diseases in sib-pairs with depression? 
 
In my first study (Chapter 3), I attempted to replicate previous findings from our 
group indicating that physical diseases are more prevalent in individuals with MDD 
(Farmer et al., 2008). Analyses were conducted on an independent sample, the 
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Depression Network study (DeNT), to examine the hypothesis that there are higher 
prevalence rates of various physical diseases in depressed people. One strength of the 
DeNT study sample is that it consists of sibling pairs with depression. This allowed 
me to further examine familial aggregation of physical diseases and their inter-
correlation in depressed families. 
 
The results indicated that eight out of 16 common chronic physical diseases were 
more prevalent in individuals with MDD after controlling age, sex, body mass index 
(BMI), depression status and family membership.The following disorders were 
significantly more frequent in depressed patients:  hypertension, 
hypercholesterolemia, myocardial infarction, asthma, allergic rhinitis/ hay fever, 
gastric ulcer, osteoarthritis and thyroid disease. The results are largely in line with 
the previous report from our group (Farmer et al 2008), except that two additional 
depression-associated conditions, namely hypercholesterolemia and myocardial 
infarction, were identified in my analysis. In addition, not only affected siblings, but 
also unaffected siblings of depressed patients had similarly high prevalence rates for 
various physical diseases. Notably, hypertension, hypercholesterolemia, asthma, 
osteoarthritis and gastric ulcer were familial in depressed patients. Factor analysis on 
disease patterns across the sample suggested that there were six groups of disorders, 
with the most significant factor relating to a ‘metabolic syndrome’ group, which 





Our data indicated that, in line with other studies, obesity was more common in 
depressed patients. Increased BMI has been shown to associate with various physical 
diseases. Our analyses suggested that the strong association between MDD and 
various physical diseases, especially metabolic related diseases, is partly due to 
increased body mass index. However, eight physical diseases were associated with 
MDD even taking account of BMI and other confounding factors. Familial 
aggregation of various physical diseases in depressed people might reflect the 
potential common genetic contribution to these diseases, although our sib-pair study 
design cannot disentangle the extent of genetic influences on physical diseases in 
depressed patients from environmental contributions. 
 
In summary, the study described in Chapter 3 suggested that there is a higher 
prevalence rate of various chronic common physical diseases in depressed families. 
Several diseases, especially metabolic related physical diseases, clustered in MDD 
families. Questions about the role of causal pathways and common genetic factors 
underpinning the relationship between obesity/ physical diseases and depression was 
explored in later chapters.  
 
Question 2: Do personality traits influence the co-morbidity between physical 
diseases and major depression, and is there any familial correlation between 




Previous studies have shown that there is a relationship between personality traits 
and MDD. Certain personality traits, for example neuroticism, are associated with 
the development of MDD (Farmer et al., 2002) and the prognosis of MDD (Ranjith 
et al., 2005). In addition, some studies have suggested that personality traits are 
associated with various physical diseases (Charles et al., 2008). Chapter 4 aimed to 
explore whether the association between MDD and various physical diseases was 
driven, at least in part, by personality traits.   
 
As in Chapter 3, analyses were conducted in the DeNT sample. Results indicated that 
neuroticism was modestly but significantly positively associated with the number of 
physical diseases, while extraversion and psychoticism were negatively associated 
with the number of physical diseases. However, the effect sizes were small and only 
neuroticism was still significantly associated with the number of physical diseases 
after taking into account depressive status, sex, age and BMI. A similar pattern was 
found when the relationship between personality traits and the presence of any 
physical disease was examined: neuroticism was modestly positively associated with 
the presence of any physical disease.  
To determine whether neuroticism was associated with any of the specific physical 
diseases under study, the analysis was repeated for each disease separately. Only 
asthma was significantly associated with neuroticism, and again the coefficient was 
small. Subsequently, bivariate structural equation modelling was used to explore 
whether there is familial overlap between asthma and neuroticism. The model I 
tested made a number of assumptions, including using published parameter estimates 
for the familiality of asthma. However, model comparison indicated that the 
parameter estimating the familial correlation between asthma and neuroticism could 
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be dropped from the model without worsening the fit, suggesting that the association 
between higher neuroticism score and asthma is unlikely to reflect familial factors 
common to these two traits. 
 
In summary, this study was in agreement with previous reports suggesting that 
neuroticism is associated with an increased number of reported physical diseases/ 
complaints, although the magnitude of the effect is small. The bivariate modeling 
analysis did not support the hypothesis that there is a familial correlation between 
asthma and neuroticism. Notably, because the study was conducted in a sample of 
depressed patients, restricted variance on trait neuroticism may have contributed to 
this negative finding.  
 
Question 3: What is the ‘SNP heritability’ of major depression and body mass 
index estimated from a large case control study, and is there a genetic 
correlation between these two traits that is tagged by common variants? 
 
The results of Chapter 4 suggested that the personality trait of neuroticism does not 
play a major role in the relationship between physical diseases and MDD. Obesity on 
the other hand contributes significantly to numerous physical diseases, especially 
metabolic related diseases, in individuals with MDD. This motivated an investigation 
using GWAS data to estimate the heritability of both MDD and body mass index, 
and examine the genetic correlation between these two trait/ diseases. This analysis 
used a new analysis method called genome-wide complex trait analysis (GCTA) 
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(Yang et al., 2011) developed to investigate the phenotype variance explained by 
common genetic variants captured by microarray platform, often now referred to as 
‘SNP heritability’. Furthermore, a bivariate extension of this method makes it 
possible to examine the genetic correlation between the two diseases/ traits using 
GWAS data. 
Analyses were conducted using data from the RADIANT studies, which include 
DeNT (Depression Network Study), DeCC (Depression case control study) and 
GENDEP (Genome-based Therapeutic Drugs for Depression), in order to enlarge the 
sample size to get better estimates using GCTA. An additional independent sample, 
the Munich-GSK depression case control study, was added to these data to further 
increase power. Results based on analyses conducted in the RADIANT sample 
suggested that the additive genetic variance of BMI and MDD related to common 
SNPs were 0.17 (S.E.=0.12, P=0.10) and 0.36 (S.E.=0.12, P=0.001), respectively. 
The estimated genetic correlation between BMI and MDD was 0.61 (SE=0.26, 
P=0.02). On combining the Munich and RADIANT samples, variance in BMI 
attributable to common SNPs was 0.15 (SE=0.09, P=0.04), and variance in MDD 
was 0.33 (SE=0.08, P=5*10-6). However, the estimated genetic correlation between 
BMI and MDD was no longer significantly different from zero, due to the large 
standard error (rG=0.40, SE=0.23, P=0.08). These results indicate that a substantial 
proportion of phenotypic variance of both MDD and BMI can be explained by 
common genetic variants. With respect to MDD, it appears that there is actually little 
‘missing heritability’ compared with estimates of heritability derived from 
population based twin studies (Sullivan et al., 2000). This is of interest in particular 
for MDD, where GWAS approaches have so far been singularly unsuccessful in 
identifying any consistent genome-wide ‘hits’ (Wray et al., 2012). Analyses based on 
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the RADIANT study data further indicated a substantial and significant genetic 
correlation between BMI and MDD. Unfortunately, the estimate was imprecise with 
large confidence interval, and the addition of a smaller dataset provided by 
colleagues in Munich rendered the genetic correlation non-significant by the 
conventional criterion of p<0.05. However, the results remain somewhat suggestive 
of a genetic correlation between BMI and MDD and are therefore certainly require 
investigation in larger samples. 
 
Question 4: To what extent can genetic risk score for BMI constructed using 
identified risk SNPs from a large meta-analysis of GWAS explain the variation 
in BMI in depressed patients and improve the prediction of obesity in 
individuals with major depressive disorder? 
 
One paradox of the findings in Chapter 4 suggesting that MDD actually has a higher 
SNP heritability than BMI is that published GWAS of BMI and obesity have so far 
actually been more successful than GWAS of MDD in identifying risk loci that are 
genome wide significant and replicable. The analyses reported in Chapter 5 
capitalised on these identified risk loci for BMI identified from a large meta-analysis 
of GWAS to construct a genetic risk score (GRS). This was used to estimate the 
extent to which variation in BMI can be explained by the GRS in a sample of 
depressed patients. Analyses also examined whether the GRS was a useful predictor 
of obesity in individuals with MDD, both on its own and in combination with other 




A large GWAS of BMI identified 32 SNPs at genome-wide significance (Speliotes et 
al., 2010). Two GRS were constructed on the basis of the number of risk alleles for 
these loci in patients within our sample. Both un-weighted GRS (uGRS, the count of 
risk alleles), and weighted GRS (wGRS, the sum of the the products of each risk 
allele multiplied by its effect size), were calculated. The frequencies of uGRS and 
wGRS were approximately normally distributed. Both the mean uGRS and wGRS 
were higher in obese people compared to non-obese people. Demographic predictors 
of high BMI consisting of age, sex and depression status together explained 8.29% 
variance of BMI, and adding either uGRS or wGRS to the model only explained an 
extra 1.27% of variance of BMI in our RADIANT sample, suggesting that the 
clinical utility of the GRS is at best modest. Underlining this conclusion further, 
when the area under (AUC) was calculated on the basis of a  receiver operating 
characteristics (ROC) analysis to discriminate the presence /absence of obesity, the 
AUC was only 0.58 if only included GRS and ancestry were included in the 
regression model. The AUC increased to 0.65 when age and sex were included in the 
model, and it further increased to 0.71 if depression status was also included.  
 
In summary, the findings of Chapter 5 indicated that whilst uGRS or wGRS were 
normally distributed in both cases and controls, and were significantly associated 
with higher BMI, both types of GRS explained only a modest proportion of the 
variance in BMI. As such, whilst molecular markers can at present be used to 
construct a score that is a significant predictor of obesity, many more markers will 
need to be identified before we can construct a risk score that has utility clinically. 
Even adding other non-molecular risk factors, such as age, sex and depression status 
into the predictive model could not turn it into a useful screening tool. 
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 Question 5:  Can Mendelian randomization analysis using instrumental 
variables disentangle the causal relationship between increased BMI and MDD? 
 
Although it is well established that obesity is overrepresented in individuals with 
MDD, the causal relationship between increased BMI and MDD remains unclear. 
Recently, Mendelian randomization (MR), a method that applies genetic information 
to disentangle the causal relationship between a risk exposure and a disease has been 
developed. The basic idea of MR analysis is that genetic variants are allocated during 
meiosis, and are therefore independent of common confounding factors that could 
contribute to the relationship between the exposure (e.g. high BMI) and the disease 
(e.g. MDD). Since genetic variants influence the disease outcome only via exposure, 
MR analysis can provide estimates of association that are free of confounding 
environmental factors (e.g. stress exposure).  
 
Two instrumental variables (IVs), FTO genotype and weighted GRS were used for 
MR analysis. Both IVs were significantly associated with BMI, suggesting that they 
are valid indicators of adiposity. BMI was also associated with MDD in the 
regression analysis. However, our the instrumental variable analyses did not support 
a causal relationship between higher BMI and major depression, with FTO genotype 
and GRS not acting as significant predictors of MDD. As such, the findings did not 
support the hypothesis that increased BMI causes clinically significant MDD, whilst 
applying either FTO genotype or wGRS as instrumental variables. However, one 
limitation of this study is the fact that the study was cross sectional, meaning that 
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BMI obtained at interview was used as the proxy of premorbid BMI, on the basis that 
that previous studies have shown that BMI in adolescence is highly associated with 
BMI in adulthood. Future studies using longitudinal designs are needed to address 
this limitation.  In addition, the negative result could represent either a true negative 
one or a false negative. One difficulty of conducting Mendelian randomization 
studies is that no satisfactory formal power calculation methods have yet been 
developed, meaning that this study may have been underpowered.  That said, our 
sample size is comparable to or larger than those of previous MR studies including 
one which purported to show a causal relationship between high BMI and depressive 
symptoms.   
 
Question 6: Can genetic association studies of physical diseases shed light on the 
co-occurrence between physical illnesses and MDD? 
 
Because as yet, no replicable genetic variants reaching genome-wide significance 
have been identified in GWAS of MDD (Wray et al., 2012), there is no simple, direct 
means to determine whether MDD has a molecular genetic overlap with other 
diseases by looking up overlapping associations. Chapter 7 described several 
methods to investigate this problem. Two of the approaches identified (the polygenic 
score approach or GCTA analysis) were not possible due to the lack of availability of 
genome-wide data on the physical diseases on which my analysis was focused. 
Therefore, I used publicly available GWAS data on physical diseases to identify the 
genetic variants reaching genome-wide significance for the physical diseases of 
interest. I then tested case/ control differences in a large GWAS dataset on MDD. 
One SNP that is a risk loci consistently associated with asthma (rs1342326, which is 
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near the IL33 gene) was significantly over-represented in individuals with MDD. 
Subsequently, a weighted genetic risk score (wGRS) was constructed for asthma 
using twelve SNPs identified in published GWAS. However, a further Mendelian 
randomization (MR) analysis conducted using instrumental variables of risk alleles 
for rs1342326 and GRS for asthma did not support the hypothesis of a causal 
relationship between suffering from asthma and developing MDD. Rather, the results 
suggest a single marker indicating a point of genetic overlap between the liability to 
develop both MDD and asthma, which might in part contribute to the excess of 
asthma in individuals with MDD compared to healthy controls. Examinations of the 
odds ratios derived from our results suggests that variation in rs1342326 explains 
only part of the asthma/MDD association. The OR for asthma in MDD cases versus 
controls is 1.79, whereas the OR for the rs1342326/MDD association is 1.15 and the 
OR for the rs1342326/asthma association is 1.31. Thus, there may be other points of 
genetic overlap between asthma and MDD and/or other as yet unidentified 
environmental causes of the asthma/MDD association. 
 
9.2 Clinical implications 
 
The studies presented in this thesis highlight the importance of understanding the co-
morbidity between physical diseases and MDD, not only in individuals with MDD, 
but also in their unaffected relatives. Perhaps the most striking and arguably the most 
clinically important result is the association between MDD and ‘metabolic syndrome’ 
(Chapter 3). The term metabolic syndrome has often been criticized as not 
encompassing a ‘real’ syndrome, but simply a cluster of disorders all related to being 
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overweight. Certainly, there was good evidence of this clustering in the RADIANT 
sample, as well as obesity being over-represented in depressed people. In looking for 
possible reasons for the over representation of physical disorders in MDD generally, 
the personality trait of neuroticism did not seem to play a major role (Chapter 4). Nor 
was there evidence of a ‘direction of cause’ effect from high BMI to MDD. Rather 
there was evidence, at least in the RADIANT sample, of a significant, perhaps 
substantial genetic correlation between MDD and BMI. This would be in keeping 
with the finding that some of the disorders in the ‘metabolic syndrome’ category 
were over-represented not just in MDD sufferers, but also in their unaffected siblings. 
The other disorder with evidence for a modest genetic overlap with MDD was 
asthma, which again showed a tendency to be increased in unaffected siblings.  
 
There are two clinical implications from these studies. First, results, when published 
in academic journals, may serve as a reminder to clinicians (either general 
practitioners or psychiatrists) to investigate metabolic related physical diseases or 
their risk factors when diagnosing an individual with MDD. When people report their 
family history of MDD, clinicians should consider the associated increased risk of 
various physical diseases. The findings presented here are in line with previous 
studies (Cuijpers and Smit, 2002, Wulsin et al., 1999), suggesting that there is an 
increased risk of mortality in depression. Although I did not find gender differences 
in morbidity, previous studies (Wulsin et al., 1999, Joukamaa et al., 2001) have 
suggested differences in mortality; with an increased risk of dying from 
cardiovascular diseases in depressed men, and an increased risk of dying from 
respiratory diseases in depressed women.  
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 A second finding with potential clinical implications is the observation of a 
substantial “SNP heritability” in both MDD and BMI, and a significant genetic 
correlation between these two diseases/ traits in our RADIANT data. These findings 
raise the question of whether this observed genetic overlap could help to identify 
physiological or psychological pathways that might point to treatments that could be 
applied in a clinical setting. However, the straightforward answer so far is rather 
disappointingly ‘no’. The analysis did not identify any actual genes that contribute to 
variance in both MDD and ‘metabolic syndrome’ disorders, and using a GRS 
approach derived from GWAS of BMI suggested that this score could only explained 
a modest proportion of variance of BMI, and is not likely to be of any predictive 
clinical utility. In fact, it could be argued that so far  genetic tests generally have 
been disappointing in providing clinically useful information to inform the prediction 
of onset of complex diseases, except for those where there are subtypes with a 
monogenic basis, e.g. Maturity Onset Diabetes of the Young (MODY) (Mitchell, 
2012). 
 
With GWAS identifying numerous risk variants responsible for various complex 
diseases/ traits, the public expects some translation of the genetic findings and the 
development of novel clinical applications. For example, one important application 
would be the use of genetic information to identify individuals at risk of developing 
certain diseases. Unlike monogenic diseases, mounting evidence has shown that 
multiple genetic and environmental factors contribute to the etiology of complex 
diseases/ traits. Therefore, genetic information usually provides a continuum of risk 
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for complex diseases, rather than distinct risk category of risk. Given that 
environmental factors contribute a substantial proportion of the variance of complex 
diseases, diagnosis by genetic tests alone is likely to be impractical and unnecessary 
given that there is a long way to go before all causal genetic variants for any complex 
disease are identified (Belsky et al., 2013). Since the predictive value is limited for 
each single genetic variant due to their small effects, using a composite risk 
assessment such as genetic risk score (GRS) to take account multiple genetic variants 
simultaneously, also named genomic profiling (Ehret et al., 2011), is an alternative 
for risk assessment of certain complex diseases. Our findings suggest that using a 
composite genetic risk assessment is not yet suitable for individual level use, due to 
low predictive utility. This raises a particular concern, given that recently some 
commercial companies have begun to advertise genetic testing, including estimation 
of risk of certain diseases, despite the limited evidence base at present. There seems 
little doubt that immature genetic prediction based on current knowledge has the 
potential to cause confusion, unnecessary medical examination or heighted 
psychological distress (Caulfield et al., 2010). A recent large scale study suggested 
that genome-wide testing did not cause any short term changes in psychological 
health, diet or exercise behavior or use of screening tests, although the results are 
weakened by the lack of a control sample (Bloss et al., 2011). As such, clinicians 






Several limitations of the studies described in this thesis need to be addressed. First, 
these studies were mainly based on secondary analysis of existing datasets were not 
purpose built for the types of analysis that I aimed to carry out. Thus, for example, I 
did not have information about smoking, diet and exercise, all of which would have 
been desirable for comprehensively assessing physical health and its relationship 
with MDD. Second, most of BMI and physical disease data were based on self-
reported information. However, I was able to compare self-report with objectively 
measured height and weight in a large subset of over 800 participants, which 
indicated a very high correlation. Similarly a previous study on the DeCC component 
of the RADIANT data found very good agreement between self-report and general 
practitioner reports of the presence of physical disorders. A third limitation of these 
studies is that the DeNT study mainly comprised depressed probands, affected 
siblings and a small number of unaffected siblings. It would have been desirable to 
have data on siblings of healthy controls, and more data on unaffected siblings. Lack 
of such data prevented us from determining with greater confidence the co- 
familiality of certain physical diseases and depression. Fourth, the study designs 
were cross-sectional not longitudinal. Therefore, it was difficult to ascertain the 
causal relationship between the risk factors and the outcomes even after applying 
Mendelian randomization (MR) analysis.  
 
9.4 Future research directions 
 
Although the association between MDD and various physical diseases, especially 
metabolic related diseases, has been confirmed in various studies including those 
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presented here, at present, little is known about the causal underpinnings of the co-
morbidity between MDD and physical diseases. I have demonstrated that genetic 
factors play an important role for both MDD and BMI, and that there may be overlap 
between such factors. However, it would have been desirable to be able to explore 
environmental factors that may contribute to the covariance between MDD and BMI 
to a greater extent. Epidemiological studies have found that childhood adversity and 
poverty contribute to obesity (Thomas et al., 2008, Drewnowski and Specter, 2004) 
and MDD (Belle Doucet, 2003, Batten et al., 2004). Gene-environment interactions 
require exploration in future studies (Belsky et al., 2013). Critical periods for gene 
environment interactions may also require examination, which would necessitate 
longitudinal investigation over an extended age range and time period. In addition, 
the heterogeneity of major depressive disorder, as discussed in Chapter 1, should be 
considered in future studies, because different phenotypic manifestations may 
represent different underling disease-causing mechanisms, which might relate to 
different physical diseases. It would also be desirable in future studies to include 
samples derived from and representative of the general population, rather than just 
clinically ascertained samples such as those considered in this thesis.  
 
The genetic correlation between MDD and BMI suggests that both diseases/ traits 
share some genetic variants, although we cannot determine which ones are 
responsible for the overlap between these phenotypes. Increasing the sample size of 
GWAS data available on both MDD and BMI would facilitate the identification of 
risk variants. Both MDD and obesity are thought to involve chronic inflammatory 
processes (Dantzer et al., 2008, Monteiro and Azevedo, 2010). It might therefore be 
of interest to focus in particular on genetic variants related to pro-inflammatory 
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makers such TNF-alpha, IL-1, and IL-6. For example a genetic risk score approach 
for inflammation could be useful in the prediction of co-susceptibility to 
inflammation-related mental and physical diseases. As discussed in Chapter 8,  
inflammation is associated with depression and physical disease. However, the true 
causal factor might be the toxic metabolites, rather than the inflammatory markers 
per se. Future studies should take account inflammation and associated toxic 
metabolites to investigate the relationship between major depression and physical 
diseases. It would also be desirable, as I have already mentioned, to explore genome-
wide genetic information for various physical diseases and construct a polygenic risk 
score to see to what extent this score can explain the variance of MDD. Similarly, the 
time is ripe to use the bivariate GCTA analysis approaches to estimate genetic 
correlation between MDD and various physical diseases. For the time being, these 
ideas will be best pursued through collaborations among research groups with access 
to large existing data sets. There are however even larger more ambitious studies in 
progress involving very large cohorts. These include the UK Biobank project, which 
involves half a million adults of middle / late middle age on whom basic phenotypic 
data on depression, as well as data on the physical disorders is being acquired. There 
will soon be GWAS data on the UK Biobank sample, and in the not too distant future 








ADAMIS, D. & BALL, C. 2000. Physical morbidity in elderly psychiatric inpatients: 
prevalence and possible relations between the major mental disorders and physical 
illness. International journal of geriatric psychiatry, 15, 248-253. 
AFARI, N., NOONAN, C., GOLDBERG, J., ROY‐BYRNE, P., SCHUR, E., GOLNARI, G. 
& BUCHWALD, D. 2010. Depression and obesity: do shared genes explain the 
relationship? Depression and anxiety, 27, 799-806. 
AFARI, N., SCHMALING, K. B., BARNHART, S. & BUCHWALD, D. 2001. Psychiatric 
comorbidity and functional status in adult patients with asthma. Journal of Clinical 
Psychology in Medical Settings, 8, 245-252. 
AKINBAMI, O. J., MOORMAN, J. E. & LIU, X. 2011. Asthma prevalence, health care use, 
and mortality: United States, 2005-2009, US Department of Health and Human 
Services, Centers for Disease Control and Prevention, National Center for Health 
Statistics. 
ALLISON, D., KAPRIO, J., KORKEILA, M., KOSKENVUO, M., NEALE, M. & 
HAYAKAWA, K. 1996. The heritability of body mass index among an international 
sample of monozygotic twins reared apart. International journal of obesity, 20, 501-
506. 
AMERICAN PSYCHIATRIC ASSOCIATION 2000. Diagnostic and statistical manual of 
mental disorders: DSM-IV-TR®, American Psychiatric Pub. 
ANDERSON, S. E., COHEN, P., NAUMOVA, E. N., JACQUES, P. F. & MUST, A. 2007. 
Adolescent obesity and risk for subsequent major depressive disorder and anxiety 
disorder: prospective evidence. Psychosomatic Medicine, 69, 740-747. 
171 
 
AOKI, A., OZAKI, K., SATO, H., TAKAHASHI, A., KUBO, M., SAKATA, Y., 
ONOUCHI, Y., KAWAGUCHI, T., LIN, T.-H. & TAKANO, H. 2010. SNPs on 
chromosome 5p15. 3 associated with myocardial infarction in Japanese population. 
Journal of human genetics, 56, 47-51. 
ARMON, G., MELAMED, S., SHIROM, A., BERLINER, S. & SHAPIRA, I. 2013. The 
associations of the Five Factor Model of personality with inflammatory biomarkers: 
A four-year prospective study. Personality and Individual Differences. 
ASNIS, G. M. & DE LA GARZA, R. 2006. Interferon-induced depression in chronic 
hepatitis C: a review of its prevalence, risk factors, biology, and treatment 
approaches. Journal of clinical gastroenterology, 40, 322-335. 
ATLANTIS, E. & BAKER, M. 2008. Obesity effects on depression: systematic review of 
epidemiological studies. International Journal of Obesity, 32, 881-891. 
AUNG, T., BISOGNANO, J. D. & MORGAN, M. A. 2010. Allergic respiratory disease as a 
potential co-morbidity for hypertension. Cardiol J, 17, 443-447. 
AXON, R. N., ZHAO, Y. & EGEDE, L. E. 2010. Association of depressive symptoms with 
all-cause and ischemic heart disease mortality in adults with self-reported 
hypertension. American Journal of Hypertension, 23, 30-37. 
BALL H, SAMAAN Z, BREWSTER S, CRADDOCK N, GILL M, KORSZUN A, et al. 
2009. Depression, migraine with aura and migraine without aura: their familiality 
and interrelatedness. Cephalalgia.;29(8):848-54. 
BARSH, G. S., FAROOQI, I. S. & O'RAHILLY, S. 2000. Genetics of body-weight 
regulation. Nature, 404, 644-651. 
BATTEN, S. V., ASLAN, M., MACIEJEWSKI, P. K. & MAZURE, C. M. 2004. Childhood 
maltreatment as a risk factor for adult cardiovascular disease and depression. 
Journal of Clinical Psychiatry. 
172 
 
BEAGLEHOLE, R. & YACH, D. 2003. Globalisation and the prevention and control of 
non-communicable disease: the neglected chronic diseases of adults. The Lancet, 
362, 903-908. 
BECK, A. T., STEER, R. A. & BROWN, G. K. 1996. Manual for the Beck depression 
inventory-II. San Antonio, TX: Psychological Corporation, 1, 82. 
BELLE DOUCET, D. 2003. Poverty, inequality, and discrimination as sources of depression 
among US women. Psychology of Women Quarterly, 27, 101-113. 
BELMAKER, R. & AGAM, G. 2008. Major depressive disorder. New England Journal of 
Medicine, 358, 55-68. 
BELSKY, D. W., MOFFITT, T. E. & CASPI, A. 2013. Genetics in population health science: 
strategies and opportunities. American journal of public health, 103, S73-S83. 
BELSKY, D. W., MOFFITT, T. E., HOUTS, R., BENNETT, G. G., BIDDLE, A. K., 
BLUMENTHAL, J. A., EVANS, J. P., HARRINGTON, H. L., SUGDEN, K. & 
WILLIAMS, B. 2012. Polygenic Risk, Rapid Childhood Growth, and the 
Development of ObesityEvidence From a 4-Decade Longitudinal Study. Archives of 
pediatrics & adolescent medicine, 166, 515-521. 
BERKSON, J. 1946. Limitations of the application of fourfold table analysis to hospital data. 
Biometrics Bulletin, 2, 47-53. 
BETANCOURT, M. C. C., CAILOTTO, F., KERKHOF, H. J., CORNELIS, F. M. F., 
DOHERTY, S. A., HART, D. J., HOFMAN, A., LUYTEN, F. P., MACIEWICZ, R. 
A. & MANGINO, M. 2012. Genome-wide association and functional studies 
identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis. 
Proceedings of the National Academy of Sciences, 109, 8218-8223. 
173 
 
BEYDOUN, M. A. & WANG, Y. 2010. Pathways linking socioeconomic status to obesity 
through depression and lifestyle factors among young US adults. J Affect Disord, 
123, 52-63. 
BLACK, S. A., GOODWIN, J. S. & MARKIDES, K. S. 1998. The association between 
chronic diseases and depressive symptomatology in older Mexican Americans. The 
Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 53, 
M188-M194. 
BLAINE, B. 2008. Does depression cause obesity? A meta-analysis of longitudinal studies 
of depression and weight control. Journal of Health Psychology, 13, 1190-1197. 
BLAZER, D. G. & KESSLER, R. C. 1994. The prevalence and distribution of major 
depression in a national community sample: the National Comorbidity Survey. Age 
(years), 15, 24.7. 
BLOSS, C. S., SCHORK, N. J. & TOPOL, E. J. 2011. Effect of direct-to-consumer 
genomewide profiling to assess disease risk. New England Journal of Medicine, 364, 
524-534. 
BOGARDUS, C. 2009. Missing heritability and GWAS utility. Obesity (Silver Spring, Md.), 
17, 209. 
BOUCHARD JR, T. J. & LOEHLIN, J. C. 2001. Genes, evolution, and personality. 
Behavior genetics, 31, 243-273. 
BRADFIELD, J. P., TAAL, H. R., TIMPSON, N. J., SCHERAG, A., LECOEUR, C., 
WARRINGTON, N. M., HYPPONEN, E., HOLST, C., VALCARCEL, B. & 
THIERING, E. 2012. A genome-wide association meta-analysis identifies new 
childhood obesity loci. Nature genetics, 44, 526. 
BRAIDO, F., BAIARDINI, I., LAGASIO, C., SCLIFÒ, F. & CANONICA, G. 2011. 
Allergic rhinitis in asthma. Panminerva medica, 53, 97. 
174 
 
BRÄMER, G. R. 1988. International statistical classification of diseases and related health 
problems. Tenth revision. World health statistics quarterly. Rapport trimestriel de 
statistiques sanitaires mondiales, 41, 32. 
BREEN, G., WEBB, B. T., BUTLER, A. W., VAN DEN OORD, E. J., TOZZI, F., 
CRADDOCK, N., GILL, M., KORSZUN, A., MAIER, W. & MIDDLETON, L. 
2011. A genome-wide significant linkage for severe depression on chromosome 3: 
the Depression Network Study. American Journal of Psychiatry, 168, 840-847. 
BROGGER, J., BAKKE, P., EIDE, G. E., JOHANSEN, B., ANDERSEN, A. & GULSVIK, 
A. 2003. Long-term changes in adult asthma prevalence. European Respiratory 
Journal, 21, 468-472. 
BROWNING, S. R. & BROWNING, B. L. 2011. Population structure can inflate SNP-based 
heritability estimates. American journal of human genetics, 89, 191. 
CAREY G. 2005. Cholesky problems. Behavior Genetics.;35(5):653-65. 
CARPENTER, K. M., HASIN, D. S., ALLISON, D. B. & FAITH, M. S. 2000. Relationships 
between obesity and DSM-IV major depressive disorder, suicide ideation, and 
suicide attempts: results from a general population study. American Journal of 
Public Health, 90, 251. 
CARROLL, D., PHILLIPS, A. C., GALE, C. R. & BATTY, G. D. 2010. Generalized 
anxiety and major depressive disorders, their comorbidity and hypertension in 
middle-aged men. Psychosomatic medicine, 72, 16-19. 
CASPI, A., SUGDEN, K., MOFFITT, T. E., TAYLOR, A., CRAIG, I. W., HARRINGTON, 
H., MCCLAY, J., MILL, J., MARTIN, J. & BRAITHWAITE, A. 2003. Influence of 




CASSIDY, K., KOTYNIA‐ENGLISH, R., ACRES, J., FLICKER, L., 
LAUTENSCHLAGER, N. T. & ALMEIDA, O. P. 2004. Association between 
lifestyle factors and mental health measures among community‐dwelling older 
women. Australian and New Zealand Journal of Psychiatry, 38, 940-947. 
CAULFIELD, T., RIES, N. M., RAY, P. N., SHUMAN, C. & WILSON, B. 2010. Direct‐to‐
consumer genetic testing: good, bad or benign? Clinical genetics, 77, 101-105. 
CHAITON, M., COHEN, J., O'LOUGHLIN, J. & REHM, J. 2009. A systematic review of 
longitudinal studies on the association between depression and smoking in 
adolescents. BMC Public Health, 9, 356. 
CHAPMAN, D. P., PERRY, G. S. & STRINE, T. W. 2005. The Vital Link Between Chronic 
Disease and Depressive Disorders. Preventing chronic disease 2. 
CHARLES, S. T., GATZ, M., KATO, K. & PEDERSEN, N. L. 2008. Physical health 25 
years later: the predictive ability of neuroticism. Health Psychology, 27, 369. 
CHIEN, I., LIN, C.-H., CHOU, Y.-J. & CHOU, P. 2013. Increased risk of hyperlipidemia in 
patients with major depressive disorder: A population-based study. Journal of 
psychosomatic research. 
CHOY, W. C., LÓPEZ-LEÓN, S., AULCHENKO, Y. S., MACKENBACH, J. P., OOSTRA, 
B. A., VAN DUIJN, C. M. & JANSSENS, A. C. J. 2009. Role of shared genetic and 
environmental factors in symptoms of depression and body composition. Psychiatric 
genetics, 19, 32-38. 
COCCARO, E. F. 2006. Association of C-reactive protein elevation with trait aggression and 
hostility in personality disordered subjects: a pilot study. Journal of psychiatric 
research, 40, 460-465. 
176 
 
COHEN-WOODS, S., GAYSINA, D., CRADDOCK, N., FARMER, A., GRAY, J., 
GUNASINGHE, C., HODA, F., JONES, L., KNIGHT, J. & KORSZUN, A. 2009. 
Depression Case Control (DeCC) Study fails to support involvement of the 
muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major depressive 
disorder. Human molecular genetics, 18, 1504-1509. 
COMINGS, D., GADE, R., MACMURRAY, J., MUHLEMAN, D. & PETERS, W. 1996. 
Genetic variants of the human obesity (OB) gene: association with body mass index 
in young women, psychiatric symptoms, and interaction with the dopamine D2 
receptor (DRD2) gene. Molecular Psychiatry, 1, 325. 
CORYELL W, KELLER M, LAVORI P, ENDICOTT J. 1990. Affective syndromes, 
psychotic features, and prognosis: I. depression. Archives of general psychiatry. 
47(7):651-7. 
COSTA, P. T. & MCCRAE, R. R. 1985. Hypochondriasis, neuroticism, and aging: When are 
somatic complaints unfounded? American Psychologist, 40, 19. 
CREED, F., MORGAN, R., FIDDLER, M., MARSHALL, S., GUTHRIE, E. & HOUSE, A. 
2002. Depression and Anxiety Impair Health-Related Quality of Life and Are 
Associated With Increased Costs in General Medical Inpatient. Psychosomatics, 43, 
302-309. 
CUIJPERS, P. & SMIT, F. 2002. Excess mortality in depression: a meta-analysis of 
community studies. Journal of affective disorders, 72, 227-236. 
DANAEI, G., DING, E. L., MOZAFFARIAN, D., TAYLOR, B., REHM, J., MURRAY, C. 
J. & EZZATI, M. 2009. The preventable causes of death in the United States: 
comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS 
medicine, 6, e1000058. 
177 
 
DANTZER, R., O'CONNOR, J. C., FREUND, G. G., JOHNSON, R. W. & KELLEY, K. W. 
2008. From inflammation to sickness and depression: when the immune system 
subjugates the brain. Nature Reviews Neuroscience, 9, 46-56. 
DAVIDSON, S., LEAR, M., SHANLEY, L., HING, B., BAIZAN-EDGE, A., HERWIG, A., 
QUINN, J. P., BREEN, G., MCGUFFIN, P. & STARKEY, A. 2011. Differential 
activity by polymorphic variants of a remote enhancer that supports galanin 
expression in the hypothalamus and amygdala: Implications for obesity, depression 
and alcoholism. Neuropsychopharmacology, 36, 2211-2221. 
DE BELLIS, M. D., GOLD, P. W., GERACIOTI, T. D. & LISTWAK, S. J. 1993. 
Association of fluoxetine treatment with reductions in CSF concentrations of 
corticotropin-releasing hormone and arginine vasopressin in patients with major 
depression. The American journal of psychiatry. 
DE MIRANDA CHAGAS, S., KANAAN, S., CHUNG KANG, H., CAGY, M., DE ABREU, 
R., DA SILVA, L., GARCIA, R. & GARCIA ROSA, M. 2011. Environmental 
factors, familial aggregation and heritability of total cholesterol, low density 
lipoprotein-cholesterol and high density lipoprotein-cholesterol in a Brazilian 
population assisted by the Family Doctor Program. Public health, 125, 329-337. 
DE MOOR, M. H., COSTA, P., TERRACCIANO, A., KRUEGER, R., DE GEUS, E., 
TOSHIKO, T., PENNINX, B., ESKO, T., MADDEN, P. & DERRINGER, J. 2010. 
Meta-analysis of genome-wide association studies for personality. Molecular 
psychiatry, 17, 337-349. 
DE WIT, L., LUPPINO, F., VAN STRATEN, A., PENNINX, B., ZITMAN, F. & 
CUIJPERS, P. 2010. Depression and obesity: A meta-analysis of community-based 
studies. Psychiatry Research, 178, 230-235. 
178 
 
DE WIT, L. M., FOKKEMA, M., VAN STRATEN, A., LAMERS, F., CUIJPERS, P. & 
PENNINX, B. W. 2010. Depressive and anxiety disorders and the association with 
obesity, physical, and social activities. Depression and anxiety, 27, 1057-1065. 
DIMATTEO, M. R., LEPPER, H. S. & CROGHAN, T. W. 2000. Depression is a risk factor 
for noncompliance with medical treatmentmeta-analysis of the effects of anxiety and 
depression on patient adherence. Archives of internal medicine, 160, 2101-2107. 
DOGRA, S., ARDERN, C. I. & BAKER, J. 2007. The relationship between age of asthma 
onset and cardiovascular disease in Canadians. Journal of Asthma, 44, 849-854. 
DOMINICK, C. H., BLYTH, F. M. & NICHOLAS, M. K. 2012. Unpacking the burden: 
understanding the relationships between chronic pain and comorbidity in the general 
population. Pain, 153, 293-304. 
DONG, C., SANCHEZ, L. & PRICE, R. 2004. Relationship of obesity to depression: a 
family-based study. International Journal of Obesity, 28, 790-795. 
DREWNOWSKI, A. & SPECTER, S. E. 2004. Poverty and obesity: the role of energy 
density and energy costs. The American journal of clinical nutrition, 79, 6-16. 
EDWARDS, J. H. 1965. The meaning of the associations between blood groups and disease. 
Annals of Human Genetics, 29, 77-83. 
EHRET, G. B., MUNROE, P. B., RICE, K. M., BOCHUD, M., JOHNSON, A. D., 
CHASMAN, D. I., SMITH, A. V., TOBIN, M. D., VERWOERT, G. C. & HWANG, 
S.-J. 2011. Genetic variants in novel pathways influence blood pressure and 
cardiovascular disease risk. Nature, 478, 103-109. 
EL-GABALAWY, R., KATZ, L. Y. & SAREEN, J. 2010. Comorbidity and associated 
severity of borderline personality disorder and physical health conditions in a 
nationally representative sample. Psychosomatic medicine, 72, 641-647. 
179 
 
EMANUELE, E., CARLIN, M. V., D’ANGELO, A., PEROS, E., BARALE, F., GEROLDI, 
D. & POLITI, P. 2006. Elevated plasma levels of lipoprotein (a) in psychiatric 
patients: a possible contribution to increased vascular risk. European psychiatry, 21, 
129-133. 
EVERSON SA, MATY SC, LYNCH JW, KAPLAN GA. 2002. Epidemiologic evidence for 
the relation between socioeconomic status and depression, obesity, and diabetes. 
Journal of psychosomatic research. 53(4):891-5. 
EYSENCK, H. J. & EYSENCK, S. B. G. 1975. Manual of the Eysenck Personality 
Questionnaire (junior and adult), Hodder and Stoughton. 
FAGNANI, C., ANNESI-MAESANO, I., BRESCIANINI, S., D'IPPOLITO, C., MEDDA, 
E., NISTICÒ, L., PATRIARCA, V., ROTONDI, D., TOCCACELI, V. & STAZI, M. 
A. 2008. Heritability and shared genetic effects of asthma and hay fever: an Italian 
study of young twins. Twin research and human genetics, 11, 121-131. 
FAITH, M. S., MATZ, P. E. & JORGE, M. A. 2002. Obesity–depression associations in the 
population. Journal of Psychosomatic Research, 53, 935-942. 
FARMER A, MCGUFFIN P. 1989. The classification of the depressions. Contemporary 
confusion revisited. The British Journal of Psychiatry. 155(4):437-43. 
FARMER, A., BREEN, G., BREWSTER, S., CRADDOCK, N., GILL, M., KORSZUN, A., 
MAIER, W., MIDDLETON, L., MORS, O. & OWEN, M. 2004. The Depression 
Network (DeNT) Study: methodology and sociodemographic characteristics of the 
first 470 affected sibling pairs from a large multi-site linkage genetic study. BMC 
psychiatry, 4, 42. 
FARMER, A., KORSZUN, A., OWEN, M. J., CRADDOCK, N., JONES, L., JONES, I., 
GRAY, J., WILLIAMSON, R. J. & MCGUFFIN, P. 2008. Medical disorders in 
people with recurrent depression. The British Journal of Psychiatry, 192, 351-355. 
180 
 
FARMER, A., REDMAN, K., HARRIS, T., MAHMOOD, A., SADLER, S., PICKERING, 
A. & MCGUFFIN, P. 2002. Neuroticism, extraversion, life events and depression 
The Cardiff Depression Study. The British Journal of Psychiatry, 181, 118-122. 
FERRARO KF, SU Y-p, GRETEBECK RJ, BLACK DR, BADYLAK SF. 2002. Body mass 
index and disability in adulthood: a 20-year panel study. American Journal of Public 
Health. 92(5):834-40. 
FERREIRA, M. A. R., MATHESON, M. C., DUFFY, D. L., MARKS, G. B., HUI, J., LE 
SOUËF, P., DANOY, P., BALTIC, S., NYHOLT, D. R. & JENKINS, M. 2011. 
Identification of IL6R and chromosome 11q13. 5 as risk loci for asthma. The Lancet, 
378, 1006-1014. 
FIEST, K. M., CURRIE, S. R., WILLIAMS, J. V., WANG, J., FIEST, K. M., CURRIE, S. 
R., WILLIAMS, J. V. A. & WANG, J. 2011. Chronic conditions and major 
depression in community-dwelling older adults. Journal of Affective Disorders, 131, 
172-8. 
FLEGAL, K. M., CARROLL, M. D., OGDEN, C. L. & CURTIN, L. R. 2010. Prevalence 
and trends in obesity among US adults, 1999-2008. JAMA: the journal of the 
American Medical Association, 303, 235-241. 
FLEGAL, K. M., CARROLL, M. D., OGDEN, C. L. & JOHNSON, C. L. 2002. Prevalence 
and trends in obesity among US adults, 1999-2000. JAMA: the journal of the 
American Medical Association, 288, 1723-1727. 
FRAYLING, T. M., TIMPSON, N. J., WEEDON, M. N., ZEGGINI, E., FREATHY, R. M., 
LINDGREN, C. M., PERRY, J. R., ELLIOTT, K. S., LANGO, H. & RAYNER, N. 
W. 2007. A common variant in the FTO gene is associated with body mass index 
and predisposes to childhood and adult obesity. Science, 316, 889-894. 
181 
 
FRIEDMAN, H. S. & BOOTH-KEWLEY, S. 1987. The" disease-prone personality": A 
meta-analytic view of the construct. American Psychologist, 42, 539. 
FRIEDMAN KE, REICHMANN SK, COSTANZO PR, MUSANTE GJ. 2002. Body image 
partially mediates the relationship between obesity and psychological distress. 
Obesity Research. 10(1):33-41. 
FUENTES, R., NOTKOLA, I.-L., SHEMEIKKA, S., TUOMILEHTO, J. & NISSINEN, A. 
2000. Familial aggregation of blood pressure: a population-based family study in 
eastern Finland. Journal of human hypertension, 14, 441-445. 
FUENTES, R. M., NOTKOLA, I.-L., SHEMEIKKA, S., TUOMILEHTO, J. & NISSINEN, 
A. 2000. Familial aggregation of serum total cholesterol: a population-based family 
study in eastern Finland. Preventive Medicine, 31, 603-607. 
GATCHEL, R. J., PENG, Y. B., PETERS, M. L., FUCHS, P. N. & TURK, D. C. 2007. The 
biopsychosocial approach to chronic pain: scientific advances and future directions. 
Psychological bulletin, 133, 581. 
GAVIN AR, SIMON GE, LUDMAN EJ. 2010. The association between obesity, depression, 
and educational attainment in women: the mediating role of body image 
dissatisfaction. Journal of psychosomatic research. 69(6):573-81. 
GEIS, G., STEAD, H., WALLEMARK, C. B. & NICHOLSON, P. 1991. Prevalence of 
mucosal lesions in the stomach and duodenum due to chronic use of NSAID in 
patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention 
by misoprostol of diclofenac associated lesions. The Journal of rheumatology. 
Supplement, 28, 11-14. 
GILI, M., GARCIA‐TORO, M., VIVES, M., ARMENGOL, S., GARCIA‐CAMPAYO, J., 
SORIANO, J. & ROCA, M. 2011. Medical comorbidity in recurrent versus first‐
episode depressive patients. Acta Psychiatrica Scandinavica, 123, 220-227. 
182 
 
GLYMOUR, M. M., TCHETGEN, E. J. & ROBINS, J. M. 2012. Credible Mendelian 
randomization studies: approaches for evaluating the instrumental variable 
assumptions. Am J Epidemiol, 175, 332-9. 
GOLD, P. & CHROUSOS, G. 2002. Organization of the stress system and its dysregulation 
in melancholic and atypical depression: high vs low CRH/NE states. Molecular 
psychiatry, 7, 254-275. 
GOLDBERG, D. P. 1972. The detection of psychiatric illness by questionnaire: A technique 
for the identification and assessment of non-psychotic psychiatric illness, London, 
United Kingdom, Oxford University Press. 
GOLDNEY, R. D., DUNN, K. I., AIR, T. M., DAL GRANDE, E. & TAYLOR, A. W. 2009. 
Relationships between body mass index, mental health, and suicidal ideation: 
population perspective using two methods. Australian and New Zealand Journal of 
Psychiatry, 43, 652-658. 
GOODWIN, R. D., FERGUSSON, D. M. & HORWOOD, L. J. 2004. Asthma and 
depressive and anxiety disorders among young persons in the community. 
Psychological Medicine, 34, 1465-74. 
GOODWIN, R. D. & FRIEDMAN, H. S. 2006. Health status and the five-factor personality 
traits in a nationally representative sample. Journal of Health Psychology, 11, 643-
654. 
GOODWIN, R. D., KEYES, K. M., STEIN, M. B. & TALLEY, N. J. 2009. Peptic ulcer and 
mental disorders among adults in the community: the role of nicotine and alcohol 
use disorders. Psychosomatic medicine, 71, 463-468. 
GORBER, S. C., TREMBLAY, M., MOHER, D. & GORBER, B. 2007. A comparison of 
direct vs. self‐report measures for assessing height, weight and body mass index: a 
systematic review. Obesity reviews, 8, 307-326. 
183 
 
GUIMARÃES, J. M. N., DE SOUZA LOPES, C., BAIMA, J. & SICHIERI, R. 2009. 
Depression symptoms and hypothyroidism in a population-based study of middle-
aged Brazilian women. Journal of affective disorders, 117, 120-123. 
GUO, S., HUANG, C., MAYNARD, L. M., DEMERATH, E., TOWNE, B., CHUMLEA, W. 
C. & SIERVOGEL, R. 2000. Body mass index during childhood, adolescence and 
young adulthood in relation to adult overweight and adiposity: the Fels Longitudinal 
Study. Int J Obes Relat Metab Disord, 24, 1628. 
GUZE SB. 1990. Secondary depression: Observations in alcoholism, Briquet's syndrome, 
anxiety disorder, schizophrenia, and antisocial personality: A form of comorbidity? 
Psychiatric Clinics of North America. 
HÄMÄLÄINEN, J., KAPRIO, J., ISOMETSÄ, E., HEIKKINEN, M., POIKOLAINEN, K., 
LINDEMAN, S. & ARO, H. 2001. Cigarette smoking, alcohol intoxication and 
major depressive episode in a representative population sample. Journal of 
epidemiology and community health, 55, 573-576. 
HARRIS, T., COOK, D. G., VICTOR, C., DEWILDE, S. & BEIGHTON, C. 2006. Onset 
and persistence of depression in older people—results from a 2-year community 
follow-up study. Age and ageing, 35, 25-32. 
HASLER, G., LISSEK, S., AJDACIC, V., MILOS, G., GAMMA, A., EICH, D., RÖSSLER, 
W. & ANGST, J. 2005. Major Depression Predicts an Increase in Long-Term Body 
Weight Variability in Young Adults. Obesity Research, 13, 1991-1998. 
HAWKER, G. A., GIGNAC, M. A., BADLEY, E., DAVIS, A. M., FRENCH, M. R., LI, Y., 
PERRUCCIO, A. V., POWER, J. D., SALE, J. & LOU, W. 2011. A longitudinal 
study to explain the pain‐depression link in older adults with osteoarthritis. Arthritis 
care & research, 63, 1382-1390. 
184 
 
HAWORTH, C., CARNELL, S., MEABURN, E. L., DAVIS, O. S., PLOMIN, R. & 
WARDLE, J. 2008. Increasing heritability of BMI and stronger associations with the 
FTO gene over childhood. Obesity, 16, 2663-2668. 
HEATH, A. C. & MADDEN, P. A. F. 2012. Genome-wide association studies of asthma in 
population-based cohorts confirm known and suggested loci and identify an 
additional association near HLA. 
HELGADOTTIR, A., THORLEIFSSON, G., MANOLESCU, A., GRETARSDOTTIR, S., 
BLONDAL, T., JONASDOTTIR, A., JONASDOTTIR, A., SIGURDSSON, A., 
BAKER, A. & PALSSON, A. 2007. A common variant on chromosome 9p21 
affects the risk of myocardial infarction. Science, 316, 1491-1493. 
HETTEMA, J. M., NEALE, M. C. & KENDLER, K. S. 1995. Physical similarity and the 
equal-environment assumption in twin studies of psychiatric disorders. Behavior 
genetics, 25, 327-335. 
HICKIE, I., SCOTT, E., NAISMITH, S., WARD, P., TURNER, K., PARKER, G., 
MITCHELL, P. & WILHELM, K. 2001. Late-onset depression: genetic, vascular 
and clinical contributions. Psychol Med, 31, 1403-1412. 
HIRSCHHORN, J. N. & DALY, M. J. 2005. Genome-wide association studies for common 
diseases and complex traits. Nature Reviews Genetics, 6, 95-108. 
HOLAHAN, C. J., PAHL, S. A., CRONKITE, R. C., HOLAHAN, C. K., NORTH, R. J. & 
MOOS, R. H. 2010. Depression and vulnerability to incident physical illness across 
10years. Journal of affective disorders, 123, 222-229. 
HOSMER JR, D. W., LEMESHOW, S. & STURDIVANT, R. X. 2013. Applied logistic 
regression, Wiley. com. 
185 
 
HUOVINEN, E., KAPRIO, J. & KOSKENVUO, M. 2001. Asthma in relation to personality 
traits, life satisfaction, and stress: a prospective study among 11 000 adults. Allergy, 
56, 971-977. 
HURWITZ, E. L. & MORGENSTERN, H. 1999. Cross-sectional associations of asthma, 
hay fever, and other allergies with major depression and low-back pain among adults 
aged 20–39 years in the United States. American journal of epidemiology, 150, 
1107-1116. 
JANG, K. L., LIVESLEY, W. J. & VEMON, P. A. 1996. Heritability of the big five 
personality dimensions and their facets: a twin study. Journal of personality, 64, 
577-592. 
JIAO, H., ARNER, P., HOFFSTEDT, J., BRODIN, D., DUBERN, B., CZERNICHOW, S., 
VAN'T HOOFT, F., AXELSSON, T., PEDERSEN, O. & HANSEN, T. 2011. 
Genome wide association study identifies KCNMA1 contributing to human obesity. 
BMC medical genomics, 4, 51. 
JOHNSON, M. 2003. The vulnerability status of neuroticism: over-reporting or genuine 
complaints? Personality and Individual Differences, 35, 877-887. 
JOKELA, M., ELOVAINIO, M., KELTIKANGAS-JARVINEN, L., BATTY, G. D., 
HINTSANEN, M., SEPPALA, I., KAHONEN, M., VIIKARI, J. S., RAITAKARI, 
O. T., LEHTIMAKI, T. & KIVIMAKI, M. 2012. Body mass index and depressive 
symptoms: instrumental-variables regression with genetic risk score. Genes Brain 
Behav. 
JONAS, B. S., FRANKS, P. & INGRAM, D. D. 1997. Are symptoms of anxiety and 
depression risk factors for hypertension? longitudinal evidence from the National 
Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. 
Archives of family medicine, 6, 43. 
186 
 
JOUKAMAA, M., HELIÖVAARA, M., KNEKT, P., AROMAA, A., RAITASALO, R. & 
LEHTINEN, V. 2001. Mental disorders and cause-specific mortality. The British 
Journal of Psychiatry, 179, 498-502. 
KASEN, S., COHEN, P., CHEN, H. & MUST, A. 2008. Obesity and psychopathology in 
women: a three decade prospective study. International Journal of Obesity, 32, 558-
566. 
KATON, W. J. 2003. Clinical and health services relationships between major depression, 
depressive symptoms, and general medical illness. Biological psychiatry, 54, 216-
226. 
KENDLER, K. S., NEALE, M. C., KESSLER, R. C., HEATH, A. C. & EAVES, L. J. 1993. 
The lifetime history of major depression in women: reliability of diagnosis and 
heritability. Archives of General Psychiatry, 50, 863.  
KENDLER, K. & MYERS, J. 2010. The genetic and environmental relationship between 
major depression and the five-factor model of personality. Psychol Med, 40, 801-806. 
KENDLER KS, AGGEN SH, NEALE MC. 2013. Evidence for multiple genetic factors 
underlying DSM-IV criteria for major depression. JAMA psychiatry. 70(6):599-607. 
KENDELL R. 1977. The classification of depression. A review of contemporary confusion. 
Handbook of Studies on Depression:  Excerpta Medica Amsterdam. 
KENIS, G. & MAES, M. 2002. Effects of antidepressants on the production of cytokines. 
The International Journal of Neuropsychopharmacology, 5, 401-412. 
KESSLER RC, MICKELSON KD, WILLIAMS DR. 1999. The prevalence, distribution, and 
mental health correlates of perceived discrimination in the United States. Journal of 
health and social behavior. 208-30. 
187 
 
KESSLER, R. C., BERGLUND, P., DEMLER, O., JIN, R., MERIKANGAS, K. R. & 
WALTERS, E. E. 2005. Lifetime prevalence and age-of-onset distributions of DSM-
IV disorders in the National Comorbidity Survey Replication. Archives of general 
psychiatry, 62, 593. 
KESSLER, R. C., MCGONAGLE, K. A., SWARTZ, M., BLAZER, D. G. & NELSON, C. 
B. 1993. Sex and depression in the National Comorbidity Survey I: Lifetime 
prevalence, chronicity and recurrence. Journal of affective disorders, 29, 85-96. 
KESSLER, R. C., MCGONAGLE, K. A., ZHAO, S., NELSON, C. B., HUGHES, M., 
ESHLEMAN, S., WITTCHEN, H.-U. & KENDLER, K. S. 1994. Lifetime and 12-
month prevalence of DSM-III-R psychiatric disorders in the United States: results 
from the National Comorbidity Survey. Archives of general psychiatry, 51, 8. 
KESSLER RC, B. P. D. O. & ET AL. 2003. The epidemiology of major depressive disorder: 
Results from the national comorbidity survey replication (ncs-r). JAMA: The Journal 
of the American Medical Association, 289, 3095-3105. 
KIM, K. W., HAN, J. W., CHO, H. J., CHANG, C. B., PARK, J. H., LEE, J. J., LEE, S. B., 
SEONG, S. C. & KIM, T. K. 2011. Association between comorbid depression and 
osteoarthritis symptom severity in patients with knee osteoarthritis. The Journal of 
Bone & Joint Surgery, 93, 556-563. 
KIVIMAKI, M., JOKELA, M., HAMER, M., GEDDES, J., EBMEIER, K., KUMARI, M., 
SINGH-MANOUX, A., HINGORANI, A. & BATTY, G. D. 2011. Examining 
overweight and obesity as risk factors for common mental disorders using fat mass 
and obesity-associated (FTO) genotype-instrumented analysis: The Whitehall II 
Study, 1985-2004. Am J Epidemiol, 173, 421-9. 
KLABBERS, G., BOSMA, H., KEMPEN, G. I. J. M., BENZEVAL, M., VAN DEN 
AKKER, M. & VAN EIJK, J. T. M. 2013. Do psychosocial profiles predict self-
188 
 
rated health, morbidity and mortality in late middle-aged and older people? Journal 
of behavioral medicine, 1-12. 
KLING, M. A., ALESCI, S., CSAKO, G., COSTELLO, R., LUCKENBAUGH, D. A., 
BONNE, O., DUNCKO, R., DREVETS, W. C., MANJI, H. K. & CHARNEY, D. S. 
2007. Sustained low-grade pro-inflammatory state in unmedicated, remitted women 
with major depressive disorder as evidenced by elevated serum levels of the acute 
phase proteins C-reactive protein and serum amyloid A. Biological psychiatry, 62, 
309-313. 
KORSZUN A, MOSKVINA V, BREWSTER S, CRADDOCK N, FERRERO F, GILL M, et 
al. 2004. Familiality of symptom dimensions in depression. Archives of General 
Psychiatry. 61(5):468-74. 
KOSCHKE, M., BOETTGER, M. K., SCHULZ, S., BERGER, S., TERHAAR, J., VOSS, A., 
YERAGANI, V. K. & BÄR, K.-J. 2009. Autonomy of autonomic dysfunction in 
major depression. Psychosomatic medicine, 71, 852-860. 
KUPPER, N., WILLEMSEN, G., RIESE, H., POSTHUMA, D., BOOMSMA, D. I. & DE 
GEUS, E. J. 2005. Heritability of daytime ambulatory blood pressure in an extended 
twin design. Hypertension, 45, 80-85. 
KWIDZINSKI E, BECHMANN I. 2007. IDO expression in the brain: a double-edged sword. 
Journal of Molecular Medicine. 85(12):1351-9. 
LAMBERT, E., DAWOOD, T., STRAZNICKY, N., SARI, C., SCHLAICH, M., ESLER, M. 
& LAMBERT, G. 2010. Association between the sympathetic firing pattern and 
anxiety level in patients with the metabolic syndrome and elevated blood pressure. 
Journal of hypertension, 28, 543-550. 
LAMERS, F., DE JONGE, P., NOLEN, W. A., SMIT, J. H., ZITMAN, F. G., BEEKMAN, 
A. T. & PENNINX, B. W. 2010. Identifying depressive subtypes in a large cohort 
189 
 
study: results from the Netherlands Study of Depression and Anxiety (NESDA). The 
Journal of clinical psychiatry, 71, 1582-1589. 
LASKY‐SU, J. A., FARAONE, S. V., GLATT, S. J. & TSUANG, M. T. 2005. Meta‐
analysis of the association between two polymorphisms in the serotonin transporter 
gene and affective disorders. American Journal of Medical Genetics Part B: 
Neuropsychiatric Genetics, 133, 110-115. 
LAURSEN, T. M., MUNK-OLSEN, T., NORDENTOFT, M. & MORTENSEN, P. B. 2007. 
Increased mortality among patients admitted with major psychiatric disorders: a 
register-based study comparing mortality in unipolar depressive disorder, bipolar 
affective disorder, schizoaffective disorder, and schizophrenia. Journal of Clinical 
Psychiatry, 68, 899-907. 
LAWLOR, D. A., HARBORD, R. M., TYBJAERG-HANSEN, A., PALMER, T. M., 
ZACHO, J., BENN, M., TIMPSON, N. J., SMITH, G. D. & NORDESTGAARD, B. 
G. 2011. Using genetic loci to understand the relationship between adiposity and 
psychological distress: a Mendelian Randomization study in the Copenhagen 
General Population Study of 53,221 adults. J Intern Med, 269, 525-37. 
LEAS, L. & MCCABE, M. 2007. Health behaviors among individuals with schizophrenia 
and depression. Journal of health psychology, 12, 563-579. 
LEE, S., YANG, J., GODDARD, M., VISSCHER, P. & WRAY, N. 2012. Estimation of 
pleiotropy between complex diseases using SNP-derived genomic relationships and 
restricted maximum likelihood. Bioinformatics. 
LEE, S. H., DECANDIA, T. R., RIPKE, S., YANG, J., SULLIVAN, P. F., GODDARD, M. 
E., KELLER, M. C., VISSCHER, P. M. & WRAY, N. R. 2012. Estimating the 
proportion of variation in susceptibility to schizophrenia captured by common SNPs. 
Nature genetics, 44, 247-250. 
190 
 
LEE, S. H., WRAY, N. R., GODDARD, M. E. & VISSCHER, P. M. 2011. Estimating 
missing heritability for disease from genome-wide association studies. The American 
Journal of Human Genetics, 88, 294-305. 
LESPÉRANCE, F., FRASURE-SMITH, N., TALAJIC, M. & BOURASSA, M. G. 2002. 
Five-year risk of cardiac mortality in relation to initial severity and one-year changes 
in depression symptoms after myocardial infarction. Circulation, 105, 1049-1053. 
LEVINSON, D. F. 2006. The genetics of depression: a review. Biological psychiatry, 60, 84-
92. 
LEVY, D., EHRET, G. B., RICE, K., VERWOERT, G. C., LAUNER, L. J., DEHGHAN, A., 
GLAZER, N. L., MORRISON, A. C., JOHNSON, A. D. & ASPELUND, T. 2009. 
Genome-wide association study of blood pressure and hypertension. Nature genetics, 
41, 677-687. 
LEWIS, C. M., NG, M. Y., BUTLER, A. W., COHEN-WOODS, S., UHER, R., PIRLO, K., 
WEALE, M. E., SCHOSSER, A., PAREDES, U. M. & RIVERA, M. 2010. 
Genome-wide association study of major recurrent depression in the UK population. 
American Journal of Psychiatry, 167, 949-957. 
LI, S., ZHAO, J. H., LUAN, J., LUBEN, R. N., RODWELL, S. A., KHAW, K. T., ONG, K. 
K., WAREHAM, N. J. & LOOS, R. J. F. 2010. Cumulative effects and predictive 
value of common obesity-susceptibility variants identified by genome-wide 
association studies. The American journal of clinical nutrition, 91, 184-190. 
LICHTMAN, J. H., BIGGER, J. T., BLUMENTHAL, J. A., FRASURE-SMITH, N., 
KAUFMANN, P. G., LESPÉRANCE, F., MARK, D. B., SHEPS, D. S., TAYLOR, 
C. B. & FROELICHER, E. S. 2008. Depression and coronary heart disease 
recommendations for screening, referral, and treatment: a science advisory from the 
American Heart Association Prevention Committee of the Council on 
191 
 
Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology 
and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes 
Research: endorsed by the American Psychiatric Association. Circulation, 118, 
1768-1775. 
LICINIO, J., O'KIRWAN, F., IRIZARRY, K., MERRIMAN, B., THAKUR, S., JEPSON, R., 
LAKE, S., TANTISIRA, K., WEISS, S. & WONG, M. 2004. Association of a 
corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment 
response in Mexican-Americans. Molecular psychiatry, 9, 1075-1082. 
LIEW, F. Y., PITMAN, N. I. & MCINNES, I. B. 2010. Disease-associated functions of IL-
33: the new kid in the IL-1 family. Nature Reviews Immunology, 10, 103-110. 
LOERBROKS, A., APFELBACHER, C., THAYER, J., DEBLING, D. & STÜRMER, T. 
2009. Neuroticism, extraversion, stressful life events and asthma: a cohort study of 
middle‐aged adults. Allergy, 64, 1444-1450. 
LOERBROKS, A., HERR, R. M., SUBRAMANIAN, S. & BOSCH, J. A. 2012. The 
association of asthma and wheezing with major depressive episodes: an analysis of 
245 727 women and men from 57 countries. International Journal of Epidemiology. 
LOHMUELLER, K. E., PEARCE, C. L., PIKE, M., LANDER, E. S. & HIRSCHHORN, J. 
N. 2003. Meta-analysis of genetic association studies supports a contribution of 
common variants to susceptibility to common disease. Nature genetics, 33, 177-182. 
LOOS, R. J. F., LINDGREN, C. M., LI, S., WHEELER, E., ZHAO, J. H., PROKOPENKO, 
I., INOUYE, M., FREATHY, R. M., ATTWOOD, A. P. & BECKMANN, J. S. 2008. 
Common variants near MC4R are associated with fat mass, weight and risk of 
obesity. Nature genetics, 40, 768-775. 
LOUTEN, J., RANKIN, A. L., LI, Y., MURPHY, E. E., BEAUMONT, M., MOON, C., 
BOURNE, P., MCCLANAHAN, T. K., PFLANZ, S. & DE WAAL MALEFYT, R. 
192 
 
2011. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses 
during allergic airway inflammation. International immunology, 23, 307-315. 
LU, X.-Y. 2007. The leptin hypothesis of depression: a potential link between mood 
disorders and obesity? Current opinion in pharmacology, 7, 648-652. 
LUBKE, G. H., HOTTENGA, J. J., WALTERS, R., LAURIN, C., DE GEUS, E. J., 
WILLEMSEN, G., SMIT, J. H., MIDDELDORP, C. M., PENNINX, B. W. & VINK, 
J. M. 2012. Estimating the genetic variance of major depressive disorder due to all 
single nucleotide polymorphisms. Biological psychiatry, 72, 707-709. 
LUCIANO, M., HUFFMAN, J. E., ARIAS‐VÁSQUEZ, A., VINKHUYZEN, A. A., 
MIDDELDORP, C. M., GIEGLING, I., PAYTON, A., DAVIES, G., ZGAGA, L. & 
JANZING, J. 2012. Genome‐wide association uncovers shared genetic effects 
among personality traits and mood states. American Journal of Medical Genetics 
Part B: Neuropsychiatric Genetics, 159, 684-695. 
LUPPINO, F. S., DE WIT, L. M., BOUVY, P. F., STIJNEN, T., CUIJPERS, P., PENNINX, 
B. W. & ZITMAN, F. G. 2010. Overweight, obesity, and depression: a systematic 
review and meta-analysis of longitudinal studies. Archives of general psychiatry, 67, 
220. 
MA, J. & XIAO, L. 2010. Obesity and depression in US women: results from the 2005–2006 
National Health and Nutritional Examination Survey. Obesity, 18, 347-353. 
MARKOWITZ S, FRIEDMAN MA, ARENT SM. 2008. Understanding the relation 
between obesity and depression: causal mechanisms and implications for treatment. 
Clinical Psychology: Science and Practice. 15(1):1-20. 
MAES, H. H., NEALE, M. C. & EAVES, L. J. 1997. Genetic and environmental factors in 
relative body weight and human adiposity. Behavior genetics, 27, 325-351. 
193 
 
MAJOR DEPRESSIVE DISORDER WORKING GROUP OF THE PSYCHIATRIC GWAS 
CONSORTIUM 2012. A mega-analysis of genome-wide association studies for 
major depressive disorder. Mol Psychiatry. 
MANOLIO, T. A., COLLINS, F. S., COX, N. J., GOLDSTEIN, D. B., HINDORFF, L. A., 
HUNTER, D. J., MCCARTHY, M. I., RAMOS, E. M., CARDON, L. R. & 
CHAKRAVARTI, A. 2009. Finding the missing heritability of complex diseases. 
Nature, 461, 747-753. 
MARSLAND, A. L., PRATHER, A. A., PETERSEN, K. L., COHEN, S. & MANUCK, S. B. 
2008. Antagonistic characteristics are positively associated with inflammatory 
markers independently of trait negative emotionality. Brain, behavior, and immunity, 
22, 753-761. 
MCCAFFERY, J. M., DUAN, Q. L., FRASURE-SMITH, N., BARHDADI, A., 
LESPÉRANCE, F., THÉROUX, P., ROULEAU, G. A. & DUBÉ, M.-P. 2009. 
Genetic predictors of depressive symptoms in cardiac patients. American Journal of 
Medical Genetics Part B: Neuropsychiatric Genetics, 150B, 381-388. 
MCCAFFERY, J. M., NIAURA, R., TODARO, J. F., SWAN, G. E. & CARMELLI, D. 
2003. Depressive symptoms and metabolic risk in adult male twins enrolled in the 
National Heart, Lung, and Blood Institute twin study. Psychosomatic Medicine, 65, 
490-497. 
MCCARTHY, S., MOTTAGUI-TABAR, S., MIZUNO, Y., SENNBLAD, B., HOFFSTEDT, 
J., ARNER, P., WAHLESTEDT, C. & ANDERSSON, B. 2005. Complex HTR2C 
linkage disequilibrium and promoter associations with body mass index and serum 
leptin. Human genetics, 117, 545-557. 
194 
 
MCELROY, S. L., KOTWAL, R., MALHOTRA, S., NELSON, E. B., KECK, P. E. & 
NEMEROFF, C. B. 2004. Are mood disorders and obesity related? A review for the 
mental health professional. J Clin Psychiatry, 65, 634-651. 
MCGUFFIN, P., KATZ, R. & ALDRICH, J. 1986. Past and present state examination: the 
assessment of ‘lifetime ever’psychopathology. Psychological medicine, 16, 461-465. 
MCGUFFIN, P., KATZ, R., WATKINS, S. & RUTHERFORD, J. 1996. A hospital-based 
twin register of the heritability of DSM-IV unipolar depression. Archives of General 
Psychiatry, 53, 129. 
MEYRE, D., DELPLANQUE, J., CHÈVRE, J.-C., LECOEUR, C., LOBBENS, S., 
GALLINA, S., DURAND, E., VATIN, V., DEGRAEVE, F. & PROENÇA, C. 2009. 
Genome-wide association study for early-onset and morbid adult obesity identifies 
three new risk loci in European populations. Nature genetics, 41, 157-159. 
MIDDELDORP, C., CATH, D., VAN DYCK, R. & BOOMSMA, D. 2005. The co-
morbidity of anxiety and depression in the perspective of genetic epidemiology. A 
review of twin and family studies. Psychological Medicine, 35, 611-624. 
MILLER, A. M. & LIEW, F. Y. 2011. The IL-33/ST2 pathway-A new therapeutic target in 
cardiovascular disease. Pharmacology & therapeutics. 
MILLER, A. M., XU, D., ASQUITH, D. L., DENBY, L., LI, Y., SATTAR, N., BAKER, A. 
H., MCINNES, I. B. & LIEW, F. Y. 2008. IL-33 reduces the development of 
atherosclerosis. The Journal of experimental medicine, 205, 339-346. 
MILLER AH. 2009. Mechanisms of cytokine-induced behavioral changes: 




MILLER, G. E., STETLER, C. A., CARNEY, R. M., FREEDLAND, K. E. & BANKS, W. 
A. 2002. Clinical depression and inflammatory risk markers for coronary heart 
disease. The American journal of cardiology, 90, 1279-1283. 
MITCHELL, F. 2012. Diabetes: Extended genetic testing improves MODY diagnosis. 
Nature Reviews Endocrinology, 8, 319-319. 
MIZUTA, E., KOKUBO, Y., YAMANAKA, I., MIYAMOTO, Y., OKAYAMA, A., 
YOSHIMASA, Y., TOMOIKE, H., MORISAKI, H. & MORISAKI, T. 2008. Leptin 
gene and leptin receptor gene polymorphisms are associated with sweet preference 
and obesity. Hypertension Research, 31, 1069-1077. 
MOFFATT, M. F., GUT, I. G., DEMENAIS, F., STRACHAN, D. P., BOUZIGON, E., 
HEATH, S., VON MUTIUS, E., FARRALL, M., LATHROP, M. & COOKSON, W. 
O. C. M. 2010. A large-scale, consortium-based genomewide association study of 
asthma. New England Journal of Medicine, 363, 1211-1221. 
MONTEIRO, R. & AZEVEDO, I. 2010. Chronic inflammation in obesity and the metabolic 
syndrome. Mediators of inflammation, 2010. 
MORIMOTO, K., HORIO, J., SATOH, H., SUE, L., BEACH, T., ARITA, S., TOOYAMA, 
I. & KONISHI, Y. 2011. Expression Profiles of Cytokines in the Brains of 
Alzheimer's Disease (AD) Patients Compared to the Brains of Non-Demented 
Patients with and without Increasing AD Pathology. Journal of Alzheimer's Disease, 
25, 59-76. 
MUMBY, H. S., ELKS, C. E., LI, S., SHARP, S. J., KHAW, K.-T., LUBEN, R. N., 
WAREHAM, N. J., LOOS, R. J. & ONG, K. K. 2011. Mendelian randomisation 
study of childhood BMI and early menarche. J Obes, 2011. 
NAKATANI, D., SATO, H., SAKATA, Y., SHIOTANI, I., KINJO, K., MIZUNO, H., 
SHIMIZU, M., ITO, H., KORETSUNE, Y. & HIRAYAMA, A. 2005. Influence of 
196 
 
serotonin transporter gene polymorphism on depressive symptoms and new cardiac 
events after acute myocardial infarction. American heart journal, 150, 652-658. 
NASH, M. W., HUEZO-DIAZ, P., WILLIAMSON, R. J., STERNE, A., PURCELL, S., 
HODA, F., CHERNY, S. S., ABECASIS, G. R., PRINCE, M. & GRAY, J. A. 2004. 
Genome-wide linkage analysis of a composite index of neuroticism and mood-
related scales in extreme selected sibships. Human Molecular Genetics, 13, 2173-
2182. 
NEALE, M., BOKER, S., XIE, G. & MAES, H. 2006. Statistical modelling, Richmond, VA, 
Department of Psychiatry, VCU. 
NEELEMAN, J., BIJL, R. & ORMEL, J. 2004. Neuroticism, a central link between somatic 
and psychiatric morbidity: path analysis of prospective data. Psychological Medicine, 
34, 521-531. 
NEELEMAN, J., WESSELY, S. & WADSWORTH, M. 1998. Predictors of suicide, 
accidental death, and premature natural death in a general-population birth cohort. 
The Lancet, 351, 93-97. 
NEJTEK, V. A., BROWN, E. S., KHAN, D. A., MOORE, J. J., WAGNER, J. V. & 
PERANTIE, D. C. 2001. Prevalence of mood disorders and relationship to asthma 
severity in patients at an inner-city asthma clinic. Annals of Allergy, Asthma & 
Immunology, 87, 129-133. 
NG, T.-P., CHIAM, P.-C. & KUA, E.-H. 2007. Mental disorders and asthma in the elderly: 
A population-based study. International Journal of Geriatric Psychiatry, 22, 668-
674. 
NGUYEN, N. T., MAGNO, C. P., LANE, K. T., HINOJOSA, M. W. & LANE, J. S. 2008. 
Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with 
197 
 
obesity: findings from the National Health and Nutrition Examination Survey, 1999 
to 2004. Journal of the American College of Surgeons, 207, 928-934. 
NURNBERGER, J. I., BLEHAR, M. C., KAUFMANN, C. A., YORK-COOLER, C., 
SIMPSON, S. G., HARKAVY-FRIEDMAN, J., SEVERE, J. B., MALASPINA, D. 
& REICH, T. 1994. Diagnostic interview for genetic studies: rationale, unique 
features, and training. Archives of general psychiatry, 51, 849-859. 
 OBER, C. & NICOLAE, D. L. 2011. Meta-analysis of genome-wide association studies of 
asthma in ethnically diverse North American populations. Nature genetics, 43, 887-
892. 
O'CARROLL, R. E., SMITH, K. B., GRUBB, N. R., FOX, K. A. A. & MASTERTON, G. 
2001. Psychological factors associated with delay in attending hospital following a 
myocardial infarction. Journal of psychosomatic research, 51, 611-614. 
ODE, J. J., PIVARNIK, J. M., REEVES, M. J. & KNOUS, J. L. 2007. Body mass index as a 
predictor of percent fat in college athletes and nonathletes. Medicine and science in 
sports and exercise, 39, 403. 
ORTEGA, A., FELDMAN, J., CANINO, G., STEINMAN, K. & ALEGRÍA, M. 2006. Co-
occurrence of mental and physical illness in US Latinos. Social Psychiatry and 
Psychiatric Epidemiology, 41, 927-934. 
PADMANABHAN, S., MELANDER, O., JOHNSON, T., DI BLASIO, A. M., LEE, W. K., 
GENTILINI, D., HASTIE, C. E., MENNI, C., MONTI, M. C. & DELLES, C. 2010. 
Genome-wide association study of blood pressure extremes identifies variant near 
UMOD associated with hypertension. PLoS genetics, 6, e1001177. 
PALMER TM, STERNE JA, HARBORD RM, LAWLOR DA, SHEENHAN NA, MENG S, 
et al. 2011. Instrumental variable estimation of causal risk ratios and causal odds 
198 
 
ratios in Mendelian randomization analyses. American journal of epidemiology. 
173(12):1392-403. 
PALMER, T. M., LAWLOR, D. A., HARBORD, R. M., SHEEHAN, N. A., TOBIAS, J. H., 
TIMPSON, N. J., SMITH, G. D. & STERNE, J. A. C. 2012. Using multiple genetic 
variants as instrumental variables for modifiable risk factors. Stat Methods Med Res, 
21, 223-242. 
PAPAKOSTAS, G. I., ÖNGÜR, D., IOSIFESCU, D. V., MISCHOULON, D. & FAVA, M. 
2004. Cholesterol in mood and anxiety disorders: review of the literature and new 
hypotheses. European Neuropsychopharmacology, 14, 135-142. 
PAPAKOSTAS, G. I., PETERSEN, T., IOSIFESCU, D. V., BURNS, A. M., NIERENBERG, 
A. A., ALPERT, J. E., ROSENBAUM, J. F. & FAVA, M. 2005. Obesity among 
outpatients with major depressive disorder. The International Journal of 
Neuropsychopharmacology, 8, 59-63. 
PASCO, J. A., JACKA, F. N., WILLIAMS, L. J., HENRY, M. J., NICHOLSON, G. C., 
KOTOWICZ, M. A. & BERK, M. 2008. Leptin in depressed women: cross-sectional 
and longitudinal data from an epidemiologic study. Journal of affective disorders, 
107, 221-225. 
PASQUALI, R., VICENNATI, V. & GAMBUNERI, A. 2002. Adrenal and gonadal function 
in obesity. Journal of endocrinological investigation, 25, 893-898. 
PATTEN, S. B. 2000. Exogenous corticosteroids and major depression in the general 
population. Journal of psychosomatic research, 49, 447-449. 
PATTEN, S. B., WILLIAMS, J. V., LAVORATO, D. H., BROWN, L., MCLAREN, L. & 
ELIASZIW, M. 2009. Major depression, antidepressant medication and the risk of 
obesity. Psychotherapy and psychosomatics, 78, 182-186. 
199 
 
PATTEN, S. B., WILLIAMS, J. V., LAVORATO, D. H., MODGILL, G., JETTÉ, N. & 
ELIASZIW, M. 2008. Major depression as a risk factor for chronic disease incidence: 
longitudinal analyses in a general population cohort. General hospital psychiatry, 30, 
407-413. 
PENG, S., ZHU, Y., XU, F., REN, X., LI, X. & LAI, M. 2011. FTO gene polymorphisms 
and obesity risk: a meta-analysis. BMC medicine, 9, 71. 
PERGADIA, M. L., GLOWINSKI, A. L., WRAY, N. R., AGRAWAL, A., SACCONE, S. F., 
LOUKOLA, A., BROMS, U., KORHONEN, T., PENNINX, B. W. & GRANT, J. D. 
2011. A 3p26-3p25 genetic linkage finding for DSM-IV major depression in heavy 
smoking families. The American journal of psychiatry, 168, 848. 
PERNEGER TV. 1998. What’s wrong with Bonferroni adjustments. BMJ: British Medical 
Journal. 316(7139):1236. 
PETERSON, R. E., MAES, H. H., HOLMANS, P., SANDERS, A. R., LEVINSON, D. F., 
SHI, J., KENDLER, K. S., GEJMAN, P. V. & WEBB, B. T. 2011. Genetic risk sum 
score comprised of common polygenic variation is associated with body mass index. 
Human genetics, 129, 221-230. 
PHILLIPS, A. C., BATTY, G. D., GALE, C. R., DEARY, I. J., OSBORN, D., 
MACINTYRE, K. & CARROLL, D. 2009. Generalized anxiety disorder, major 
depressive disorder, and their comorbidity as predictors of all-cause and 
cardiovascular mortality: the Vietnam experience study. Psychosomatic Medicine, 
71, 395-403. 
PIERCE, B. L., AHSAN, H. & VANDERWEELE, T. J. 2011. Power and instrument 
strength requirements for Mendelian randomization studies using multiple genetic 
variants. Int J Epidemiol, 40, 740-752. 
200 
 
PIETRZAK, R. H., WAGNER, J. A. & PETRY, N. M. 2007. DSM-IV personality disorders 
and coronary heart disease in older adults: Results from the National Epidemiologic 
Survey on Alcohol and Related Conditions. The Journals of Gerontology Series B: 
Psychological Sciences and Social Sciences, 62, P295-P299. 
PINE, D. S., GOLDSTEIN, R. B., WOLK, S. & WEISSMAN, M. M. 2001. The association 
between childhood depression and adulthood body mass index. Pediatrics, 107, 
1049-1056. 
POWERS, A. D. & OLTMANNS, T. F. 2012. Personality disorders and physical health: A 
longitudinal examination of physical functioning, healthcare utilization, and health-
related behaviors in middle-aged adults. Journal of personality disorders, 26, 524. 
PREISIG, M., WAEBER, G., VOLLENWEIDER, P., BOVET, P., ROTHEN, S., 
VANDELEUR, C., GUEX, P., MIDDLETON, L., WATERWORTH, D. & 
MOOSER, V. 2009. The PsyCoLaus study: methodology and characteristics of the 
sample of a population-based survey on psychiatric disorders and their association 
with genetic and cardiovascular risk factors. BMC psychiatry, 9, 9. 
 PRICE, A. L., PATTERSON, N. J., PLENGE, R. M., WEINBLATT, M. E., SHADICK, N. 
A. & REICH, D. 2006. Principal components analysis corrects for stratification in 
genome-wide association studies. Nature genetics, 38, 904-909. 
PUHL, R. M. & BROWNELL, K. D. 2003. Psychosocial origins of obesity stigma: toward 
changing a powerful and pervasive bias. Obesity reviews, 4, 213-227. 
PUHL, R. M. & HEUER, C. A. 2010. Obesity Stigma: Important Considerations for Public 
Health. Am J Public Health, 100, 1019-1028. 
PURCELL, S. M., WRAY, N. R., STONE, J. L., VISSCHER, P. M., O'DONOVAN, M. C., 
SULLIVAN, P. F., SKLAR, P., RUDERFER, D. M., MCQUILLIN, A. & MORRIS, 
201 
 
D. W. 2009. Common polygenic variation contributes to risk of schizophrenia and 
bipolar disorder. Nature, 460, 748-752. 
RAISON CL, DANTZER R, KELLEY KW, LAWSON MA, WOOLWINE BJ, VOGT G, et 
al. 2010. CSF concentrations of brain tryptophan and kynurenines during immune 
stimulation with IFN-α: relationship to CNS immune responses and depression. 
Molecular psychiatry. 15(4):393-403. 
RAMASAMY, A., CURJURIC, I., COIN, L. J., KUMAR, A., MCARDLE, W. L., 
IMBODEN, M., LEYNAERT, B., KOGEVINAS, M., SCHMID-GRENDELMEIER, 
P. & PEKKANEN, J. 2011. A genome-wide meta-analysis of genetic variants 
associated with allergic rhinitis and grass sensitization and their interaction with 
birth order. Journal of Allergy and Clinical Immunology, 128, 996-1005. 
RANJITH, G., FARMER, A., MCGUFFIN, P. & CLEARE, A. J. 2005. Personality as a 
determinant of social functioning in depression. Journal of affective disorders, 84, 
73-76. 
REICH, M. 2008. Depression and cancer: recent data on clinical issues, research challenges 
and treatment approaches. Current opinion in oncology, 20, 353-359. 
RENNIE, K. & JEBB, S. 2005. Prevalence of obesity in Great Britain. Obesity reviews, 6, 
11-12. 
RIJSDIJK, F. V., VAN HAREN, N. E. M., PICCHIONI, M. M., MCDONALD, C., 
TOULOPOULOU, T., POL, H. E. H., KAHN, R. S., MURRAY, R. & SHAM, P. C. 
2005. Brain MRI abnormalities in schizophrenia: same genes or same environment? 
Psychological medicine, 35, 1399-1410. 
RISCH, N., HERRELL, R., LEHNER, T., LIANG, K.-Y., EAVES, L., HOH, J., GRIEM, A., 
KOVACS, M., OTT, J. & MERIKANGAS, K. R. 2009. Interaction between the 
202 
 
serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression. 
JAMA: the journal of the American Medical Association, 301, 2462-2471. 
RITZ, T., CLAUSSEN, C. & DAHME, B. 2001. Experimentally induced emotions, facial 
muscle activity, and respiratory resistance in asthmatic and non‐asthmatic 
individuals. British Journal of Medical Psychology, 74, 167-182. 
RIVERA, M., COHEN-WOODS, S., KAPUR, K., BREEN, G., NG, M., BUTLER, A. W., 
CRADDOCK, N., GILL, M., KORSZUN, A. & MAIER, W. 2012. Depressive 
disorder moderates the effect of the FTO gene on body mass index. Molecular 
psychiatry, 17, 604-611. 
RIYAZI, N., MEULENBELT, I., KROON, H. M., RONDAY, K. H., LE GRAVERAND, M. 
H., ROSENDAAL, F. R., BREEDVELD, F. C., SLAGBOOM, P. & 
KLOPPENBURG, M. 2005. Evidence for familial aggregation of hand, hip, and 
spine but not knee osteoarthritis in siblings with multiple joint involvement: the 
GARP study. Annals of the rheumatic diseases, 64, 438-443. 
ROBERTS, R. E., DELEGER, S., STRAWBRIDGE, W. J. & KAPLAN, G. A. 2003. 
Prospective association between obesity and depression: evidence from the Alameda 
County Study. Int J Obes, 27, 514-521. 
ROHDE P, ICHIKAWA L, SIMON GE, LUDMAN EJ, LINDE JA, JEFFERY RW, et al. 
2008. Associations of child sexual and physical abuse with obesity and depression in 
middle-aged women. Child abuse & neglect. 32(9):878-87. 
ROSMALEN, J. G., NEELEMAN, J., GANS, R. O. & DE JONGE, P. 2007. The association 
between neuroticism and self-reported common somatic symptoms in a population 
cohort. Journal of psychosomatic research, 62, 305-311. 
203 
 
ROSMOND, R., BOUCHARD, C. & BJÖRNTORP, P. 2002. Increased Abdominal Obesity 
in Subjects with a Mutation in the 5‐HT2A Receptor Gene Promoter. Annals of the 
New York Academy of Sciences, 967, 571-575. 
RUGULIES, R. 2002. Depression as a predictor for coronary heart disease: a review and 
meta-analysis. American journal of preventive medicine, 23, 51-61. 
SAMAAN Z, FARMER A, CRADDOCK N, JONES L, KORSZUN A, OWEN M, et al. 
2009. Migraine in recurrent depression: case–control study. The British Journal of 
Psychiatry. 194(4):350-4. 
SANDHOLT, C. H., SPARSØ, T., GRARUP, N., ALBRECHTSEN, A., ALMIND, K., 
HANSEN, L., TOFT, U., JØRGENSEN, T., HANSEN, T. & PEDERSEN, O. 2010. 
Combined analyses of 20 common obesity susceptibility variants. Diabetes, 59, 
1667-1673. 
SCHERRER, J. F., XIAN, H., BUCHOLZ, K. K., EISEN, S. A., LYONS, M. J., 
GOLDBERG, J., TSUANG, M. & TRUE, W. R. 2003. A twin study of depression 
symptoms, hypertension, and heart disease in middle-aged men. Psychosomatic 
medicine, 65, 548-557. 
SCHOUSBOE, K., WILLEMSEN, G., KYVIK, K. O., MORTENSEN, J., BOOMSMA, D. 
I., CORNES, B. K., DAVIS, C. J., FAGNANI, C., HJELMBORG, J. & KAPRIO, J. 
2003. Sex differences in heritability of BMI: a comparative study of results from 
twin studies in eight countries. Twin Research, 6, 409-421. 
SECKL, J. R. & MEANEY, M. J. 2004. Glucocorticoid programming. Annals of the New 
York Academy of Sciences, 1032, 63-84. 
SERRETTI, A. & MANDELLI, L. 2010. Antidepressants and body weight: a comprehensive 
review and meta-analysis. The Journal of clinical psychiatry, 71, 1259-1272. 
204 
 
SHEEHAN, N. A., DIDELEZ, V., BURTON, P. R. & TOBIN, M. D. 2008. Mendelian 
randomisation and causal inference in observational epidemiology. PLoS Med, 5, 
e177. 
SHIFMAN, S., BHOMRA, A., SMILEY, S., WRAY, N., JAMES, M., MARTIN, N., 
HETTEMA, J., AN, S., NEALE, M. & VAN DEN OORD, E. 2008. A whole 
genome association study of neuroticism using DNA pooling. Molecular psychiatry, 
13, 302-312. 
SHYN, S. I., SHI, J., KRAFT, J., POTASH, J., KNOWLES, J., WEISSMAN, M., 
GARRIOCK, H., YOKOYAMA, J., MCGRATH, P. & PETERS, E. 2011. Novel 
loci for major depression identified by genome-wide association study of Sequenced 
Treatment Alternatives to Relieve Depression and meta-analysis of three studies. 
Molecular psychiatry, 16, 202-215. 
SIMON, G. E., VON KORFF, M., SAUNDERS, K., MIGLIORETTI, D. L., CRANE, P. K., 
VAN BELLE, G. & KESSLER, R. C. 2006. Association between obesity and 
psychiatric disorders in the US adult population. Archives of General Psychiatry, 63, 
824. 
SMALL, G. W., BIRKETT, M., MEYERS, B. S., KORAN, L. M., BYSTRITSKY, A. & 
NEMEROFF, C. B. 1996. Impact of physical illness on quality of life and 
antidepressant response in geriatric major depression. Fluoxetine Collaborative 
Study Group. Journal of the American Geriatrics Society, 44, 1220. 
SMITH, G. D. & EBRAHIM, S. 2003. â€˜Mendelian randomizationâ€™: can genetic 
epidemiology contribute to understanding environmental determinants of disease? 
International Journal of Epidemiology, 32, 1-22. 
205 
 
SNIEDER, H., HARSHFIELD, G. A. & TREIBER, F. A. 2003. Heritability of blood 
pressure and hemodynamics in African-and European-American youth. 
Hypertension, 41, 1196-1201. 
SOLIS, O. L., KHAN, D. A. & BROWN, E. S. 2006. Age at onset of major depression in 
inner-city adults with asthma. Psychosomatics, 47, 330-2. 
SOOKOIAN, S., GEMMA, C., GARCÍA, S. I., GIANOTTI, T. F., DIEUZEIDE, G., 
ROUSSOS, A., TONIETTI, M., TRIFONE, L., KANEVSKY, D. & GONZÁLEZ, C. 
D. 2007. Short allele of serotonin transporter gene promoter is a risk factor for 
obesity in adolescents. Obesity, 15, 271-276. 
SPELIOTES, E. K., WILLER, C. J., BERNDT, S. I., MONDA, K. L., THORLEIFSSON, G., 
JACKSON, A. U., ALLEN, H. L., LINDGREN, C. M., LUAN, J. A. & MÄGI, R. 
2010. Association analyses of 249,796 individuals reveal 18 new loci associated 
with body mass index. Nature genetics, 42, 937-948. 
SPITZ, M. R., DETRY, M. A., PILLOW, P., HU, Y., AMOS, C. I., HONG, W. K. & WU, X. 
2000. Variant alleles of the D2 dopamine receptor gene and obesity. Nutrition 
Research, 20, 371-380. 
SRINIVASAN, S. R., BAO, W., WATTIGNEY, W. A. & BERENSON, G. S. 1996. 
Adolescent overweight is associated with adult overweight and related multiple 
cardiovascular risk factors: the Bogalusa Heart Study. Metabolism, 45, 235. 
STAIGER, D. O. & STOCK, J. H. 1994. Instrumental variables regression with weak 
instruments. National Bureau of Economic Research Cambridge, Mass., USA. 
STONE T, PERKINS M. 1981. Quinolinic acid: a potent endogenous excitant at amino acid 
receptors in CNS. European journal of pharmacology. 72(4):411-2. 
206 
 
STRIK, J. J., LOUSBERG, R., CHERIEX, E. C. & HONIG, A. 2004. One year cumulative 
incidence of depression following myocardial infarction and impact on cardiac 
outcome. Journal of psychosomatic research, 56, 59-66. 
STUNKARD, A. J., FAITH, M. S. & ALLISON, K. C. 2003. Depression and obesity. 
Biological psychiatry, 54, 330-337. 
STUNKARD, A. J., SØRENSEN, T. I., HANIS, C., TEASDALE, T. W., CHAKRABORTY, 
R., SCHULL, W. J. & SCHULSINGER, F. 1986. An adoption study of human 
obesity. New England Journal of Medicine, 314, 193-198. 
STURM, R. 2002. The effects of obesity, smoking, and drinking on medical problems and 
costs. Health Affairs, 21, 245-253. 
SUGIMOTO, M., YAMAOKA, Y. & FURUTA, T. 2010. Influence of interleukin 
polymorphisms on development of gastric cancer and peptic ulcer. World journal of 
gastroenterology: WJG, 16, 1188. 
SULLIVAN, P. F., NEALE, M. C. & KENDLER, K. S. 2000. Genetic epidemiology of 
major depression: review and meta-analysis. American Journal of Psychiatry, 157, 
1552-1562. 
SURTEES, P. G., WAINWRIGHT, N. W., BOEKHOLDT, S. M., LUBEN, R. N., 
WAREHAM, N. J. & KHAW, K.-T. 2008. Major depression, C-reactive protein, 
and incident ischemic heart disease in healthy men and women. Psychosomatic 
Medicine, 70, 850-855. 
TEIXEIRA, P., ALMEIDA, C., FERREIRA, M., WAGMAN, M. & REIS, F. 2006. 
Evaluation of clinical and psychiatric symptoms in sub clinical hypothyroidism. 
Revista da Associação Médica Brasileiras, 52, 222-8. 
TERRACCIANO, A., SANNA, S., UDA, M., DEIANA, B., USALA, G., BUSONERO, F., 
MASCHIO, A., SCALLY, M., PATRICIU, N. & CHEN, W.-M. 2008. Genome-
207 
 
wide association scan for five major dimensions of personality. Molecular 
psychiatry, 15, 647-656. 
THOMAS, C., HYPPÖNEN, E. & POWER, C. 2008. Obesity and type 2 diabetes risk in 
midadult life: the role of childhood adversity. Pediatrics, 121, e1240-e1249. 
THOMAS, G. N., TOMLINSON, B. & CRITCHLEY, J. A. J. H. 2000. Modulation of Blood 
Pressure and Obesity With the Dopamine D2 Receptor Gene TaqI Polymorphism. 
Hypertension, 36, 177-182. 
THOMSEN, S. F., VAN DER SLUIS, S., KYVIK, K. O., SKYTTHE, A. & BACKER, V. 
2010. Estimates of asthma heritability in a large twin sample. Clinical & 
Experimental Allergy, 40, 1054-1061. 
THOMSEN, S. F., VAN DER SLUIS, S., KYVIK, K. O., SKYTTHE, A., SKADHAUGE, L. 
R. & BACKER, V. 2011. Increase in the heritability of asthma from 1994 to 2003 
among adolescent twins. Respiratory medicine, 105, 1147-1152. 
THORLEIFSSON, G., WALTERS, G. B., GUDBJARTSSON, D. F., 
STEINTHORSDOTTIR, V., SULEM, P., HELGADOTTIR, A., 
STYRKARSDOTTIR, U., GRETARSDOTTIR, S., THORLACIUS, S. & 
JONSDOTTIR, I. 2008. Genome-wide association yields new sequence variants at 
seven loci that associate with measures of obesity. Nature genetics, 41, 18-24. 
TURIANO, N. A., MROCZEK, D. K., MOYNIHAN, J. & CHAPMAN, B. P. 2013. Big 5 
personality traits and interleukin-6: Evidence for “healthy Neuroticism” in a US 
population sample. Brain, behavior, and immunity. 
TYROVOLAS, S., LIONIS, C., ZEIMBEKIS, A., BOUNTZIOUKA, V., MICHELI, M., 
KATSAROU, A., PAPAIRAKLEOUS, N., METALLINOS, G., MAKRI, K. & 
POLYCHRONOPOULOS, E. 2009. Increased body mass and depressive 
208 
 
symptomatology are associated with hypercholesterolemia, among elderly 
individuals; results from the MEDIS study. Lipids Health Dis, 8. 
UHER R, FARMER A, MAIER W, RIETSCHEL M, HAUSER J, MARUSIC A, et al. 2008. 
Measuring depression: comparison and integration of three scales in the GENDEP 
study. Psychological medicine. 38(02):289-300. 
UHER, R., HUEZO-DIAZ, P., PERROUD, N., SMITH, R., RIETSCHEL, M., MORS, O., 
HAUSER, J., MAIER, W., KOZEL, D. & HENIGSBERG, N. 2009. Genetic 
predictors of response to antidepressants in the GENDEP project. The 
pharmacogenomics journal, 9, 225-233. 
UHER, R. & MCGUFFIN, P. 2010. The moderation by the serotonin transporter gene of 
environmental adversity in the etiology of depression: 2009 update. Molecular 
psychiatry, 15, 18-22. 
VALDES, A. M. & SPECTOR, T. D. 2010. The genetic epidemiology of osteoarthritis. 
Current opinion in rheumatology, 22, 139-143. 
VAN DER KOOY, K., VAN HOUT, H., MARWIJK, H., MARTEN, H., STEHOUWER, C. 
& BEEKMAN, A. 2007. Depression and the risk for cardiovascular diseases: 
systematic review and meta analysis. International journal of geriatric psychiatry, 
22, 613-626. 
VAN EDE, L., YZERMANS, C. J. & BROUWER, H. J. 1999. Prevalence of depression in 
patients with chronic obstructive pulmonary disease: a systematic review. Thorax, 
54, 688-692. 
VAN LIESHOUT, R. J., BIENENSTOCK, J. & MACQUEEN, G. M. 2009. A review of 
candidate pathways underlying the association between asthma and major depressive 
disorder. Psychosomatic Medicine, 71, 187-195. 
209 
 
VASSEND, O., RØYSAMB, E. & NIELSEN, C. S. 2012. Neuroticism and self-reported 
somatic health: a twin study. Psychology & Health, 27, 1-12. 
VINKHUYZEN, A., PEDERSEN, N., YANG, J., LEE, S., MAGNUSSON, P., IACONO, 
W., MCGUE, M., MADDEN, P., HEATH, A. & LUCIANO, M. 2012. Common 
SNPs explain some of the variation in the personality dimensions of neuroticism and 
extraversion. Translational psychiatry, 2, e102. 
VISSCHER, P. M., BROWN, M. A., MCCARTHY, M. I. & YANG, J. 2012. Five Years of 
GWAS Discovery. American journal of human genetics, 90, 7. 
WAINWRIGHT, N., SURTEES, P., WAREHAM, N. & HARRISON, B. 2007. Psychosocial 
factors and incident asthma hospital admissions in the EPIC‐Norfolk cohort study. 
Allergy, 62, 554-560. 
WALSH, M.-T., DINAN, T. G., CONDREN, R. M., RYAN, M. & KENNY, D. 2002. 
Depression is associated with an increase in the expression of the platelet adhesion 
receptor glycoprotein Ib. Life sciences, 70, 3155-3165. 
WALTERS, P., SCHOFIELD, P., HOWARD, L., ASHWORTH, M. & TYLEE, A. 2011. 
The relationship between asthma and depression in primary care patients: A 
historical cohort and nested case control study. PLoS ONE, 6. 
WAMBOLDT, M. Z., HEWITT, J. K., SCHMITZ, S., WAMBOLDT, F. S., RÄSÄNEN, M., 
KOSKENVUO, M., ROMANOV, K., VARJONEN, J. & KAPRIO, J. 2000. 
Familial association between allergic disorders and depression in adult Finnish twins. 
American journal of medical genetics, 96, 146-153. 
WAN, Y. I., SHRINE, N. R. G., ARTIGAS, M. S., WAIN, L. V., BLAKEY, J. D., 
MOFFATT, M. F., BUSH, A., CHUNG, K. F., COOKSON, W. & STRACHAN, D. 
P. 2012. Genome-wide association study to identify genetic determinants of severe 
asthma. Thorax, 67, 762-768. 
210 
 
WANG, K., LI, W.-D., ZHANG, C. K., WANG, Z., GLESSNER, J. T., GRANT, S. F. A., 
ZHAO, H., HAKONARSON, H. & PRICE, R. A. 2011. A genome-wide association 
study on obesity and obesity-related traits. PloS one, 6, e18939. 
WANG, Y. C., MCPHERSON, K., MARSH, T., GORTMAKER, S. L. & BROWN, M. 
2011. Health and economic burden of the projected obesity trends in the USA and 
the UK. The Lancet, 378, 815-825. 
WEN, W., CHO, Y.-S., ZHENG, W., DORAJOO, R., KATO, N., QI, L., CHEN, C.-H., 
DELAHANTY, R. J., OKADA, Y. & TABARA, Y. 2012. Meta-analysis identifies 
common variants associated with body mass index in east Asians. Nature genetics, 
44, 307-311. 
WHITAKER RC, PHILLIPS SM, ORZOL SM, BURDETTE HL. 2007. The association 
between maltreatment and obesity among preschool children. Child abuse & neglect. 
31(11):1187-99. 
WHITE P, THOMAS J, AMESS J, CRAWFORD D, GROVER S, KANGRO H, et al. 1998. 
Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric 
disorders after glandular fever. The British Journal of Psychiatry. 173(6):475-81. 
WILLEMSEN, G., VAN BEIJSTERVELDT, T., VAN BAAL, C., POSTMA, D. & 
BOOMSMA, D. I. 2008. Heritability of self-reported asthma and allergy: a study in 
adult Dutch twins, siblings and parents. Twin Research and Human Genetics, 11, 
132-142. 
WILLER, C. J., SPELIOTES, E. K., LOOS, R. J. F., LI, S., LINDGREN, C. M., HEID, I. M., 
BERNDT, S. I., ELLIOTT, A. L., JACKSON, A. U. & LAMINA, C. 2008. Six new 
loci associated with body mass index highlight a neuronal influence on body weight 
regulation. Nature genetics, 41, 25-34. 
211 
 
WILLETT, W. C., HU, F. B. & THUN, M. 2013. Overweight, Obesity, and All-Cause 
Mortality. JAMA, 309, 1681-1682. 
WILLIAMS, P. G., O'BRIEN, C. D. & COLDER, C. R. 2004. The effects of neuroticism 
and extraversion on self-assessed health and health-relevant cognition. Personality 
and individual differences, 37, 83-94. 
WING, J. K., BABOR, T., BRUGHA, T., BURKE, J., COOPER, J., GIEL, R., JABLENSKI, 
A., REGIER, D. & SARTORIUS, N. 1990. SCAN: Schedules fonr Clinical 
Assessment in Neuropsychiatry. Archives of general psychiatry, 47, 589. 
WOOD, A. C., RIJSDIJK, F., JOHNSON, K. A., ANDREOU, P., ALBRECHT, B., ARIAS-
VASQUEZ, A., BUITELAAR, J. K., MCLOUGHLIN, G., ROMMELSE, N. N. J. & 
SERGEANT, J. A. 2011. The relationship between ADHD and key cognitive 
phenotypes is not mediated by shared familial effects with IQ. Psychological 
medicine, 41, 861-871. 
WOODRUFF, P. G., MODREK, B., CHOY, D. F., JIA, G., ABBAS, A. R., ELLWANGER, 
A., ARRON, J. R., KOTH, L. L. & FAHY, J. V. 2009. T-helper type 2–driven 
inflammation defines major subphenotypes of asthma. American journal of 
respiratory and critical care medicine, 180, 388. 
WORLD HEALTH ORGANIZATION 1997. Obesity: Preventing and Managing the Global 
Epidemic, Geneva, World Health Organization. 
WORLD HEALTH ORGANIZATION 2008. The global burden of disease: 2004 update. 
World Health Organization. 
WRAY, N., PERGADIA, M., BLACKWOOD, D., PENNINX, B., GORDON, S., NYHOLT, 
D., RIPKE, S., MACINTYRE, D., MCGHEE, K. & MACLEAN, A. 2012. Genome-
wide association study of major depressive disorder: new results, meta-analysis, and 
lessons learned. Molecular psychiatry, 17, 36-48. 
212 
 
WU, E.-L., CHIEN, I., LIN, C.-H., CHOU, Y.-J. & CHOU, P. 2012. Increased risk of 
hypertension in patients with major depressive disorder: A population-based study. 
Journal of Psychosomatic Research. 
WULSIN, L. R. & SINGAL, B. M. 2003. Do depressive symptoms increase the risk for the 
onset of coronary disease? A systematic quantitative review. Psychosomatic 
Medicine, 65, 201-210. 
WULSIN, L. R., VAILLANT, G. E. & WELLS, V. E. 1999. A systematic review of the 
mortality of depression. Psychosomatic medicine, 61, 6-17. 
YANG, J., BENYAMIN, B., MCEVOY, B. P., GORDON, S., HENDERS, A. K., NYHOLT, 
D. R., MADDEN, P. A., HEATH, A. C., MARTIN, N. G. & MONTGOMERY, G. 
W. 2010. Common SNPs explain a large proportion of the heritability for human 
height. Nature genetics, 42, 565-569. 
YANG, J., LEE, S. H., GODDARD, M. E. & VISSCHER, P. M. 2011. GCTA: a tool for 
genome-wide complex trait analysis. The American Journal of Human Genetics, 88, 
76-82. 
YANG, J., LOOS, R. J. F., POWELL, J. E., MEDLAND, S. E., SPELIOTES, E. K., 
CHASMAN, D. I., ROSE, L. M., THORLEIFSSON, G., STEINTHORSDOTTIR, V. 
& MÄGI, R. 2012. FTO genotype is associated with phenotypic variability of body 
mass index. Nature, 490, 267-272. 
YANG, J., MANOLIO, T. A., PASQUALE, L. R., BOERWINKLE, E., CAPORASO, N., 
CUNNINGHAM, J. M., DE ANDRADE, M., FEENSTRA, B., FEINGOLD, E. & 
HAYES, M. G. 2011. Genome partitioning of genetic variation for complex traits 
using common SNPs. Nature genetics, 43, 519-525. 
213 
 
YARY, T., SOLEIMANNEJAD, K., RAHIM, A., KANDIAH, M., AAZAMI, S., POOR, J., 
WEE, T. & AAZAMI, G. 2010. Contribution of diet and major depression to 
incidence of acute myocardial infarction (AMI). Lipids in health and disease, 9, 133. 
YERAGANI, V. K., RAO, K., SMITHA, M. R., POHL, R. B., BALON, R. & 
SRINIVASAN, K. 2002. Diminished chaos of heart rate time series in patients with 
major depression. Biological psychiatry, 51, 733-744. 
YUDKIN, J. S., KUMARI, M., HUMPHRIES, S. E. & MOHAMED-ALI, V. 2000. 
Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? 
Atherosclerosis, 148, 209-214. 
YULUG, B., OZAN, E. & KILIC, E. 2010. Brain-derived neurotrophic factor polymorphism 
as a genetic risk for depression? A short review of the literature. Journal of 
Neuropsychiatry and Clinical Neurosciences, 22, 123. 
ZEGGINI, E., PANOUTSOPOULOU, K., SOUTHAM, L., RAYNER, N. W., DAY-
WILLIAMS, A. G., LOPES, M. C., BORASKA, V., ESKO, T., EVANGELOU, E. 
& HOFMAN, A. 2012. Identification of new susceptibility loci for osteoarthritis 
(arcOGEN): a genome-wide association study. Lancet, 380, 815-823. 
ZHANG, C., REXRODE, K. M., VAN DAM, R. M., LI, T. Y. & HU, F. B. 2008. 
Abdominal Obesity and the Risk of All-Cause, Cardiovascular, and Cancer 
Mortality. Circulation, 117, 1658-1667. 
ZHAO, G., FORD, E., DHINGRA, S., LI, C., STRINE, T. & MOKDAD, A. 2009. 
Depression and anxiety among US adults: associations with body mass index. 
International Journal of Obesity, 33, 257-266. 
ZHOU, D., KUSNECOV, A., SHURIN, M., DEPAOLI, M. & RABIN, B. 1993. Exposure to 
physical and psychological stressors elevates plasma interleukin 6: relationship to 
214 
 
the activation of hypothalamic-pituitary-adrenal axis. Endocrinology, 133, 2523-
2530. 
ZIMMERMAN M, CORYELL W, PFOHL B. 1986. The validity of the dexamethasone 
suppression test as a marker for endogenous depression. Archives of general 
psychiatry. 43(4):347-55. 
 
 
215 
 
